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Hydrogel-based biomaterials are often used for biomolecule delivery or 
encapsulation of cells for tissue engineering and regenerative medicine applications. 
However, utilizing hydrogels in dynamic cell systems can be challenging, as hydrogels 
must be engineered to account for changes in cellular behavior. For example, the 
hydrogel cell culture platforms and analyses techniques employed to investigate cell 
response to disease conditions should account for the variations in cellular 
communication resulting from changes in the external stimuli inherent to the disease. In 
addition, the hydrogels used to modulate cellular differentiation, either through protein 
delivery or direct interactions with cells, should account for the evolving cell phenotype. 
Thus, in this work, hydrogel-based technologies were developed and utilized to 
interrogate and modulate dynamic cellular behavior. 
A PEG-based platform was designed and utilized to interrogate MSCs, 
adipocytes, and osteoblasts under hyperglycemic conditions via multivariate analyses, as 
these three cell types are implicated in abnormal deposition of marrow adipose tissue and 
bone in diabetes and osteoporosis. Then, as heparin is known to bind many growth 
factors involved in cellular differentiation processes, heparin-based MPs were used to 
temporally modulate endochondral ossification of ATDC5 cells, possibly through 
heparin-mediated protein sequestration. To further modulate the timing of protein 
sequestration, heparin-PEG core-shell MPs were designed to enable sequestration and 
temporally controlled redelivery of protein. Finally, hydrolytically degradable heparin-
PEG-based MPs were engineered with tunable heparin content and degradation rate, to 
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enable temporally controlled protein release. Overall, this work demonstrates the ability 
of PEG and heparin-based hydrogels to investigate and regulate cellular processes that 










 Hydrogel-based biomaterials are often employed in regenerative medicine due to 
their high water content, biocompatibility, amenability to chemical modification, and 
potential to evolve with time [1–3]. For example, three-dimensional (3D) hydrogel in 
vitro cell culture systems have provided extensive knowledge about cell behavior that 
would have be difficult to obtain in vivo due to the inability to assess subtle, cell-level 
changes to chemical and physical stimuli in animal models [4–8]. In addition, hydrogel-
based delivery systems have enabled entrapment and controlled release of various 
biomolecules by employing protein-attractive and biodegradable materials [9–12]. 
However, a major obstacle in the utilization of biomaterials can be ensuring that they are 
engineered to permit analysis or modulation of dynamic cellular processes such as those 
observed in disease states and during differentiation, in which cell behaviors fluctuates in 
both space and time in response to various stimuli.  
As tools to enable 3D cell culture, hydrogel-based platforms have facilitated 
capturing important aspects of the in vivo microenvironment during in vitro studies [2,8]. 
For example, cellular communication is a dynamic process that is critical to normal cell 
function, and by using co-culture to permit cellular communication in vitro, better 
understandings of in vivo cell behavior have emerged [13–15]. In addition, interactions 
between cells and the ECM in which they reside are implicated in modulating dynamic 
cellular processes like differentiation, and by integrating ECM molecules, such as 
integrin-binding peptide sequences or glycosaminoglycans, into hydrogel culture 
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systems, a deeper knowledge of how these materials might affect cells in vivo or how 
they could be used as tools for tissue regeneration might be gained [9,16].  
Thus, the research presented in this thesis strives to develop hydrogel-based 
materials to enable interrogation and modulation of dynamic cellular processes. First, 
investigation of the complex interactions between multiple cell types under pathological 
conditions could provide further insight into disease progression and potential treatment. 
For example, it has been hypothesized that dysregulation of mesenchymal stem cell 
(MSC) commitment to adipogenic and osteogenic lineages could be the cause of 
increased marrow fat and elevated cases of osteoporosis in patients with diabetes mellitus 
[17–21]. As MSC lineage commitment is partially controlled by signals from mature 
adipocytes and osteoblasts, it is possible that dysregulation occurs due to altered cellular 
cross-talk in hyperglycemic conditions [22], but further studies are required to confirm 
this hypothesis. Therefore, development of in vitro biomaterials platforms that enable 
advanced analyses of cell co-culture could aid in understanding the complicated 
interactions between MSCs, adipocytes, and osteoblasts and could be applied to the study 
of other dynamic cellular behavior. However, challenges in designing materials that 
allow cell type-specific analyses, including post-culture functional assays, still must be 
overcome. 
Second, utilization of ECM-mimicking materials could enhance control over the 
dynamic process of cellular differentiation, a common goal in tissue repair and 
regeneration [3]. For example, endochondral ossification involves the conversion of 
proliferating chondrocytes into bone through a process tightly regulated by signaling 
molecules [23], and modulation of this process could lead to improved therapies for 
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growth plate or articular cartilage injuries [24]. GAGs are known to bind many of the 
growth factors involved in endochondral ossification and other differentiation processes, 
including IHH, FGFs, TGFβs, BMPs, and IGFs [25,26], and this protein-binding ability 
could enable temporal modulation of cellular differentiation. While GAGs have been 
used to deliver biomolecules in a variety of tissue-engineering applications [26], their 
ability to act as the sole modulator of differentiation by the mechanism of protein binding 
has not been fully explored. In addition, the goal of designing materials to temporally 
control GAG-mediated protein sequestration and release has not yet been fully realized. 
1.2 Research Objectives 
 Thus, the goal of this work was to develop hydrogel-based technologies to 
analyze and modulate dynamic cell processes. This was achieved by pursuing two 
parallel focus areas: 1) development of a PEG-based hydrogel co-culture platform to 
permit analysis of cellular cross-talk in pathological conditions and 2) implementation 
and development of heparin-based MPs to temporally modulate protein presentation in 
cellular differentiation processes. The biomaterials employed in these studies include 
heparin, which has a high affinity for growth factors involved in differentiation and 
developmental processes [25], and PEG, which has low affinity for proteins and permits 
protein diffusion when cross-linked into hydrogels [27–29].  
To achieve the goals in the first focus area, a PEG-based hydrogel system was 
developed to evaluate the effects of cellular cross-talk in osteoblasts, adipocytes, and 
MSCs in co-culture under hyperglycemic conditions. Each cell type was cultured in 
separate PEG hydrogel blocks in a laminated co-culture system, allowing cell type-
specific retrieval for analysis after culture. In addition, the MSC block was enzymatically 
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degradable, permitting clonogenicity studies after co-culture. Finally, multivariate 
analyses were applied to better understand which variables contributed to observed cell 
phenotypes.  Overall, these studies were performed as a proof-of-concept experiment to 
demonstrate the utility in hydrogel-based co-culture systems for understanding how cells 
respond to dynamic cellular cross-talk in a disease model. 
In the second focus area, the ability of heparin to modulate cellular differentiation 
was assessed by incorporating heparin-based MPs into ATDC5 cell aggregates (a model 
cell line for endochondral ossification) and culturing monolayer ATDC5 cells in 
transwell culture with heparin MPs. To understand the mechanism behind heparin MP-
mediated changes in differentiation, PEG MP controls were evaluated alongside heparin 
MPs and protein sequestration in cell-conditioned media was studied. In addition, core-
shell heparin-PEG MPs were designed as a tool to temporally modulate soluble factors. 
By encapsulating heparin MPs in a degradable PEG-based shell that permitted protein 
diffusion, protein could be sequestered by the heparin MP and isolated from the 
surrounding environment prior to degradation of the PEG-based shell. Finally, degradable 
heparin-PEG-based MPs were developed to better control protein sequestration and 
release. 
The overarching rationale for this project is that development and utilization of 
hydrogel-based technologies can enable interrogation and modulation of cell behavior in 
dynamic systems. The overarching hypothesis of this work is that PEG-based hydrogels 
can be engineered to permit culture conditions and analysis techniques that account for 
cellular cross-talk, and heparin-based hydrogels can be employed to temporally modulate 
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cellular differentiation and protein presentation. These hypotheses will be addressed in 
the following three specific aims:  
Hypothesis I: Mesenchymal stem cells, adipocytes, and osteoblasts will respond to 
hyperglycemic conditions in a manner that is dependent on their neighboring cell type. 
Specific Aim I: Utilize a PEG-based platform to co-culture MSCs, osteoblasts, and 
adipocytes and evaluate gene expression, viability, and clonogenicity (MSCs only) in 
normal and high glucose conditions using multivariate analyses. 
 In vitro model systems of the bone marrow microenvironment have the potential 
to reduce complexity while still maintaining relevant components of the in vivo 
microenvironment [30,31]. Recently, photolithography and cell patterning techniques 
have enabled development of highly specified co-culture hydrogel systems, allowing cell 
and biomolecule patterning for a variety of applications [29]. In addition, the ability to 
maintain separation between cell populations while still permitting cellular 
communication in PEG-based hydrogels has been demonstrated [32,33]. Thus, PEG-
based hydrogels were used to investigate the potential role of MSCs in the dysregulation 
of adipocyte and osteoblast behavior observed in diabetic patients [30,34]. A deeper 
understanding of how MSCs cause and are affected by abnormal levels of marrow fat and 
bone mineral density could lead to new therapeutic approaches for osteoporosis in 
diabetic patients [22], and could lead to therapies that specifically target the stem cell 
niche [31,35].  
 In these studies, MSCs, adipocytes, and osteoblasts were cultured in mono-, co-, 
and tri-culture in laminated PEG hydrogel blocks in normal or high glucose conditions 
for 7 days, with timepoints at day 1 and 7. Each block was retrieved and analyzed for cell 
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viability and gene expression markers for osteogenesis, pro-bone formation, 
adipogenesis, pro-adipocyte function, energy metabolism, and glucose-responsiveness. 
The MSC block was designed to be enzymatically degradable by integrating an MMP-
sensitive sequence (GGGLGPAGGK) into the PEG network, and live MSCs were 
retrieved after collagenase-mediated degradation of the hydrogel. MSCs were then plated 
at clonal density to assess clonogenicity. Finally, multivariate analyses were employed to 
better understand how measured gene expression variables interacted to produce 
observed cell outcomes.   
Hypothesis II: Heparin MPs can temporally modulate endochondral ossification through 
sequestration of soluble factors in a dose-dependent manner. 
Specific Aim II: Evaluate the extent and timing of endochondral ossification in ATDC5 
cells with high and low doses of heparin MPs, in comparison to a low protein-binding 
PEG MP control.  
 A variety of techniques have been employed to modulate endochondral 
ossification and chondrogenesis, including culturing cells in aggregate or pellet culture to 
better mimic the 3D microenvironment [36], co-culture of MSCs and chondrocytes, and 
delivery of growth factors such as TGFβ and FGFs [37]. However, achieving a stable 
chondrocytic phenotype is still a challenge, and dedifferentiation in chondrocytes and 
hypertrophic differentiation in MSCs often occurs [37]. Heparin, a highly sulfated GAG, 
is known to bind a variety of growth factors involved in endochondral ossification [25]. 
Recently, the ability of heparin-based hydrogels to sequester cell-secreted growth factors 
and modulate cellular behavior has been demonstrated in models of angiogenesis, 
chondrogenesis, and osteogenesis [38–41]. Thus, by culturing heparin MPs with cells 
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undergoing endochondral ossification, it may be possible to use heparin to capture cell-
secreted growth factors and harness their pro-differentiation potential, thus controlling 
cell access to these growth factors and subsequent differentiation.  
 In this work, similarly sized heparin and PEG-based MPs were integrated into 
ATDC5 cell spheroids. Spheroids were cultured for 18 days and chondrocytic gene 
expression and matrix molecule deposition was assessed at days 1, 6, 12, and 18. To 
better understand if observed changes in cellular differentiation were due to the ability of 
heparin MPs to increase or decrease local concentrations of growth factors, monolayer 
ATDC5 cells were cultured in transwell with heparin and PEG MPs for 12 days. 
Chondrocytic gene expression was measured at days 6 and 12, GAG and mineral 
deposition was measured at day 12, and DNA content was measured at day 12. Finally, to 
evaluate the mechanism of action of heparin MP-mediated changes in cellular 
differentiation, protein sequestration in conditioned media and SDS-PAGE studies of 
proteins bound to heparin and PEG MPs were conducted.    
Hypothesis III: Heparin-based MPs can temporally control protein sequestration and 
release. 
Hypothesis IIIA: Core-shell MPs with a hydrolytically degradable PEG-based shell and 
heparin core can temporally control BMP-2 protein presentation to modulate C2C12 cell 
behavior.  
Specific Aim IIIA: Develop and characterize heparin-PEG core-shell MPs and evaluate 
their ability to sequester and release BMP-2-laden heparin core to elicit a response in 
C2C12 cells. 
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 Cell differentiation and tissue development processes require tight temporal 
control over growth factor presentation [3]. Traditionally, controlled delivery vehicles 
have been used to sustain the release of therapeutic proteins [10,42], but more precise 
temporal control over protein presentation is often required for tissue regeneration [3]. It 
has recently been suggested that biomaterials be used to modulate cell access to cell-
secreted growth factors, which would harness the potency of endogenous protein and 
eliminate the need for exogenous protein delivery [3]. For instance, protein-sequestering 
biomaterials could be used to either amplify the signals of desirable proteins [40,43–45] 
or eliminate those of undesirable proteins [46]. Combining these two techniques, it could 
be possible to sequester and isolate a protein that is undesirable at one point in time, then 
re-present that protein when its function is desirable at a later point in time [3]. As core-
shell MPs have been used both to sequester and isolate protein [47–50] as well as release 
it [51,52], it may be possible to utilize core-shell MPs to sequester and isolate cell-
secreted proteins until degradation of the shell, at which point the sequestered protein 
would be released back into the microenvironment.   
 In this work, heparin-PEG core-shell MPs were fabricated using a re-
emulsification technique to encapsulate pre-formed heparin MPs within a hydrolytically 
degradable PEG-based shell. Quantification methods indicated that core-shell MPs had 
tunable and predictable amounts of encapsulated heparin, and degradation studies 
indicated the ability of the shell to degrade and release the heparin core. Two loading 
methods were used to load BMP-2 onto core-shell MPs. In “pre-fabrication loading” the 
heparin core was loaded prior to formation of core-shell MPs, a technique that could be 
used for exogenous protein delivery from these core-shell MPs. In “post-fabrication 
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loading” the core-shell MPs were loaded after formation of core-shell MPs, a technique 
that could permit sequestration and eventual re-presentation of cell-secreted protein. 
Loading and release studies and a C2C12 BMP-2 bioactivity assay were conducted to 
evaluate the ability of core-shell MPs to temporally modulate release of a protein-laden 
heparin core.  
Hypothesis IIIB: Increasing the heparin content in hydrolytically degradable heparin-
PEG-based MPs will enhance protein loading and decrease protein release rate.  
Specific Aim IIIB: Develop and characterize hydrolytically degradable heparin-PEG-
based MPs with varying amounts of heparin and evaluate loading and release of histone, 
a model protein. 
 As heparin is a potent binder of proteins, it is often integrated into hydrogel 
delivery systems to enhance protein loading and prevent premature protein denaturation 
[53–56]. Recently, heparin MP delivery vehicles have been designed for release of 
therapeutic growth factors [57–59]. However, these heparin-based MPs have either been 
non-degradable or had degradation profiles that were difficult to control due to cross-
linking techniques. For tissue engineering applications that require precisely timed 
delivery of protein, a heparin-based MP with tunable degradation profile is required. In 
addition, a heparin-based MP with tunable amounts of heparin would allow more control 
over protein loading and release, as well as protein sequestration after delivery in vivo. 
Thus, in these studies, heparin-PEG-based MPs were developed and characterized. 
Dithiothreitol (DTT) was integrated into the MP network to accelerate hydrolytic 
degradation [60]. 0, 10, 20, 30, and 40 wt% heparin MPs were fabricated and evaluated 
for heparin content, degradation rate, and histone protein loading and release.  
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1.3 Significance and Scientific Contribution
1
 
 The work described in this thesis develops and utilizes biomaterials to both 
investigate and control complex and dynamic cell systems. For example, the abnormal 
conditions in disease states can cause changes in cell-cell crosstalk that have major 
implications on a tissue and organ scale, and a better understanding of this altered cross-
talk could leave to new disease interventions. In addition, controlling cell phenotype as it 
evolves in time during cellular differentiation could provide novel methods by which to 
control tissue development for injury and repair purposes. Thus, in this work dynamic 
cellular processes were interrogated by enabling cellular communication within a cell 
culture platform in hyperglycemic conditions and were modulated by integrating ECM 
molecules throughout a dense cell aggregate. Through these methods, proof-of-concept 
experiments demonstrated the necessity of designing in vitro culture platforms to permit 
cellular cross-talk and the utility of integrating heparin into cell aggregates to temporally 
modulate cell differentiation. In addition, heparin-based materials were designed to better 
engage with the cellular microenvironment by temporally controlling protein 
presentation. Overall, these studies highlight hydrogel-based technologies to enable better 
understanding and control of cellular processes in normal and disease states. 
 To demonstrate how hydrogel platforms can enable culture conditions and 
analyses techniques to investigate cellular cross-talk, PEG-based hydrogels were used to 




 Portion of this section were adapted from T.E. Rinker, T.M. Hammoudi, M.L. Kemp, H. Lu, J.S. 
Temenoff, Interactions between mesenchymal stem cells, adipocytes, and osteoblasts in a 3D tri-culture 
model of hyperglycemic conditions in the bone marrow microenvironment., Integr. Biol. 6 (2014) 324–37. 
and from T.E Rinker, B.D. Philbrick, and J.S. Temenoff, Core-Shell Microparticles for Protein 
Sequestration and Controlled Release of a Protein-Laden Core, in revision. 
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co-culture MSCs, adipocytes, and osteoblasts under hyperglycemic conditions. The 
culture of each cell type in separate hydrogel blocks enabled individualized analyses of 
each cell type while still permitting cellular communication during culture. Additionally, 
the integration of an enzymatically-degradable peptide sequence within the PEG-based 
network of the MSC block allowed retrieval of viable MSCs for further culture and 
clonogenicity analysis. Finally, multivariate analyses techniques were employed to help 
identify combinations of gene expression markers that governed measured cell outcomes. 
Rather than analyze the gene expression of each protein individually, such a technique 
enables visualization of relationships between markers that can eventually be used to 
predict cell phenotype. The results of this work indicated that the primary source of 
variance in the system was a result of neighboring cell type, validating the use of 
hydrogels for co-culture systems to study disease. Thus, this hydrogel-based co-culture 
platform has unique capabilities that will enable future studies to elucidate how complex 
interactions between various cellular components are affected in pathological conditions. 
 To show the utility in incorporating ECM molecules into cell culture platforms to 
modulate cellular differentiation, heparin MPs were incorporated into ATDC5 cell 
aggregates. Unlike most biomaterial-based strategies, which depend upon protein 
delivery to elicit a cellular response, these studies rely solely on a heparin biomaterial to 
manipulate cellular differentiation. Such biomaterials-mediated sequestration strategies 
could reduce cost by eliminating the need for adding exogenous protein and may increase 
signaling efficiency, as cell-secreted growth factors are often more potent than 
recombinant protein [3]. In addition, unlike strategies that employ biomaterials that 
sequester one specific protein, heparin can sequester a multitude of proteins, enabling 
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heparin to continue to interact with a differentiating cell population as protein release 
evolves. 
Still, current methods for endogenous protein sequestration only allow immediate 
amplification or elimination of protein signals. Thus, core-shell heparin-PEG MPs were 
developed to temporally modulate protein presentation. The multifunctional core-shell 
heparin-PEG MPs presented here can evolve with time by sequestering proteins through a 
PEG-based shell onto a protein-protective heparin core, temporarily isolating bound 
proteins from the cellular microenvironment, and re-delivering these proteins only after 
degradation of the PEG-based shell. Thus, these core-shell MPs are a novel tool to 
harness and isolate proteins produced in the cellular environment and then control when 
these proteins are re-introduced for the most effective tissue regeneration and repair.  
Overall, this work shows the potential for biomaterial-based strategies to 
interrogate and modulate dynamic cell systems, both those that involve changes in cell-
cell crosstalk and those that involve changes in cell state. First, a PEG-based cell-culture 
platform that enabled culture of multiple cell types followed by individual cell-type 
analysis was combined with PCA to highlight the cell changes observed in response to 
neighboring cell type and hyperglycemic conditions. Then, heparin MPs were used to 
temporally modulate differentiation in an in vitro model of endochondral ossification, 
likely through protein sequestration. Finally, core-shell heparin-PEG-based MPs and 
hydrolytically degradable heparin-PEG MPs were developed to allow further, user-
defined control over temporally modulating protein sequestration and release. As a 
whole, this work provides insight into dynamic cellular processes and develops tools by 
which to further investigate or regulate these systems.  
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
2.1 Mesenchymal Stem Cells in the Bone Marrow Microenvironment 
2.1.1 Mesenchymal Stem Cells 
 Over the past several decades, the term “Mesenchymal Stem Cell (MSC)” has 
been used to describe two different populations of cells. The first population consists of 
postnatal, self-renewing, multipotent stem cells that give rise to skeletal tissue and are 
also referred to as skeletal stem cells [61]. This population has been rigorously tested 
through in vivo transplantation to generate replicas of bone containing host-derived 
hematopoietic marrow tissue and is known to regulate the hematopoietic 
microenvironment [61]. The second population is more heterogeneous and has been 
called several names that all fit the same acronym: multipotent stromal cells, 
mesenchymal stromal cells, and medicinal signaling cells [61]. These cells can be derived 
from every connective tissue and are defined by in vitro culture and metrics, including in 
vitro assays used independently of more stringent, in vivo assays and assessment of 
surface markers only after in vitro culture and expansion [61,62]. The inability to 
specifically and consistently refer to these two populations is one of the reasons that 
MSCs remain one of the most confusing and frustrating entities in stem cell biology 
[61,63]. In this review, we define MSCs as the cells described in the first population 
above. 
 Further confusion surrounding MSCs has arisen due to the isolation methods used 
for bone-marrow derived MSCs. Bone marrow cell suspensions contain both 
hematopoietic and non-hematopoietic stroma. Non-hematopoietic stroma, or stromal 
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cells, adhere to plastic, allowing separation of hematopoietic cells and stromal cells in 
vitro [61]. These stromal cells, called bone marrow stromal cells (BMSCs), include 
MSCs but must be further sorted to separate MSCs from other BMSCs [61]. In some 
studies, this distinction has not been made, which has led to additional confusion in 
regards to MSC function, identity, and potential applications [30,61].  
The focus of this review is bone marrow derived MSCs, which are found 
perivascular and on the endosteum, and give rise to adipocytes and osteoblasts, as well as 
support hematopoietic stem cells [62,64]. In vitro, MSCs are adherent, clonal cells 
isolated from bone marrow cell suspensions [30,62]. MSCs are defined by a set of surface 
markers (positive for CD105, CD73, and CD90; negative for CD45, CD34, CD14, 
CD11b, CD79a, CD19, and HLA-DR) and their ability to differentiation into osteoblasts, 
adipocytes, chondroblasts, fibroblasts, and hematopoiesis-supporting stroma [62,64]. 
While assessment of surface markers and differentiation potential has proven a somewhat 
effective way to identify MSCs, little to no evidence exists that these surface markers are 
present on MSCs in vivo, and many are also present on pericytes [65].   
Various applications have been proposed for MSCs, including tissue regeneration, 
immunomodulation, and release of trophic factors [64,66]. These pursuits have been met 
with varying success, as controversy about how best to expand MSCs, what is a “true” 
population of MSCs, and if it is truly MSCs responsible for immunomodulation and 
trophic factor secretion still exists [62]. In addition, little is understood about the 
anatomical location of MSCs and their role in tissue homeostasis [63,64]. For example, 
MSCs are known to reside in several different in vivo niches, and the phenotypical 
similarities between cells in each niche as well as their potential to self-replenish and 
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migrate remain poorly understood [30]. Finally, more work is required to understand 
surface marker differences between MSCs and their progeny prior to in vitro expansion 
[65]. Overall, more work must be done to trace the lineage of MSCs, better define the 
MSC population, and develop in vitro and in vivo assays to elucidate MSC function 
[30,62]. 
2.1.2 Mesenchymal Stem Cells in the Bone Marrow Microenvironment 
 Stem cell niches refer to the specific microenvironment that controls stem cell  
self-renewal, differentiation, and quiescence [67,68]. Relevant cues in the niche include 
soluble factors (growth factors, cytokines, etc.) derived from other niche cells, cell-cell 
interactions, cell-ECM interactions, oxygen level, level of reactive oxygen species, and 
tissue structure [31]. Within the bone marrow microenvironment, skeletal and 
hematopoietic progenitor cells exist alongside their progeny and other differentiated cells, 
such as sinusoidal endothelial cells, sympathetic nerve fibers, osteoblasts, osteoclasts, 
macrophages, and regulatory T cells [30,62,68,69]. Identification of other stem cells in 
the bone marrow microenvironment is still an area of active research, and will not be 
discussed here [62]. Mesenchymal stem cells are found in several locations within the 
bone marrow, including on the endosteum and perivascular, near the sinusoidal 
endothelium [68,69]. In the bone marrow microenvironment, MSCs have several 
functions, including regulating HSCs through a variety of soluble factors and giving rise 
to osteoblasts and adipocytes [68,69]. Still, much more needs to be uncovered about the 
in vivo cellular and molecular interactions of MSCs within the bone marrow niche [70]. 
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 The stem cell niche has attracted a lot of attention in the recent years, as it could 
be manipulated as a means to control stem cell behavior [30,35,67]. For example, it has 
been suggested that the niche be targeted to combat diseases like cancer and diabetes 
[67,69]. To gain a deeper understanding of 1) regulators of the stem cell niche and 2) how 
to change the niche in order to modulate stem cell behavior, development of in vitro 
model systems have been explored [30,67]. Often, these systems include multiple cell 
types and are three-dimensional, but incorporation of every aspect of the in vivo niche is 
not possible [31]. However, useful information that can be further explored in vivo can 
still be gained from these in vitro systems.  
2.1.3 Diabetes and its Effects on the Bone Marrow Microenvironment   
Diabetes mellitus types I and II affected 135 million people in 1990, and are 
predicted to affect 300 million by 2025 [71]. Categorized as a metabolic disease, diabetes 
is caused by lack of insulin production (primarily type I) and/or lack of insulin sensitivity 
(primarily type II) [72]. Insulin irregularities result in an inability to regulate blood 
glucose levels, which leads to a variety of complications, including chronic 
hyperglycemia [72]. Hyperglycemic conditions can cause debilitating dysfunction and 
failure of various organs, including eyes, kidneys, nerves, heart, and blood vessels [19]. 
In the bone marrow, hyperglycemia can result in sinusoid abnormalities and HSC 
dysregulation, as well as increased fat infiltration [69]. Additionally, hyperglycemic 
conditions result in excessive reactive oxygen species (ROS) due to glucose 
autooxidation, ROS overproduction by the mitochondria, non-enzymatic glycation, and 
the polyol pathway [73]. ROS can negatively affect cells through DNA, protein, and lipid 
damage, and increased oxidative stress can also lead to inflammation [73].  
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While diabetes alone is associated with morbidity and mortality, patients with 
diabetes are also at increased risk for diseases like osteopenia and osteoporosis, as well 
for bone fracture [19–21,74]. About 50% of patients with type I diabetes have bone loss, 
and 20% of patients ages 20-56 have osteoporosis [21]. Osteoporosis is defined by 
reduced bone mass and bone microarchitectural abnormalities, which results in reduced 
bone strength and increased fracture risk [72]. Clinically, osteoporosis is diagnosed by 
bone mineral density (BMD) measurements that are more than 2.5 standard deviations 
lower than the sex-matched young adult mean [72,75]. While decreased BMD has been 
observed in patients with type I diabetes, normal to above average bone masses have 
been observed in patients with type II diabetes [76]. However, both type I and II diabetes 
patients show higher fracture risk, indicating that other factors besides bone mass, such as 
abnormal bone microarchitecture, may be implicated in type II diabetes fractures [76,77]. 
In diabetes as well as other diseases such as osteoporosis and anorexia nervosa, BMD and 
marrow adipose tissue (MAT) are inversely related [17,18]. Increased MAT is observed 
in patients with diabetes type I and it is possible that MAT composition is different in 
patients with diabetes type II [76]. Still, this inverse relationship between BMD and MAT 
is not fully understood, and a deeper understanding of communication between cell types 
that make up these tissues could elucidate the biological processes that lead to abnormal 
levels of each tissue type. 
2.1.4 MSCs, Adipocytes, and Osteoblasts in the Bone Marrow Microenvironment 
 Within the bone marrow microenvironment, adipocytes and osteoblasts are both 
derived from MSCs and contribute to mature bone and MAT [22]. While bone has a clear 
function in adult physiology, the precise function of MAT is still unknown [18]. Some 
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speculate that MAT acts as an energy source for bone remodeling, an energy-intensive 
process, while other evidence has pointed toward MAT as actively modulating the 
hematopoietic stem cell (HSC)/MSC niche and osteogenesis through soluble factor 
signaling [18,22,74,78]. Interestingly, MSC lineage commitment to either progeny seems 
to be at the expense of the other [17,22,78]. For instance, the master regulator of 
adipogenesis,  peroxisome proliferator activated receptor gamma (PPARγ), is known to 
suppress osteogenesis, while the master regulators for osteogenesis, WNT and Runt-
related transcription factor 2 (RUNX2), are known to suppress adipogenesis [18,22]. As 
MSC lineage commitment is a result of signals from other cell types in the niche, 
including mature adipocytes and osteoblasts, as well as systemic signals, fate decisions 
are likely altered in disease states [22]. Additionally, mature adipocytes and osteoblast 
secrete signals that could affect each other. For example, adipocytes secrete leptin, which 
is believed to decrease bone mass [79–81], and adiponectin, believed to have an effect on 
proliferation and differentiation of osteoblasts [82]. Osteoblasts secrete osteocalcin, 
which aids in bone matrix mineralization [79], and osteoprotegrin, which suppresses 
osteoclastogenesis [72,82]. Thus, altered numbers of either cell type could result in 
increases or decreases in release of signaling molecules that cause and perpetuate 
abnormal levels of MAT or BMD.  
 As discussed, the inverse relationship between MAT and BMD could be a result 
of altered MSC differentiation in diabetic disease states. While the reasons for decreased 
BMD are unclear, it is speculated that higher levels of glucose could have direct, toxic 
impact on osteoblasts or negatively alter the ROS environment [21,74]. As increased 
marrow fat is observed in hyperglycemic conditions, it is possible that MSCs are 
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triggered to commit to the adipogenic lineage at the expensive of osteoblasts, thus 
shifting the bone remodeling process too far toward osteoclast-mediated resorption 
[21,22]. In addition, all three cell types have been found to respond adversely to 
hyperglycemic conditions [21]. MSCs show increased apoptosis and senescence and 
decreased colony-forming capacity and osteogenic potential in hyperglycemic conditions 
[83–86].When cultured in high glucose, adipocytes have decreased insulin sensitivity, 
dysregulated triglyceride storage, increased production of ROS and pro-inflammatory 
cytokines, and decreased adiponectin secretion [87–89]. Lastly, osteoblasts demonstrate 
reduced proliferative capacity, mineralization capabilities, collagen I synthesis, and 
expression of differentiation markers in hyperglycemic conditions [90–93]. Still, how 
hyperglycemia alters the cellular crosstalk between osteoblasts, adipocytes, and MSCs 
remains unclear.     
2.1.5 Co-Culture of Osteoblasts, Adipocytes, and MSCs
2
 
To better understand interactions between different cell populations, two- and 
three-dimensional (2D and 3D, respectively) co-culture systems have been employed in 
vitro [94,95]. Traditionally, 2D cell culture has been employed due to ease of use, 
convenience, and high cell viability [96]. Still, results from 2D culture must be 
interpreted with caution, 2D culture does not replicate many the important 3D 
components of the in vivo cellular microenvironment, including cell-cell and cell-matrix 




 Portions of this section were adapted from Rinker T.E. and Temenoff J.S. “Micro- and Nanotechnology 
Engineering Strategies for Tissue Interface Regeneration and Repair.” Tissue and Organ Regeneration: 
Advances in Micro and Nanotechnology, 105-156, 2014. 
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contacts. 2D co-culture systems were used in several studies to investigate interactions 
between MSCs, osteoblasts, and adipocytes. In general, MSCs have shown enhanced 
osteogenesis when co-cultured with osteoblasts in either direct contact or transwell 
culture [97–101]. In one study, murine MSCs were cultured with osteoblast-like 
(MC3T3) or osteocyte-like (MLO-Y4) cells, and both ALP production and calcium 
deposition were higher in MSCs cultured with osteocytes, though osteoblast cells caused 
higher levels of MSC proliferation [101]. In another transwell study with murine MSCs 
(C3H10T1/2 cell line) and murine calvaria-derived bone cells (MC3T3 cell line), few 
differences were observed, though a slight increase in MSC ALP production was 
observed when the ratio of osteoblasts was decreased [100]. Conversely, a separate study 
with human MSCs in transwell co-culture with human osteoblasts showed upregulation 
of osteogenic markers [99]. One particularly interesting study showed that in indirect 
contact, osteoblasts stimulated osteogenic differentiation of MSCs, but in direct contact, 
inhibited osteogenic differentiation. Authors determined that in direct contact, the 
cadherin pathway suppressed the WNT pathway, which otherwise would have induced 
osteogenesis in MSCs [98]. Another co-culture experiment with murine osteoblasts and 
MSCs confirmed that the enhanced osteogenesis observed in MSCs was due to the WNT 
pathway [97]. Overall, osteoblasts appear enhance MSC osteogenesis or to have a 
negligible effect on MSC behavior. 
In co-cultures between osteoblasts and adipocytes, osteogenesis is generally 
severely decreased in the presence of adipocytes [102–104]. In a study with osteoblastic 
MC3T3 cells and 3T3-L1 pre-adipocytes, the adipocyte-secreted free fatty acids inhibited 
osteoblasts proliferation, induced apoptosis, and reduced osteogenic markers (ALP 
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activity,  RUNX2, ollagen I, and osteocalcin expression, and matrix mineralization) 
[104]. Similarly, a study with human adipocytes and human osteoblasts in transwell 
culture showed decreased osteogenic and increased adipogenic markers in osteoblasts, 
suggesting that transdifferentiation of osteoblasts into adipocytes may have occurred 
[103]. In line with the studies described above, primary human adipocytes caused 
decreased primary human osteoblast proliferation in transwell co-culture [102]. Few 
studies with MSC and adipocyte cultures have been conducted, and thus little is known 
about how these two cell populations affect each other. Overall, these studies indicate 
that MSCs, adipocytes, and osteoblasts clearly affect each other, probably both through 
soluble factor signaling and direct contact. More studies, possibly those that include a 3D 
culture platform and more comprehensive outcome measures, will need to be performed 
to fully elucidate how these effects might translate to in vivo observations within the bone 
marrow microenvironment.  
2.2 Endochondral Ossification 
2.2.1 Endochondral Ossification and the Growth Plate  
Endochondral ossification occurs in the process of bone development, during 
which mesenchymal cells condense to form a cartilage anlagen and either permanently 
differentiate into articular chondrocytes or take on a transient chondrogenic phenotype 
before proceeding through endochondral ossification [105]. Endochondral ossification 
begins when mesenchymal cells condense via adhesion factors and then begin to 
differentiate into chondrocytes, enlarging the cartilage anlagen [23,106]. The primary 
ossification center forms when a portion of these chondrocytes stop proliferating and 
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undergo hypertrophy, resulting in mineralization and vascularization of the tissue near 
what will become the diaphysis of the bone [23,106]. While this occurs, chondrocytes 
continue to proliferate and the cartilage grows [23,106]. These proliferative chondrocytes 
assume a flattened shape and stack on top of one another to form columns, oriented in the 
direction of developing bone [23,106]. Then, secondary ossification sites are formed at 
each end (epiphysis) of the bone [23,106]. The remaining cartilaginous tissue trapped 
between the two ossification centers is called the growth plate [23,106]. Chondrocytes in 
the growth plate continue to proliferate and undergo hypertrophy in a process tightly 
controlled by both local and systemic signals, allowing bone elongation until closure of 
the growth plate during puberty [23,106].  
Maintenance of these spatially and temporally distinct developmental stages 
depends on both systemic hormones and cellular communication between mesenchymal 
cells, chondroprogenitor cells, chondrocytes, and other cells in and around the growth 
plate [23,107]. The mechanisms behind how these growth factors travel long-range 
through the growth plate ECM and form concentration gradients are not entirely 
understood, but current evidence points towards GAGs as having a significant role [108]. 
Both chondroitin sulfate (CS) and heparan sulfate (HS) are thought to be involved in 
developing morphogen gradients and promoting receptor-ligand binding within the 
growth plate [106,107] (see Section 2.4.2 for more details). Additional studies should aim 
to use histological approaches to track protein and GAG movement and localization in 
organ culture or animal studies to further elucidate the role of GAGs in regulating growth 
factor-cell interactions. 
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At the first stage of endochondral ossification, SOX9 is required for the 
commitment of mesenchymal cells into chondrocytes, and growth hormone stimulates 
these resting zone (pre-proliferative) chondrocytes to secrete IGF-1, which enhances 
chondrocyte proliferation [106,109]. Several factors regulate proliferative chondrocytes. 
First, a negative feedback loop is created between Indian Hedgehog (IHH) and 
parathyroid hormone-related protein (PTHrP) to modulate the transition of proliferative 
chondrocytes into hypertrophic chondrocytes [23,106,109,110]. PTHrP is secreted by 
chondrocytes at the epiphysis of long bones, and prevents proliferative chondrocytes 
from undergoing hypertrophy [23,106,109,110]. However, when chondrocytes are out of 
range of PTHrP, they enter a pre-hypertrophic stage and begin to secrete IHH 
[23,106,109,110]. IHH acts to increase the rate of chondrocyte proliferation, delays 
hypertrophy, and through unknown mechanisms, stimulates the PTHrP secretion from 
chondrocytes at the end of long bones [23,106,109,110]. Another signaling molecule 
implicated in enhancing chondrocyte proliferation is BMP. BMP-2, 3, 4, 6, and 7 are 
expressed in the perichondrium, BMP-7 in proliferative chondrocytes, and BMP-2 and 6 
in hypertrophic chondrocytes [23,110]. Overall, BMPs are known to promote 
chondrocyte proliferation and also induce IHH expression [23,106,109,110]. FGFs are 
also important in growth plate regulation, and several receptors, including fibroblast 
growth factor receptor (FGFR) 2, FGFR3, and FGFR1 are expressed in mesenchymal 
condensations, proliferative chondrocytes, and hypertrophic chondrocytes, respectively 
[23]. FGF-1, 2, 15, 18, and 19 are all expressed in the growth plate and act through 
FGFR3 to repress proliferation and inhibit IHH production [23,106]. GAGs, most likely 
heparan sulfate, are necessary for these interactions [106]. During proliferation, 
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chondrocytes actively lay down ECM molecules like collagen II and aggrecan, and to a 
lesser extent biglycan and glypican [106,109]. Expression and secretion of these 
molecules are also controlled by the growth factors mentioned above [106].  
Finally, RUNX2 and WNT induce chondrocyte hypertrophy [23,106,110]. 
Hypertrophic chondrocytes are critical in bone development, as they provide a scaffold 
for subsequent bone formation [110]. These chondrocytes have increased levels of 
intracellular calcium and secrete collagen X as well as matrix vesicles that contain 
calcium phosphate, hydroxyapatite, and matrix metalloproteinases (MMPs) [109]. One of 
these secreted MMPs, MMP13, can degrade the collagen II matrix previously laid down 
by proliferative chondrocytes [106]. Hypertrophic chondrocytes also secrete vascular 
endothelial growth factor (VEGF), which, along with the hypoxic conditions in the 
growth plate, attracts blood vessels to the matrix [23,106,109,110]. Finally, hypertrophic 
chondrocytes near the ossification front undergo apoptosis, which is regulated by 
intracellular calcium levels, retinoic acids, and vitamin D [106,109]. Then, osteoclasts, 
osteoblasts, and bone marrow cells invade the newly ossified tissue [106]. Overall, 
endochondral ossification and maintenance of the growth plate are very tightly controlled 
processes, and disruption of even one of these signaling pathways can have severe 
consequences in long bone development. 
2.2.2 Growth Plate Injuries and Repair Strategies 
Injuries to the growth plate cartilage occur in 20% of childhood bone fractures 
and can result in bony bridge formation that hinders normal growth, resulting in limb 
length disparities, bone angulation deformities, and in severe cases, growth arrest 
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[111,112]. Current treatments involve correcting angular deformations and limb length 
discrepancies, and in some cases, removal of the bony bridge [112,113]. In an effort to 
prevent reformation of the bony bridge, filler substances such as transplanted fat, muscle, 
polymeric silicone, bone wax, and bone cement are injected into the defect [112]. These 
strategies are only partially successful and do not allow the tissue to return to its normal 
structure or function [112]. Currently, no biological therapies are clinically available, and 
development of a therapy that could promote regeneration and repair of the growth plate 
would be greatly beneficial [112,113].  
 Recent in vivo studies have highlighted the utility of using tissue engineering 
approaches to repair growth plate defects. In most approaches, a therapeutic cell type, 
either MSCs or chondrocytes, are seeded onto scaffolds made of collagen, chitosan, 
hyaluronic acid, agarose, or gelatin and then implanted into growth plate defects 
[111,113–118]. For example, chondrocytes within a collagen gel were implanted into a 
physeal defect in rabbits, which prevented early ossification and growth plate closure, 
and reduced angular deformity and limb length discrepancy [114]. In studies with 
miniature pigs, growth plate defects filled with MSCs within a collagen/chitosan gel did 
not show bone bridge formation, and affected limbs with MSC implants grew more than 
control limbs [118].   
In contrast to these positive results, implantation of a gelatin sponge seeded with 
MSCs into a growth plate injury in an ovine model caused formation of fibrous tissue and 
similar functional outcomes as control groups [113]. One particularly interesting study 
could point to reasons why variability is observed in MSC-based growth plate therapies. 
MSCs were either undifferentiated or pre-differentiated down a chondrocytic lineage, 
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then seeded onto an agarose gel and implanted into a growth plate defect in rats. While 
bone bridge formation was observed in all cases, limb length discrepancy was only 
observed in the group with undifferentiated MSCs [116]. This study highlights the 
necessity of ensuring high-quality MSCs for growth-plate cell therapies. Finally, one 
study attempted to deliver an IGF-loaded poly(lactic-co-glycolic acid) (PLGA) scaffold 
rather than a cell-seeded scaffold in a rabbit model, in an effort to stimulate endogenous 
cells in the growth plate. This technique was partially successful, as a thin layer of 
disorganized cartilage remained in groups with IGF-loaded scaffolds, compared to bony 
infiltration observed in all other groups [111]. Overall, tissue engineering strategies for 
growth plate injuries are promising, but more work needs to be done to evaluate proper 
cell types and scaffold materials. For example, due to their tendency to undergo 
endochondral ossification in vitro and in vivo [37], MSCs may be an ideal candidate cell 
type for growth plate regeneration, and as these studies indicate, control of this 
differentiation process through proper growth factor presentation as well as material 
interactions could improve outcomes.   
2.2.3 Articular Cartilage and Chondrogenesis 
 Articular cartilage is a hyaline cartilage found on the articulating surface of bones 
in joints, where it acts to provide a smooth, articulating surface and allows resistance of 
compressive forces [119]. Hypocellular in nature, cartilage consists primarily of collagen 
II, the proteoglycan aggrecan, and water [119,120]. Articular cartilage has a zonal 
arrangement in which cell and collagen fiber organization differ [119,120]. The 
superficial zone is in contact with the synovial fluid and consists of flattened 
chondrocytes and parallel collagen fibrils [119]. Moving toward the bone, the 
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intermediate or transitional zone consists of rounded chondrocytes and less organized 
collagen fibers [119]. Finally, in the deep/basal zone, the last layer prior to calcified 
tissue and the tidemark, rounded chondrocytes are oriented in vertical columns 
perpendicular to the articular surface [119]. Chondrocytes have long half-lives in normal, 
non-diseased states and act to balance matrix synthesis with matrix breakdown [119]. 
However, if this balance is disturbed by disease or injury, it can be very detrimental to the 
tissue and quite challenging to reestablish [119].  
   The formation and maintenance of adult articular cartilage remains poorly 
understood, but it is believed that as joints begin to form in the cartilage anlagen 
(“interzone” regions), both pre-existing chondrocytes and migrating progenitor cells 
make up the cell populations that become articular cartilage as cavitation and 
morphogenesis proceed [121,122]. Many of the same growth factors involved in 
endochondral ossification, including BMPs, growth differentiation factors (GDFs), 
TGFβ, and IHH, are thought to be involved in the development and maintenance of 
articular cartilage [121]; however, the mechanism by which these growth factors function 
in articular cartilage remain unknown. Though chondrocytes of the articular cartilage are 
more stable than growth plate chondrocytes, articular chondrocyte dedifferentiation can 
occur with age and during disease, suggesting that maintenance of articular cartilage 
requires strict control over environmental factors throughout life [121,123].   
2.2.4 Cartilage Injury and Repair 
Injuries to articular cartilage, resulting from degenerative joint diseases or 
traumatic injury [124], can result in pain, loss of mobility, and disability [37,125]. In 
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2005, arthritis, one of the degenerative joint diseases aforementioned, affected 70 million 
US adults, and the economic burden of arthritis in the US was estimated to be $60 billion 
in 2000, and estimated to increase to $100 billion by 2020 [126]. The severity of cartilage 
injuries can vary depending upon the type of trauma and the zones affected [119]. 
However, common to most injuries is the increased concentration of proteolytic enzymes 
and cytokines, leading to tissue degradation [119]. As previously mentioned, high rates of 
collagen turnover in disease states or injuries can result in chondrocytes unable to replace 
lost collagen, resulting in loss of a well-organized matrix, mechanical failure, matrix 
degeneration, and arthritis [119]. In addition, if a large portion of cartilage is lost, severe 
degradation of the remaining matrix can occur [119]. If the injury penetrates the 
tidemark, a temporary fibrocartilage matrix may be secreted to fill the defect, but this 
matrix does not have the same mechanical properties as cartilage and is often lost over 
time, resulting in areas of exposed bone [119].  Overall, due to its low capacity for 
healing, articular cartilage injuries have poor clinical outcomes [119,120]. 
Several treatments are used for articular cartilage therapies, including non-
reparative strategies like debridement, chondral shaving, and lavage; reparative methods 
such as arthroplasty and microfracture; and finally regenerative methods such as joint 
replacements, cartilage autografts and allografts, and autologous chondrocyte 
transplantation [126,127]. Some of these regenerative methods have proved promising. 
For example, in autologous chondrocyte transfer, cartilage from a non-load bearing 
region is used to obtain autologous chondrocytes for re-implantation in the defect 
[37,125]. While this procedure is partially successful in many  cases, it is associated with 
several problems, including growth of fibrous tissue, creation of additional injury site 
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when obtaining autologous chondrocytes, low cell yield of the cartilage biopsy, 
dedifferentiation of autologous chondrocytes in monolayer expansion, reduced 
chondrogenic potential of chondrocytes from aged patients or patients with osteoarthritis, 
and large inter-donor variability in the performance of autologous chondrocytes 
[125,128]. 
To mitigate these challenges, MSCs have been explored as an alternate cell source 
for cartilage repair, but inducing MSC chondrogenesis and maintaining a stable 
chondrogenic phenotype has thus far proved challenging, limiting their therapeutic 
potential [125]. When MSCs undergo chondrogenic differentiation in vivo, the 
chondrocytic phenotype is transient, as cells appear to be programmed for endochondral 
ossification, and thus eventually undergo hypertrophy and mineralization [37]. A variety 
of techniques have improved outcomes, including delivery of growth factors such as 
TGFβs, BMPs, FGFs, IGFs and PTHrP [37,129,130] as well as co-culture with articular 
chondrocytes [128,131–135].  Still, investigation of new techniques to promote and 
maintain the MSC chondrocytic phenotype is an active field of study.   
2.3 In Vitro Cell Culture Systems 
2.3.1 Hydrogels for In Vitro Cell Culture
3
 
 Recently, it has been realized that the culture of cells in 2D  limits the inclusion of 
parameters known to be important in the 3D in vivo environment, where cells have an 
ECM meshwork on which to communicate [2,4,96,136–139]. These parameters include 
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mechanical cues, communication between cells and matrix, and communication between 
adjacent cells [4]. To integrate these parameter into in vitro cell culture systems, 
hydrogels are  often used, as they are versatile, porous 3D constructs consisting primarily 
of water, providing a low barrier to soluble factor diffusion between cells [2,140,141]. In 
addition, hydrogels tend to be biocompatible and nonimmunogenic, and able to mimic the 
physical properties of tissues [29,142]. Synthetic and natural polymers can be used to 
form gels, either of which can be modified to achieve desired bioactivity [2,140,141]. 
Examples of natural materials include collagen, fibrin, hyaluronic acid, Matrigel, 
alginate, agarose, and GAG based scaffolds [29,143]. While natural materials can be 
useful, given their potential to provide cells with signals commonly found in the ECM, 
they tend to be heterogeneous and can have ill-defined properties [29].  
 Synthetic materials often cannot interact with cells prior to modification, 
providing researchers with a blank template to chemically modify [29]. Examples of 
synthetic materials include PEG, poly(2-hydrosy ethyl methacrylate), poly(acrylamide), 
and poly(N-isopropyl acrylamide), which do not naturally promote cell attachment, but 
can be modified with a variety of ECM protein sequences (i.e. RGD from fibronectin, 
YIGSR from laminin, or GFOGER from collagen) that encourage cell adhesion 
[29,143,144]. PEG is especially useful as it is FDA approved and tends to be protein, and 
thus cell, repulsive, allowing patterning of cells through specific placement of 
biomolecules [29,143,144]. Thus, established and emerging techniques to modify both 
natural and synthetic materials have allowed 3D hydrogel culture systems to better mimic 
the in vivo cellular microenvironment, and promise to enable more accurate analyses of 
dynamic cell behavior. 
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2.3.2 Integrating Complexity into Hydrogel-Based Culture Platforms 
 3D cell culture platforms are most often engineered to achieve one of two goals: 
1) develop a template to form a functional tissue or 2) create a platform for disease 
models [29,145,146]. Both of these applications require precise control over spatial 
localization of biomolecules, geometries, and mechanical properties [29]. Several 
techniques are used to pattern hydrogels for tissue engineering applications. Traditional 
techniques, such as solvent casting/particle leaching, freeze drying, and gas foaming 
allow for porous scaffolds with controllable mechanical properties, but are not able to 
provide the spatial patterns often desired for cell culture systems [29,143]. Recently, 
bioprinting has been used to deposit cells and prepolymer hydrogel solutions in specific 
spatial locations in a layer-by-layer approach [29]. While this technique is automated and 
can be used to develop relatively large layers of cells/polymer solutions, it is limited in its 
polymer and cell compatibility [29].  
 Photolithography, the use of light or photons to transfer the shape of a mask onto 
a light-sensitive surface, has been used to successfully pattern a variety of cell types, 
including hepatocytes, fibroblasts, C2C12 cells, endothelial cells, cardiac stem cells, 
HT1080 cells, embryonic stem cells, neurons, MSCs, osteoblasts, and adipocytes 
[29,32,33]. This technique can be applied in several different manners. In the simplest 
method, a photomask is developed and UV light is used to crosslink a photo-sensitive 
polymer solution that is not covered by the mask [29,33,147,148]. This method has been 
used to pattern RGD peptide sequences into PEG-DA hydrogels, achieving specific 
localization of human dermal fibroblasts [148]. In addition, a co-culture hydrogel with 
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spatially patterned tendon fibroblasts and MSCs was developed through use of 
photolithography and microfluidics [33].  
 Lithography techniques can also be carried out with lasers, in which multi-photon 
laser scanning techniques can be used to generate free-radicals at precise spatial 
locations, thus enabling reactions between the functional groups of a scaffold and 
biomolecules only at desired locations [146]. For example, multi-photon laser scanning 
was used to pattern RGD-peptides into vessel features, promoting human umbilical vein 
endothelial cells (HUVECs) and mesenchymal progenitor cells to organize around 
tubular networks in PEG-DA hydrogels [146]. In another study, two-photon laser 
scanning was used to pattern RGD into PEG-DA hydrogels to guide cell migration, as 
human dermal fibroblasts only migrated to areas of the hydrogel functionalized with 
RGD [149]. Finally, multi-photon lithography has also been used to develop selective 
patterning of a collagenase-sensitive peptide in PEG-DA hydrogels, which in the future 
could allow for cell-mediated gel degradation in specific, user-defined locations [150]. 
Thus, a variety of techniques are available to integrate complexity into 3D hydrogel cell 
culture systems. This complexity, which enables scaffolds to evolve with time through 
use of temporally controlled degradation or patterning of biomolecules, can guide 
dynamic cell behavior using strategies that mimic functions of the native ECM. Further 
assessment of ECM-cell interactions should be used to guide the design of future cell 
scaffolds. 
2.3.3 In Vitro Disease Model Systems for the Bone Marrow Microenvironment 
 In vitro models of disease can often enable deeper understanding of disease 
progression and potential therapies than can be gained in vivo [5,151]. While in vitro 
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model systems cannot account for systemic effects of disease or the drugs that treat them, 
they do allow for specific questions to be asked and assessed in an isolated system with 
reduced complexity as compared to the in vivo environment [5,151]. In addition, in vitro 
model systems allow for the use of human cells, which is helpful for cases in which 
animal and human cells behave differently and can reduce the likelihood of failure in 
clinical trials [5,151]. Finally, in vitro models allow for high-throughput assessment of 
various disease conditions and drugs [5,151]. Recently, it has been realized that relevant 
cellular communication as well as three-dimensional microenvironments are important 
factors for many disease models, and co-culture of two or more cell types as well as 
utilizing 3D scaffolds and hydrogels are frequently employed in disease models [5,151].  
 As discussed in Section 2.1, the bone marrow microenvironment is home to 
multiple cell types, including at least two stem cell populations, the mesenchymal stem 
cell and the hematopoietic stem cells, as well as mature endothelial cells, adipocytes, 
osteoblasts, and other hematopoietic progeny [31]. While the bone marrow 
microenvironment has been studied in vivo, in vitro models of the bone marrow 
microenvironment could be a powerful tool to study hematological diseases, MSC 
behavior in various conditions, and the relative contribution of different cell types in the 
niche to stem cell maintenance and behavior [31,152]. Historically, models of the bone 
marrow microenvironment have strived to better understand HSC behavior [31,152].  
Conventionally, a stromal feeder cell layer has been used to maintain HSCs in vitro, but 
these experiments have often been conducted on 2D surfaces that do not mimic the 3D 
microenvironment [31].  
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 In response, 3D models of the bone marrow microenvironment have been 
generated. In one example, 3D spheroids of MSCs and osteoblasts were used to study the 
migration, lodgment, and proliferation of HSCs [153]. It was observed that HSCs were 
more likely to home and remain inside spheroids with MSCs and osteoblasts as opposed 
to just MSCs alone [153], a result that would not have been possible to observe in a 2D 
system. In another system, bone marrow stromal cells were cultured on 3D ceramic 
scaffolds with hematopoietic cells under perfusion, and higher rates of bone formation 
were observed as compared to 2D cultures [154].  Another study showed that MSCs, 
which can reside in the perivascular niche, had enhanced osteogenesis and inhibited 
adipogenesis when cultured with HUVECS as opposed to fibroblasts [155]. These in 
vitro models of the bone marrow microenvironment indicate that cellular communication, 
as well as a 3D environment, are important for cell function and lay foundations for 
future disease models and in vitro drug testing.  
 Several in vitro model systems of the bone marrow microenvironment have 
demonstrated investigation of disease conditions and testing of therapeutics. One system 
modeled the ability of “third party”, or undamaged, MSCs to aid in hematopoietic cell 
transplantation after the damaging of resident stroma by toxic conditioning regimes 
(conducted to prepare tissues for transplantation) [156]. Third party MScs were able to 
enhance growth of the damaged stroma, a potential new strategy to improve 
hematopoietic cell transplant [156]. Another system modeled chronic myeloid leukemia 
(CML) by culturing osteogenesis-induced MSCs and bone marrow mononuclear cells 
from patients with CML on decelluralized bone [157]. Overall, results indicated that the 
3D system was more likely than a similar 2D system to recapitulate the progression of 
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leukemia, and will allow more studies to be conducted in the future [157]. Finally, an 
artificial bone marrow microenvironment was developed by implanting a 
polydimethylsiloxane (PDMS) device coated with collagen I and bone-inducing powder 
in a mouse to create functional bone and bone marrow in vivo [158]. Then, the device 
was retrieved, connected to a microfluidic device, and co-cultured with HSCs under 
perfusion, which enabled maintenance of a larger population of long-term HSCs than 
traditional stroma-feeder layer culture [158]. Finally, the system responded to radiation 
and a radiation countermeasure drug in a similar fashion to in vivo marrow, validating the 
platform for further disease and drug testing [158]. Overall, these studies highlight the 
ability to better understand the bone marrow microenvironment through in vitro models, 
and suggest that utilization of in vitro models will enable deeper understanding of bone 
marrow disease and treatments. 
2.3.4 Modulating Chondrogenesis In Vitro 
 In vitro models of chondrogenesis are often used to investigate the influence of 
various materials, soluble factors, and other cell types on chondroprogenitor cells and 
chondrocytes. In this section, the in vitro culture of bone marrow-derived MSCs will be 
considered. Chondrogenic differentiation of MSCs is generally carried out in 3D, either 
in dense cell aggregates or within a scaffold, which are often hydrogel-based [37]. A 
variety of materials have been used for hydrogel-based scaffolds for chondrogenic 
differentiation of MSCs, including CS, heparin, hyaluronic acid (HA), alginate, agarose, 
collagen, fibrin, polypeptides, chitosan, cellulose, PLGA, and poly(lactic acid) (PLA), 
and PEG [38,39,159–162]. As CS and heparin will be discussed further in Section 2.4.3, 
they will not be included here. A variety of material properties can influence 
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differentiation, including hydrogel cross-linking density. For example, increased cross-
linking density in HA-based hydrogels resulted in decreased cartilage matrix deposition 
and increased hypertrophy in encapsulated MSCs [163,164]. Similarly, enhanced MSC 
chondrocytic differentiation was observed with increased permeability of poly(ε-
caprolactone) scaffolds [165]. While the exact mechanism is unknown, it is speculated 
that increased scaffold permeability enhanced nutrient (and likely growth factor 
supplement) diffusion to MSCs, and may also be conducive to formation of cellular 
condensations [163–165].  
 Another important hydrogel property is the ability of cells to adhere to the gel, 
usually achieved by integrating biochemical moieties into the hydrogel that facilitate 
integrin binding. However, the distribution (or relative spacing) of these binding sites can 
influence MSC differentiation. For example, as the density of the fibronectin-derived 
peptide sequence RGD was increased in alginate hydrogels, MSC chondrogenesis was 
increasingly inhibited, possibly due to restrictions in integrin clustering [166]. However, 
this does not indicate that cell adhesion to hydrogels is not important for chondrogenesis, 
as a study with agarose hydrogels and polypeptide hydrogels showed significantly higher 
MSC chondrogenesis in the polypeptide hydrogels, likely due to cell adhesion [167]. 
Similarly, in a study with adipose derived stem cells, enhanced chondrogenesis was 
observed on collagen type II as compared to collagen type I gels, likely due to integrin-
mediated signaling pathways allowing cells to take on a rounded shape [168]. Finally, 
protein-binding properties of hydrogels can modulate growth factor concentration in a 
manner that enhances or restricts differentiation. While a more extensive overview is 
provided in Section 2.4.5, one example is the ability for sulfated alginate hydrogels to 
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enhance MSC chondrogenesis as compared to alginate hydrogels due to increased TGFβ-
1 binding [169]. Overall, the properties of the materials used to culture MSCs can 
influence chondrogenic potential. 
 In most cases, chondrogenesis is induced with soluble factors, which can be 
delivered individually, in combination, or over time [170]. Growth factors delivered 
include TFGβs 1,2, and 3; BMPs 2,4,6,7,9, 13, and 14; FGF-2; and IGF-1 [161,170], 
most of which are involved to some extent in endochondral ossification in vivo (see 
Section 2.2.1) [23]. While the impact of these growth factors varies greatly from 
experiment to experiment and is dependent on culture conditions, TGFβs appear to be the 
most chondro-inducive, while FGF-2 is often observed to enhance chondrocyte 
proliferation rate [170]. BMPs and IGFs are occasionally added in combination with 
TGFβs, but effects vary drastically, likely due to cell source and culture conditions 
[161,170]. Because growth factor concentrations change during chondrogenic 
differentiation in vivo, temporally controlled delivery of growth factors has been 
suggested as a means to better control differentiation [37], and has been met with some 
success [129,170]. While delivery of growth factors to induce chondrogenesis shows 
promise, optimal combinations and delivery timelines remained to be determined. 
 Recently, co-culture of MSCs with chondrocytes has been explored as an alternate 
mechanism to direct chondrogenic differentiation. Several studies have investigated the 
influence of chondrocyte-conditioned medium on MSCs [131,171], but found that direct 
co-culture between MSCs and chondrocytes produced much stronger increases in 
chondrocytic markers and decreases in hypertrophic markers [131], suggesting that 
cellular communication is required for improved MSC chondrogenesis in the co-culture 
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context. To this point, co-culture studies that have been conducted in transwell systems 
[128,132] and on scaffolds and hydrogels [133–135] have shown the potential of co-
culture to induce MSC chondrogenic differentiation. In addition, co-culture pellet 
systems have been investigated as a means to both induce MSC chondrogenesis and 
prevent MSC hypertrophy and chondrocyte de-differentiation. In several studies, it has 
been shown that MSC in pellet co-culture with chondrocytes at ratios ranging from 50:50 
to 95:5, respectively, have shown enhanced chondrogenesis and a reduction in 
hypertrophic markers as compared to monoculture controls [128,134,172,173]. These 
studies suggest that the communication between chondrocytes and MSCs allows 
maintenance of the chondrocytic phenotype. Overall, chondrogenesis is strongly 
dependent on both scaffolds and soluble factor delivery. However, techniques that utilize 
scaffolds and soluble factors in a manner that accounts for the dynamic temporal changes 
that occur during differentiation have yet to be fully realized. 
2.4 Glycosaminoglycans and Protein Sequestration 
2.4.1 Function of Heparan Sulfate and Heparin  
Heparan sulfate (HS) and heparin are GAGs of similar structure that are 
implicated in regulating both developmental processes and adult tissue homeostasis 
through their strong affinity to proteins [174,175]. The diverse function of HS and 
heparin can be attributed to their structure. HS and heparin are polysaccharide chains of 
repeating disaccharide units (uronic acid residue and a glucosamine residue) that can be 
modified by the addition of sulfate groups [26,174,176]. Overall, heparin has a much 
higher degree of sulfation, more negative charge, and is less structurally diverse than 
heparan sulfate [177]. Another difference between HS and heparin is the common uronic 
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acid residue found in their disaccharide repeat units. While an N- and 6-O-sulfated or N-
acetylated D-glucosamine residue is common for both,  2-O-sulfated L-iduronic acid and 
D-glucuronic acid are the common uronic acid residue for heparin and heparan sulfate, 
respectively [26]. The specific sulfation pattern and the overall strong negative charge of 
HS and heparin GAGs are thought to be two of the primary factors that allow protein 
interactions [175]. In the body, HS is attached to membrane-bound (syndecans, 
glypicans, betaglycans) or ECM associated (perlecan, agrin, collagen XVIII) core 
proteins to form HS proteoglycans (HSPGs) [174,175]. On the cell membrane, HS acts to 
facilitate ligand-receptor binding and in the ECM, participates in the development of 
morphogen gradients and is thought to protect growth factors from degradation 
[174,175,177,178]. Alternatively, heparin is found primarily in connective-tissue type 
mast cells, attached to the core protein serglycin in intracellular storage granules 
[26,175]. When released from the cell, heparin acts as an anticoagulant in the coagulation 
cascade either directly or indirectly by enhancing antithrombin-thrombin binding 
[177,179].  
HS has been found to bind over four hundred proteins, including growth factors, 
enzymes, cytokines, and ECM molecules, and is implicated in diverse processes such as 
ECM assembly, cell signaling, and developmental processes [180]. Growth factors are of 
particular interest in tissue engineering applications, and HS facilitates signaling and 
gradient formation for a plethora of growth factors [178]. For example, heparan sulfate is 
known to act as a co-receptor between FGF-2 and its cell surface receptor and effectively 
reduces the concentration of FGF-2 required to initiate signaling and prolongs the 
signaling response [174]. It has also been suggested that heparan sulfate modulates the 
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range that IHH can travel in vivo, and may act as a low affinity binding agent to present 
the protein at the cell surface [178]. Heparan sulfate is believed to function similarly with 
BMP-2, as studies with decapentaplegic (DPP), the drosophila homolog for BMP-2, 
found that genetic modifications reducing heparan sulfate concentrations resulted in 
decreased ability for DPP to travel long distances [181]. Finally, evidence from studies 
with Wg, the WNT homolog in drosophila, indicate that heparan sulfate likely acts to 
protect Wg and enables it to travel longer distances, and also may act as a co-receptor at 
the cell surface [182]. Overall, these studies point toward modulating growth factor 
concentration and presentation to the cell surface as a major role for heparan sulfate.   
2.4.2 Heparan Sulfate and Other Glycosaminoglycans in Chondrogenesis 
 To study how HS and HSPGs influence endochondral ossification (as well as 
many other developmental processes), typically genes or enzymes essential to HS 
production or sulfation are knocked-out or knocked-down in murine animal models and 
resulting phenotype is evaluated [183]. In one such study, the HSPG perlecan was 
knocked-out and reduced chondrogenic differentiation and matrix deposition was 
observed [184], possibly indicating a requirement for matrix-associated HS in driving 
differentiation. In contrast, another study indicated that higher than normal levels of 
sulfated GAGs reduced differentiation. In this study, knock-out of Sulfatase-Modifying 
Factor 1 (Sumf1; master regulator of proteoglycan desulfation) prevented GAG 
desufation. Overall, it appeared that higher than normal levels of GAG sulfation 
prevented differentiation from proceeding, likely due to increased FGF signaling [185]. 
Similar evidence of HS involvement in controlling spatial localization of growth factors 
has been found in several studies in which exostosin glycosyltransferase 1 (EXT1), an 
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enzyme responsible for polymerization of the HS chain, was knocked-down, resulting in 
reduced levels of HS. In one study, this increased the distance over which IHH could 
have an effect, possibly indicating that the normal function for HS is to sequester IHH 
and restrict its distribution and long range transport throughout the tissue [186]. 
Similarly, when EXT1 was knocked down in chondrocytes, ectopic cartilage formation 
was observed around the growth plate, likely due to increased proliferation of 
chondrocytes in abnormal spatial locations due to the loss of the ability of HS to control 
and restrict BMP-2 movement through the ECM [187]. Many similar studies have been 
conducted, and while these studies are only beginning to elucidate the true roles of HS 
and HSPGs in chondrogenesis, they all indicate that HS is necessary for tissue 
development, likely due to its ability to modulate growth factor signaling and matrix 
distribution. 
2.4.3 Glycosaminoglycan-Based Biomaterials for Cartilage Repair 
 GAGs such as CS, dermatan sulfate, HA, and heparin have been integrated into 
scaffolds to enhance chondrocytic differentiation of chondrocytes and mesenchymal stem 
cells [38,39,159,160]. The focus of this section will be on CS and heparin, two highly 
sulfated GAGs that are likely to be involved in protein sequestration in a chondrocytic 
environment. Cartilage tissue scaffolds are often composed of a base material, such as 
collagen II, chitosan, or synthetic polymers, into which GAGs are incorporated 
[38,160,188–191]. Chondroitin sulfate is a commonly used GAG in cartilage repair 
scaffolds, and generally enhances the chondrocytic phenotype of cells encapsulated in or 
seeded on the scaffold [160,189–192]. Heparin is used less frequently, but has been 
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incorporated into dextran-based hydrogels and shown to enhance chondrocyte 
differentiation as compared to dextran controls [38].  
 GAGs are incorporated into scaffolds for several reasons, including to better 
mimic the natural cartilage ECM, enhance cell adhesive properties, control mechanical 
properties through increased water retention, and modulate protein presentation to cells 
[38,160,189–194]. As TGFβ-1 or 3 is often used as a supplement in chondrocytic cell 
culture, it is possible that GAGs in the scaffold sequester and prolong its activity, further 
enhancing chondrocytic differentiation [38,194]. Evidence of this was found in a study in 
which heparin or desulfated heparin was coated onto MSC aggregates, and it was shown 
that chondrogenesis was enhanced in the desulfated heparin group as compared to the 
fully-sulfated group or non-coated group. In these studies, it is possible that 
supplemented TGFβ-1 was attracted to both heparin and desulfated heparin, but that 
desulfated heparin resulted in increased detachment of TGFβ-1, as the coating was less 
charged, which was then better able to interact with cells [195]. Overall, GAGs have been 
used to enhance chondrogenesis with moderate success, likely due to modulation of 
protein sequestration and presentation to cells. Interestingly, similar to their natural 
function in vivo, these GAGs are able to bind a plethora of proteins involved in 
differentiation over time, enabling them to act upon multiple differentiation stages. 
However, in-depth analyses of how GAGs themselves modulate cellular differentiation 
due to protein binding have yet to be conducted. 
2.4.4 Heparin-Based Biomaterials 
 Given their high affinity for a plethora of growth factors and proteins (often with 




 M), heparin and heparan sulfate have been 
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used for a variety of tissue engineering applications [9]. Because interactions with 
heparin and heparan sulfate are specific but not covalent, they allow for protection and 
sustained release of growth factors, mimicking the role of ECM components in vivo [9]. 
Overall, heparin and heparan sulfate are biocompatible, relatively non-toxic, and 
inexpensive [196], incentivizing their use in vivo. As such, heparin and heparan sulfate 
have been delivered to modulate endogenous protein, used in cell culture systems to 
modulate protein localization, and used in delivery vehicles to enhance protein affinity.  
 Heparan sulfate has been mixed into hydrogel-based delivery systems and 
implanted into injury models to evaluate healing without delivery of exogenous growth 
factors. In one example, heparan sulfate was mixed with carboxymethylcellulose/glycerol 
to form a gel and implanted into a critical sized bone defect in a rat femur [197]. After 
two weeks, significantly improved bone formation was observed in the low dose heparan 
sulfate group, as compared to no and high heparan sulfate groups [197]. While the 
mechanism of action is unknown, it was hypothesized that the ability of heparan sulfate 
to interact with endogenous proteins was responsible for the enhanced differentiation 
[197]. In addition, the diminished effectiveness at high dosage may have been due to 
increased binding of growth factors, therefore decreasing growth factor availability to 
cells. In another example, heparan sulfate was mixed with fibrin glue and implanted into 
a critical sized cranial defect in a rat model [198]. After 3 months, enhanced defect 
closure was observed in the group with heparan sulfate, as opposed to control groups 
[198]. These two studies indicate the ability of heparan sulfate modulate the local cellular 
microenvironment, likely through growth factor binding.  
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 Heparin has also been cross-linked into hydrogels for cell encapsulation and 
controlled growth factor delivery. Heparin can be physically encapsulated (through 
entanglement or electrostatic interactions) or covalently cross-linked into hydrogel 
matrices [9]. Heparin has been incorporated into PEG, HA, peptide-based, poly(N-
isopropylacrylamide-co-acrylic acid), poly(vinyl alcohol), poly(L-lactide-co-ε-
caprolactone), dextran, alginate, and chitosan based hydrogels [38,53,54,196,199–203]. 
Heparin-based hydrogels for cell encapsulation have often been used toward the goal of 
inducing osteogenic or chondrogenic differentiation. In one example, methacrylated 
heparin was cross-linked with PEG-dimethacrylate for encapsulation of MSCs, and was 
shown to enhance osteogenesis, possibly through enhanced presentation of fibronectin 
and BMP-2 [45]. In another example, encapsulation of cardiac progenitors in a heparin-
hyaluronic acid hydrogel enhanced cell differentiation [41]. Assessment of growth factors 
trapped within the hydrogel indicated that heparin-mediated sequestration of endogenous 
factors was likely a contributing factor to improved cell behavior [41]. Similar results 
were observed when MSCs encapsulated in PEG-DA/oligo(poly(ethylene glycol) 
fumarate) (OPF) and heparin methacrylamide (MAm) hydrogels were co-cultured with 
osteoblasts [40]. Enhanced MSC osteogenesis was observed as heparin content in the gels 
was increased, possibly due to the ability of heparin to trap osteoblast-secreted factors 
that promoted MSC differentiation [40]. Another study indicated that heparin-thiol PEG-
DA hydrogels were able to trap endogenous TGFβ-1, enabling re-differentiation of de-
differentiated chondrocytes [39]. Finally, enhanced chondrogenesis was observed in 
chondrocytes encapsulated in dextran-tyramine/heparin-tyramine gels cross-linked with 
horseradish peroxidase, likely due to either improved fibronectin or growth factor 
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presentation to cells [38]. These studies suggest that heparin-based hydrogels can 
modulate both endogenous and exogenous protein presentation to cells for enhanced 
differentiation.  
Heparin has been used to enhance protein loading and stability in many controlled 
delivery vehicles [3,11,42,196]. Often, heparin is covalently modified and cross-linked 
into hydrogels to control delivery of proteins such as FGFs, BMPs, VEGFs, TGF-βs, and 
other positively charged proteins to enhance osteogenesis, chondrogenesis and wound 
healing [53,54,56,204]. In general, reduced burst released and lower overall release is 
observed in hydrogels that contain heparin due to increased attraction of proteins to the 
hydrogel system [56,200,203,205]. In one case, this resulted in an inability to enhance in 
vivo bone formation with BMP-2 delivery from a heparin-based hydrogel, likely due to 
reduced early protein release [205]. However, sustained release of BMP-2 from a 
heparin-poly(L-lactide-co-ε-caprolactone) scaffold improved mineralization at the 
ligament-bone interface [201], indicating that heparin and BMP-2 dosage must be tightly 
controlled to achieve desired differentiation. In addition, starPEG-heparin hydrogels have 
been formed by reacting activated heparin carboxyl groups with amine-functionalized 
PEG using EDC/NHS chemistry, and used to deliver TGFβ-1 for enhanced myofibroblast 
differentiation and FGF-2 and VEGF for improved HUVEC viability [56,204]. Thus, 
incorporation of heparin into controlled delivery vehicles can modulate the rate of protein 
release, and can be tuned to enhance cell behavior. Overall, these studies indicate the 
ability of heparin to modulate protein sequestration and release when integrated into 
biomaterial scaffolds for tissue engineering regeneration and repair. Still, the contribution 
of heparin materials to endogenous protein sequestration and release has remained poorly 
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understood, and more mechanistic studies should be conducted to better understand the 
potential of heparin-based materials to interact with native proteins. 
2.4.5 Biomaterial-Mediated Protein Sequestration 
 While biomaterials have been primarily used as cell scaffolds and otherwise inert 
delivery vehicles, it has recently been suggested that biomaterials themselves be used to 
manipulate the cellular microenvironment [3]. This technique could potentially be very 
effective, as it proposes to harness potent, cell-derived protein to either reduce or amplify 
cell-signaling. Overall, this technique promises to reduce cost and lessen the 
requirements for FDA approval [3], and has just begun to be explored in tissue 
engineering applications.  
 Due to their intrinsic ability to interact with protein in vivo, natural materials such 
as heparin, chondroitin sulfate, and peptide sequences have been used to modulate 
endogenously produced proteins. One common application for material-based growth 
factor sequestration is cartilage tissue engineering, where scaffolds containing 
chondroitin sulfate and heparin are often used partially as a means to sequester both 
exogenous TGFβ added to the media and endogenously produced proteins 
[38,189,190,192,194]. A recent study proved the utility of this technique. In this study, a 
heparin-based scaffold laden with chondrocytes was investigated after in vitro culture and 
in vivo subcutaneous injection to evaluate levels of TGFβ-1. In both cases, the amount of 
TGFβ-1 increased over time, suggesting that the materials were able to effectively 
sequester and concentrate at least exogenously added TGFβ-1, and possibly cell-secreted 
TGFβ-1 as well [39].  In a similar fashion, hyaluronic acid-heparin based hydrogels were 
used to present TFG-β1 to encapsulated cardiac progenitor cells, and it was found that 
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enhanced levels of angiogenic cytokines were sequestered by heparin-containing gels, 
which likely contributed to observed increases in cell function and survival [41]. In a 
slightly different tone, heparin was used to culture MSCs and prime them toward an 
osteogenic lineage, possibly by sequestering osteogenic growth factors secreted by 
neighboring osteoblasts [40]. Finally, it was shown that self-assembling peptide fibers 
with a TGF-β binding sequence resulted in enhanced cartilage repair when implanted into 
a full thickness cartilage defect in a rabbit animal model, likely due to the ability of the 
scaffold to sequester endogenous TGF-β [44].  
 While the examples above primarily point to examples in which growth factor 
function was amplified, other materials have been used to sequester and reduce protein 
effectiveness. A VEGF-binding peptide sequences integrated into PEG MPs reduced 
proliferation of human umbilical vein endothelial cell (HUVEC), likely due to 
sequestration of VEGF away from the cells [43]. In another study, a PEG-based hydrogel 
was modified with a tumor necrosis factor-α (TNFα)-binding peptide sequence in an 
attempt to protect encapsulated cells from the pro-inflammatory environment often 
encountered after hydrogel implantation. Cells encapsulated in TNFα-antagonizing 
hydrogels were unaffected by high TNFα concentrations in in vitro experiments [46], 
pointing toward the utility in engineering hydrogels to selectively decrease the 
concentration of undesirable proteins.  In a study examining kidney development in vitro, 
normal growth of kidney rudiments from E11.5 mice was increasingly inhibited as 
heparin concentrations were increased [206], suggesting that heparin sequestered 
essential proteins away from the cells in the developing tissue.  
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 Several techniques to antagonize proteins in vivo have also been carried out in 
craniosynostosis models. Craniosynostosis involves the premature closure of cranial 
sutures, and while surgical intervention can be employed to successfully separate the 
fused bones, re-fusion, or resynostosis, often occurs [207,208]. To prevent this, collagen 
gels with antibodies against proteins implicated in the bone fusion process, including 
anti-TGFβ-2 and anti-FGF-2, have been delivered to the site of the suture [209,210].  
This therapy is only partially successful due to the limited half-life of these antibodies 
[209,210], but similar approaches with more robust protein-sequestration technique may 
be beneficial for craniosynostosis and resynostosis in the future. While still a relatively 
new concept, these studies highlight the plethora of opportunities available for 
biomaterial-mediated endogenous protein sequestration, to both eliminate and prolong 
protein presentation in the cellular microenvironment. 
2.5 Microparticles 
 Microparticles (also called microspheres) are used frequently for drug and protein 
delivery [211]. Compared to larger delivery vehicles, MPs are particular advantageous 
because they are injectable and have a high surface area to volume ratio, allowing 
enhanced cargo release [211]. In general, high encapsulation efficiency and sustained 
release of bioactive molecules are the goals for MP delivery vehicles [211]. While many 
MP formulations have an unavoidable burst release of encapsulated cargo, the goal of 
most MP technologies is sustained release [211]. Often, MPs are engineered to be 
degradable to enhance release of the loaded cargo, but release is not always directly 
correlated to degradation [211]. While many different materials have been used to 
fabricate MPs, this review will focus on PEG and GAG based MPs.  
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2.5.1 Poly(ethylene-glycol) -Based Microparticles in Tissue Engineering 
 PEG is an attractive material for protein delivery because it is hydrophilic, 
relatively inert (i.e. it does not bind many proteins), and easy to chemically modify [28]. 
Traditionally, it has been integrated into hydrophobic PLA or PLGA MPs to enhance 
protein loading and release [212–216]. PEG has both been used in combination with 
PLGA, PLA, and alginate or alone to enhance MP release of hydrophobic drugs such as 
paclitaxel [214], genistein [217], and dexamethasome [218], and proteins such as 
VEGFA [219], lysozyme [213], horseradish peroxidase [218]. More recently, PEG has 
been chemically modified with peptide sequences to impart protein-binding capabilities, 
facilitate cell adhesion, or to enhance degradation. For example, 4-arm PEG norbornene 
was functionalized with a VEGF peptide binding sequence to enhance VEGF 
sequestration onto the MPs [43]. In another study, RGD (arginine-glycine-aspartic acid, 
an amino acid sequence from the fibronectin protein that promotes cell adhesion) was 
incorporated into 8-arm PEG-vinylsulfone/PEG-amine MPs to promote MSC adhesion in 
aggregate culture [220]. Finally, a MMP-sensitive sequence was integrated into a PEG-
diacrylate (DA) hydrogels to enhance cell-mediated degradation. These MPs showed a 
faster release rate of hydrophilic and hydrophobic model drugs, as well as a model 
protein, with increased collagenase concentration [218].  
 Hydrolytically degradable PEG-DA MPs have also been fabricated by taking 
advantage of the increased susceptibility to hydrolysis of the acrylate ester bond when 
covalently bound to DTT [60]. 4-arm PEG-DA MPs exhibited accelerated rates of 
degradation as levels of DTT were increased [221]. Overall, these studies show the 
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diversity of PEG-based MPs that have been used for protein loading and release and in 
other tissue engineering applications.  
2.5.2 Glycosaminoglycan-Based Microparticles in Tissue Engineering 
 In contrast to PEG, GAG based materials have the potential to bind a plethora of 
positively charged proteins. Heparin is often used in microparticles to both prolong the 
duration of growth factor release and protect growth factors from degradation, thus 
prolonging bioactivity [53,54]. Specifically, heparin-based hydrogels have been used to 
deliver FGF, BMP-2, hepatocyte growth factor, VEGF, and other proteins to enhance 
cellular behavior [53–56]. Heparin has been integrated into a variety of MP systems and 
is often coated onto a MP template via layer-by-layer techniques. For example, heparin-
poly-L-arginine microcapsules were fabricated using a layer-by-layer approach on 
calcium carbonate microspheres and used to deliver TGF-β to fibroblasts, inducing their 
transdifferentiation into myofibroblasts [222]. Heparin coatings have been applied to both 
alginate and HA MPs and loaded with BMP-2 to enhance bone formation in vivo [223] 
and MSC chondrogenesis in vitro [224,225].  
 Pure heparin MPs have also been fabricated and used for growth factor delivery. 
In one study, low MW heparin was mixed with protamine to form MPs for FGF-2 
delivery, leading to neovascularization and fibrous tissue formation when injected 
subcutaneously into mice [57]. In another study, methacrylamide-functionalized heparin 
MPs were fabricated via free radical polymerization methods and used to deliver BMP-2 
to C2C12 cells, showing comparable ALP activity to that obtained by soluble BMP-2 
delivery [59]. In a similar set of studies, 1-10% of a thiolated heparin and several heparin 
derivatives with altered sulfation patterns were incorporated into 4-arm PEG-DA MPs, 
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and BMP-2 bioactivity was preserved in heparin and the derivative with the next highest 
level of sulfation, as compared to derivatives with lower sulfation [58].  
 CS MPs have also been fabricated, with the goal of enhancing biocompatibility 
[226] or increasing loading and release capabilities [227]. Often, complex coacervation or 
chemical cross-linking of CS and another polymer, such as gelatin, chitosan, or collagen, 
is used to form CS-containing microparticles. This technique has been used to make MPs 
for release of ovalbumin, albumin, catalase, and an anti-cancer drug, 5-fluorouracil 
[226,228–230]. CS and dermatan sulfate have also been incorporated into PLGA MPs to 
enhance protein stability and to better control loading and release [227,231]. Finally pure 
CS MPs have also been employed for tissue engineering applications. Methacrylated 
chondroitin sulfate MPs were formed and able to be incorporated into embryonic stem 
cell aggregates without affecting viability [232], and produced slight upregulation of  
chondrocytic markers when incorporated into MSC aggregates [233]. Overall, GAG-
based MPs are beneficial for preservation of protein bioactivity, enhancing release 
profiles of both hydrophilic drugs and proteins, and for enhancing MP biocompatibility. 
Due to their size and shape, MPs have the capability to interact with cells directly in the 
cellular microenvironment through material-protein-cell interactions, and possibly direct 
cell-material interactions. These interactions should be harnessed to guide and study cell 
behavior in future studies.  
2.5.3 Core-Shell Microparticles 
 When using microparticles for drug and biomolecule delivery, major obstacles 
include minimizing burst release and controlling release kinetics of bioactive cargo 
[52,234–237]. In response to these challenges, core-shell microparticles have been 
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fabricated, towards the goal of prolonging release of a drug or biomolecule encapsulated 
in an inner core by manipulating the degradation prolife of an outer shell [51,52,236]. In 
general, core-shell MPs are generated via a double emulsion process or by pre-fabricating 
the inner core and coating or re-emulsifying the inner core with the shell polymer 
solution, either in a large batch process or using a microfluidic device [236,238–242]. 
Batch emulsification fabrication methods (high-shear processes like precipitation, spray-
drying, and phase separation) have the benefit of requiring little specialized equipment 
but can have low throughput and generate heterogeneous MPs; microfluidic devices 
require extensive expertise and specialized equipment but generate uniform MPs with 
high throughput [52,240,243,244]. Depending on requirements of the MP systems and 
resources available, core-shell MPs can be fabricated in a variety of ways. 
 Core-shell MP delivery systems have been traditionally employed for small 
molecule or drug delivery [234,238,240,243], but their utility in delivery of biomolecules 
to cell-based systems has just begun to be explored. As noted by several research groups, 
core-shell MPs have the potential to enable temporal control over the release of one or 
more growth factors to cells, possibly on different time-lines, which could be beneficial 
for cell differentiation processes where temporal control over protein delivery is critical 
[237,245]. For example, VEGF was encapsulated in alginate MPs and then coated with 
chitosan and polycaprolactone, which resulted in a lower burst release and longer release 
duration [52]. Core-shell MPs also have potential to enhance protein stability. In one 
example, FGF was mixed with heparin and trapped in a calcium carbonate core MP, then 
coated with dextran sulfate and poly-l-arginine. Similar proliferation of mouse fibroblasts 
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was observed when subjected to free FGF or FGF-loaded core-shell MPs, indicating that 
entrapment in the MPs preserved protein bioactivity [246].  
 Finally, dual-release of proteins and drugs has been achieved by encapsulating 
one protein or drug into the core, and another into the shell. As the core and shell material 
can have different chemical properties, this can allow for efficient encapsulation of drugs 
and proteins with different properties. One example of this is core-shell PLGA-alginate 
MPs, fabricated to achieve dual-release of VEGF and platelet-derived growth factor 
(PDGF) to HUVECs, and cells sprouted and produced capillary-like structures in 
response to biomolecule delivery [247]. Similar core-shell MPs were used to encapsulate 
BMP-2 and dexamethasone, and BM-MSCs encapsulated in the shell layer were seen to 
undergo enhanced osteogenesis as compared to controls [245]. These studies indicate that 
core-shell MPs can be used to successfully deliver proteins and other biomolecules and 
have potential to improve protein stability and better control loading and release 
dynamics.  
 In addition to drug and biomolecule delivery, MPs have also been used to 
sequester various biological agents for diagnostic tests, removal from human plasma, and 
biosensors [47–50]. Core-shell MPs are of particular interest in these processes, as the 
materials used for the core and the shell can impart distinctly different properties onto the 
MP system. For example, in several studies that have aimed to sequester biomarkers from 
bodily fluids, the outer shell is engineered to exclude large proteins, especially albumin, 
but to allow passage of smaller proteins. Then, the inner core is designed to trap smaller 
proteins once they have entered the MP matrix, effectively allowing for the capture of 
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low-concentration biomarkers from a given fluid [48–50]. The design principles used to 
engineering these MPs could be applied to multifunctional core-shell MPs in the future.  
2.5.4 Microparticles in Cell Spheroids 
 Recently, dense cell aggregates (also called spheroids or pellets) have been used 
as an alternative to monolayer cell culture, as cell aggregates are thought to better mimic 
the in vivo cellular microenvironment [248–251]. The higher cell-cell and cell-matrix 
contacts created in aggregate culture may be contributing factors to the enhanced cell 
survival, function, and differentiation observed in cells in aggregate culture 
[248,249,252]. For example, it has been well-established that chondrogenic 
differentiation of MSCs and spontaneous differentiation of embryonic stem cells (ESCs) 
is enhanced in aggregate culture [249,253]. Furthermore, unlike larger cell-seeded 
scaffolds, cell aggregates can be injected into sites of tissue injury, possibly promoting 
regeneration and repair [254]. However, aggregate culture can be problematic due to 
diffusion limitations for nutrients and oxygen [248,252,255,256]. In addition, in cases 
where delivery of exogenous growth factors is required, cells on the exterior of the 
aggregate will be exposed to that factor at a much higher level than cells on the interior, 
creating possibly undesirable spatial variance throughout the aggregate [255]. Finally, for 
injectable cell aggregate therapies, maintaining control of cell behavior within the 
aggregate after injection could be advantageous. To overcome these limitations, MPs 
have been incorporated into aggregates, both toward the goal of reducing diffusion 
limitations and to delivery soluble factors homogenously throughout the cell aggregate 
for better controlled cell behavior.  
 55 
 A variety of materials have been used to make MPs for incorporation into cell 
aggregates, including PLGA [251,253,255,257–259], PLA [251], chitosan [251,260], 
gelatin [248,252,259–261], Sephadex (dextran) [262], polystyrene [250], heparin [263], 
agarose [259], alginate [254], and PEG [220]. For some of the initial studies that 
developed MP-containing cell aggregates, adherent cells and MPs were cultured in non-
adherent dishes or bioreactors, which promoted cell adhesion to the MP surface, and 
eventual formation of aggregates [251,262]. However, the size of these aggregates and 
the number of incorporated MPs was difficult to control, and current methods mix MPs 
and cell prior to deposition into low-binding well plates or agarose wells.  
 Several general concepts and conclusions have resulted from the numerous MP-
cell aggregate studies conducted. First, it has been observed that aggregate formation is 
dependent on the size and number of MPs used. Too many MPs or MPs that are large can 
disrupt the cell-cell contacts required for aggregate formation [252]. Incorporation of 
MPs into aggregates can affect cell behavior, even if growth factors are not delivered. For 
example, gelatin MPs have been observed to enhance chondrogenesis in MSC aggregates 
[252], which may possibly be due to (or cause) the increased stiffness observed in MSC 
aggregates containing gelatin MPs observed in a separate study [248]. Relatedly, MPs of 
similar size but composed of different materials can affect cells differently [259]. 
Additionally, when loaded with an equal amount of growth factor per MP mass, larger 
numbers of smaller MPs have more of an effect than smaller numbers of larger MPs 
[253,261], indicating that release kinetics or MP distribution throughout the matrix is 
important to consider in aggregate culture. Finally, magnetic MPs can be used to 
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assemble spheroids into larger structures, allowing for potential spatial patterning of 
discrete cellular units in future experiments [250].  
 Microparticles have often been incorporated into cell aggregates to enhance cell 
differentiation. As MSC aggregate culture is a common technique to induce chondrogenic 
differentiation, several studies have investigated the incorporation of MPs in MSC 
aggregates. Chitosan-gelatin, gelatin, PLGA, and chondroitin sulfate-based MPs have all 
been used to deliver TGFβ-1 within MSC aggregates. In general, enhanced 
chondrogenesis (as evidenced by collagen II and GAG deposition, among other markers) 
was observed in groups with MPs that delivered TGFβ-1 [256,260,261,264]. Alginate 
and 8-arm PEG-based MPs have also been functionalized with the cell-adhesive sequence 
RGD and incorporated into MSC spheroids, resulting in enhanced chondrogenesis 
without delivery of a biomolecule [220,254]. ESCs are also more likely to undergo 
differentiation in 3D, which has led to incorporation of MPs within embryoid bodies 
(EBs). Retinoic acid delivery from PLGA MPs has been shown to be more effective than 
soluble delivery, and results in cystic EB formation [253,255]. In addition, BMP-4 
delivery from heparin-gelatin MPs spatially oriented in one part of an EB showed 
localized Brachyury-T induction [263]. Several other examples of differentiation include 
gelatin MPs for osteogenic MSC differentiation [252], PLGA MPs for enhanced 
adipogenesis in the pre-adipocyte 3T3 L1 cell line [257], and nerve growth factor-loaded 
PLGA MPs for enhanced neuronal activity [258]. As a whole, these studies illustrate the 
utility of incorporating MPs in dense cell aggregates to control cellular differentiation and 
behavior. Of specific interest, the ability of protein-binding microparticles (such as those 
composed of GAGs) to sequester and release proteins within the cellular aggregate 
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microenvironment could be very beneficial to further harness the differentiation potential 
of progenitor cells for tissue regeneration and repair applications. 
2.6 Systems Biology Approaches to Tissue Engineering 
 As biological assay techniques become more high-throughput and generate large 
arrays of data, univariate analysis techniques are unable to fully elucidate interactions, 
correlations, and multi-factor responses between measured variables [265–268].  In 
addition, analyses of biological systems are most powerful if multiple cell responses are 
investigated across several timepoints and conditions [266,268,269]. Thus, multivariate 
analysis techniques have recently been implemented to gain a more comprehensive 
understanding of cell phenotype by analyzing variables as a whole, rather than 
investigating one variable at a time [265,267,268]. Several different computational 
techniques are frequently used, including clustering (hierarchical and k-means), decision 
trees, Bayesian networks, principal component analysis (PCA) and partial least-squares 
regression (PLSR) [267,268,270]. Each of these techniques allows researchers to better 
visualize interactions between the variables measured in a particular system, and of 
particular interest in this review are PCA and PLSR.   
 PCA is a technique that allows visualization of data clustering by reducing the 
dimensionality of a dataset to 2-4 dimensions, graphed on axes called principal 
components (PCs), which are able to capture the majority of the variance in the dataset 
[266,268,270]. PLSR is an extension of PCA, where an added assumption is made that a 
cell outcome measure (called “Y”; i.e. apoptosis, differentiation, migration) is dependent 
on a combination of measurable variables (called “X”; i.e. cell signaling, surface markers, 
protein phosphorylation) [266,267]. A linear regression solution is then calculated to 
 58 
show how cell outcome is a function of measureable variables (Y=f(X)) [265–267]. This 
technique can elucidate the most important combinations of measured variables that lead 
to an observed outcome, which allows this modeling technique to be predictive in 
addition to explanatory [265–267].  
 PCA and PLSR have been applied to a variety of tissue engineering applications. 
In one study, PLSR was used to analyze hepatic cytotoxicity in response to stimulation 
by various drugs through measurement of phosphoproteins. This analysis narrowed the 
original 17 phosphoproteins down to 4 that caused the largest effect on cytotoxicity 
[271]. Several studies have investigated specific cell-type responses to TNF-α, and PLSR 
analysis has indicated that these responses are dependent on cell-type and the time after 
drug administration [272,273].  Another study showed that both surface markers and 
signaling molecules can be used to predict T-cell age by using PLSR analysis [274]. 
These techniques have also been used to evaluate stem cell behavior. In one study, PLSR 
was used to establish a relationship between embryonic stem cell gene expression profiles 
and biomechanical properties as cells were directed to ectoderm or mesoderm lineages 
[275]. In another study, PLSR was used to understand how kinase pathways govern MSC 
differentiation, and behavior could be predicted based on several phosphoproteins [276]. 
Finally, PCA and PLS-Discriminate Analysis (PLS-DA, a modified version of PLSR 
using a dummy variable to stand in for a cell response) elucidated distinct expression 
dynamics for osteogenic, adipogenic, chondrogenic, and myogenic transcriptional 
regulators when MSCs were co-cultured with adipocytes and osteoblasts [32]. Overall, 
these studies indicate that PCA and PLSR are excellent tools to evaluate and develop 
predictive models for dynamic, complex cellular systems.  
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CHAPTER 3 
INTERACTIONS BETWEEN MESENCHYMAL STEM CELLS, 
ADIPOCYTES, AND OSTEOBLASTS IN A 3D TRI-CULTURE 





Diabetes is associated with insulin deficiency (Type I) or resistance (Type II) and 
consequential dysregulation in adipose tissue and energy metabolism [74]. Notably, both 
type I and II diabetes are associated with increased risk of osteoporosis, a skeletal 
disorder characterized by low bone mass and microarchitectural deterioration of bone 
[277]. Among other cell types, adipocytes and osteoblasts are dysregulated during the 
progression of diabetes and resulting secondary osteoporosis [34]. As both cell types are 
differentiated from mesenchymal stem cells (MSCs) and are components of the bone 
marrow microenvironment [34,74,278], it is possible that the progression of these 
diseases involves altered MSC behavior [34].  
The stem cell microenvironment, where stem cells derive signals from the 
extracellular matrix (ECM), cellular contacts, and both short and long range soluble 
factors, has been seen to change in disease states and has recently gained interest as a 
potential new target for disease therapies [279,280]. Within the bone marrow 




 Portion of this section were adapted from T.E. Rinker, T.M. Hammoudi, M.L. Kemp, H. Lu, J.S. 
Temenoff, Interactions between mesenchymal stem cells, adipocytes, and osteoblasts in a 3D tri-culture 
model of hyperglycemic conditions in the bone marrow microenvironment., Integr. Biol. 6 (2014) 324–37. 
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compartment, MSCs are directed to differentiate to osteoblasts or adipocytes, a process 
that is tightly regulated, partially by cellular communication between MSCs and the 
osteoblasts and adipocytes in the immediate microenvironment [34]. Irregular MSC 
behavior has been observed in abnormal environments, such as the tumor 
microenvironment, where MSCs home and potentially participate in tumor pathogenesis 
[281]. Similarly, in an in vitro model of Gaucher disease, MSCs were seen to have 
reduced proliferative capacity and may contribute to increased bone resorption [282]. As 
it has been hypothesized that alterations in the MSC microenvironment both contribute to 
and result from interactions with bone and adipose tissues [34], understanding how 
environmental changes inherent to diabetes impact these interactions may provide insight 
into the role MSCs play in the progression of diabetes and concomitant osteoporosis. 
Clinically, diabetes is often associated with hyperglycemic conditions due to the 
body’s inability to properly regulate the amounts of glucose in the blood [278]. Studies 
have shown that elevated glucose levels have negative effects on MSCs, adipocytes and 
osteoblasts, all of which are cell types that influence the MSC microenvironment. Data 
suggest that at high glucose levels, MSCs undergo increased apoptosis and senescence as 
well as lose colony forming capacity and osteogenic potential [83–86]. Adipocytes have 
demonstrated decreased insulin sensitivity, unregulated triglyceride storage, increased 
production of reactive oxygen species and pro-inflammatory cytokines, and decreased 
adiponectin secretion when cultured in high glucose conditions [87–89]. Finally, 
osteoblasts cultured in high glucose have shown reduced proliferative capacity, 
mineralization capabilities, collagen I synthesis, and expression of differentiation markers 
[90–93]. However, how these individual consequences impact cellular cross-talk between 
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all three cell types remains to be fully understood, though previous work has shown that 
intercellular communication is affected in the context of diabetes. For instance, murine 
osteoblasts in co-culture with bone marrow cells from diabetic mice undergo increased 
cell death as compared to those co-cultured with bone marrow cells from normal mice 
[283]. This indicates that MSCs derived from diabetic tissues may have an altered 
secretome, but how these changes influence interactions between MSCs and neighboring 
cell types in the bone marrow niche remains largely unexplored. Understanding how 
hyperglycemic conditions influence MSCs both directly and indirectly (through soluble 
signaling from neighboring osteoblasts and adipocytes) may provide insight into how the 
altered stem cell microenvironment contributes to tissue dysregulation, particularly in the 
development of diabetes-related osteoporosis. 
To gain such biological insight, it is necessary to use an in vitro culture system 
that permits the co-culture of multiple cell types but still allows specific cell population 
analyses. As opposed to in vivo experiments, in vitro systems can be advantageous by 
eliminating the confounding factors present in animal models and by permitting use of 
human cells. In past in vitro studies, both 2D techniques, such as transwell-based systems 
and cell patterning [284,285], and 3D techniques, involving various biomaterial-based 
scaffolds [96,286], have provided useful information about cellular interactions. 
However, in many of these systems, both separation of unique cell populations for 
analysis and retrieval of live cells for further experimentation are difficult. Therefore, this 
study demonstrates the development and implementation of a 3D tri-culture platform that 
permits individual cell type analysis [32] and on-demand retrieval and further analysis of 
live MSCs post-culture. To achieve live cell retrieval, a matrix metalloprotease (MMP)-
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degradable poly(ethylene-glycol) (PEG)-based material was included in the culture 
system. This material has been used previously to encapsulate MSCs with no decrease in 
cell viability [287–289]. With this culture system, we were able to co-culture MSCs, 
osteoblasts, and adipocytes in normal and high glucose conditions, and then analyze each 
cell type separately for gene expression, histological markers, and cell viability.  
In many in vitro studies of intercellular cross-talk, only single outcome measures 
are reported, which often does not elucidate how genes, proteins, and other measure of 
cell response interact and contribute to an observed cell behavior [267]. In recent years, 
some of these shortcomings have been addressed by developing heat-maps of gene and 
protein arrays, modeling proposed signaling networks by integrating results from many 
different experiments, and constructing multivariate statistical models [32,274,290]. In 
particular, multivariate statistical analysis techniques can provide insight into the greatest 
sources of variance in complex biological systems and can elucidate how outcome 
measures correlate with different environmental and culture conditions [291]. We have 
previously used multivariate statistical techniques to evaluate gene expression data from 
simultaneous co-culture of three cell types, showing in a proof-of-concept experiment 
that these models can provide valuable biological insight in a multicellular in vitro 
system [32]. In this study, these techniques were further utilized to gain insights into how 
neighboring cell type and environment interact to influence MSC behavior and gene 
expression in an in vitro model of hyperglycemia. Specifically, we studied cellular 
response to elevated glucose levels in three different culture configurations: monoculture 
(one cell type), co-culture (two different cell types) and tri-culture (three different cell 
types) (Figure 3.1). Cellular response was analyzed by measuring gene expression levels, 
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viability, histological markers, and MSC colony-forming potential over a seven day time 
period using both univariate and multivariate analysis approaches. 
3.2 Materials and Methods 
3.2.1 Preliminary Cell Culture 
All cell culture reagents were obtained from Mediatech unless otherwise 
specified. Primary human MSCs were obtained from Texas A&M Health Sciences Center 
and expanded in Minimal Essential Medium-Alpha (αMEM) with 16.5% fetal bovine 
serum (FBS; Hyclone), 1 g/L glucose, 2 mM L-glutamine, 1% amphotericin B, and 0.1% 
gentamicin and cultured at 37°C and 5% CO2 in a humidified incubator. Primary human 
osteoblasts (Lonza) were expanded to 4 population doublings in OGM Osteoblast Growth 
Medium (Lonza) containing 10% FBS, ascorbic acid, 50 μg/mL gentamicin, and 37 
ng/mL amphotericin B. Primary human subcutaneous pre-adipocytes (Lonza) were 
expanded to 1-2 population doublings according to the manufacturer’s protocol in PGM-
2 Basal Medium (Lonza) containing 10% FBS, 2 mM L-glutamine, 50 μg/mL 
gentamicin, and 37 ng/mL amphotericin B. Cultures at 80% confluence were 
differentiated into adipocytes for 9 days in Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% FBS, 1 g/L glucose, 60 µM indomethacin, 0.5 mM 3-isobutyl-1-
methylxanthine, 0.5 µM dexamethasone, and 45 pM insulin. 
3.2.2 Fabrication of Culture System 
Cells were encapsulated in PEG-based materials (Sigma-Aldrich, unless 
otherwise noted). PEG-diacrylate (PEG-DA) (Mn = 8kDa) was synthesized by combining 
acryloyl chloride and PEG according to previous methods [148] (See Figure 3.1C for 
PEG-DA cross-linking schematic). 
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To promote cell adhesion and viability, PEG-based materials containing 
fibronectin-derived GRGDS (Bachem) and laminin-derived YIGSR (Anaspec) were 
synthesized from Acryl-PEG-succinimidyl valerate (SVA) (Mn=3.4kDa; Laysan Bio) 
according to previous methods [32,148] to obtain Acryl-PEG-RGDS and Acryl-PEG-
YIGSR. To allow on-demand degradation of particular blocks in the culture system, a 
collagenase-degradable peptide sequence, GGGLGPAGGK (abbreviated LGPA), was bi-
functionalized with Acryl-PEG-SVA (Mn=3.4kDa) according to previous methods 
[289,292] to obtain PEG-LGPA-DA polymer chains (See Figure 3.1D for PEG-LGPA-
DA cross-linking and degradation schematic). 
To fabricate cultures, cells were suspended in precursor hydrogel solutions at 
15×10
6
 cells/mL. Solutions were formulated with 10% w/w PEG-DA (osteoblasts and 
adipocytes) or PEG-LGPA-DA (MSCs) and 0.05% w/w D2959 photoinitiator (Ciba), 
with 1 mM Acryl-PEG-RGDS and Acryl-PEG-YIGSR for MSCs and adipocytes, 
respectively. Precursor hydrogel solutions were photopatterned into 1.5 × 1.5 × 1 mm 
laminated gel structures using a PDMS mold and UV light according to previous methods 
(Figure 3.1) [32]. An opaque photomask was used in subsequent steps to prevent any 
further UV light exposure and crosslinking. Each subsequent layer is laminated to the 
prior and constructs do not separate over the course of the experiment or experience 
changes in tensile properties, as demonstrated in prior work [32,287,293]. Laminated 
constructs were extracted from the device and sectioned with a scalpel perpendicular to 
the long axis of the laminate to yield up to eighteen 1.5 mm-wide mono-, co-, and tri-
culture constructs (Figure 3.1). 
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3.2.3 Culture of Encapsulated Cells 
Gel structures were cultured in individual wells of a 12 well plate in DMEM with 
10% FBS, 5.5 mM glucose (100 mg/dL, similar concentration to normal fasting serum 
glucose level in humans), 2 mM L-glutamine, 70 µM L-ascorbate, 45 pM insulin (6.4 
μU/mL, normal fasting serum insulin level), 1% amphotericin B, and 0.1% gentamicin. 
After 1 day, a subset of constructs was switched to 22.3 mM glucose (400 mg/dL, similar 
to hyperglycemic glucose level in poorly-controlled diabetic patients). All constructs 
were then cultured for a total of 7 days with an additional media change at Day 4 (Figure 
3.1). 
 
Figure 3.1. Six culture configurations were evaluated in this study. (A) Cells were 
cultured in mono-, co-, or tri-culture hydrogel constructs for up to 7 days and then 
analyzed as depicted above. After one day in culture, media was changed and half of the 
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constructs were switched to high glucose. Shades of gray and white blocks represent 
hydrogel blocks of different types of cells in either mono-, co-, or tri-culture. (B) Tri-
culture configurations consisted of adipocytes, MSCs, and osteoblasts (designated 
OMA); co-culture configurations consisted of osteoblasts and MSCs or adipocytes and 
MSCs (designated OMO and AMA, respectively); and mono-culture configurations 
consisted of osteoblasts, MSCs or adipocytes (designated OOO, MMM, and AAA, 
respectively). (C) Schematic for PEG-DA cross-linked via photoinitiated free-radical 
polymerization. (D) Schematic of PEG-LGPA-DA cross-linking and degradation via 
collagenase. 
 
3.2.4 Cell Viability and Image Analysis 
Hydrogel constructs (n = 3 for all mono-culture, co-culture, and day 1 (D1) tri-
cultures; n = 2 for day 7 (D7) tri-cultures) were analyzed on Days 1 and 7 culture using a 
LIVE/DEAD assay (Invitrogen). Constructs were rinsed in sterile phosphate buffer saline 
(PBS) at 37 °C for 30 minutes and then incubated in LIVE/DEAD dyes (1 µM calcein 
AM, 1 µM ethidium homodimer-1) for 45 minutes at 37 °C. Constructs were then rinsed 
with PBS for 15 minutes and imaged with confocal microscopy (10x objective, LSM 700; 
Zeiss). For each construct, 1 image stack was collected for each cell type present 
(dimensions: 693 × 693 μm; stack depth = 0 – 800 µm with 10-µm intervals). Image 
stacks were analyzed using ImageJ software (version 1.46a; NIH). Each stack was split 
into green (calcein) and red (EthD-1) channels. Every fifth image was analyzed for total 
number of live and dead cells. Particles of diameter greater than 94 μm
2
 and 12 μm
2
 were 
counted for the live and dead cell analysis, respectively, using the Particle Analysis 
macro. Subsequently, fraction viable cells (# live cells/# total cells counted) was 
calculated for each stack and normalized to Day 1 normal glucose conditions. 
3.2.5 Colony Forming Unit-Fibroblasts (CFU-F) Analysis 
To evaluate clonogenicity, at day 7, MSC-containing PEG-LGPA-DA hydrogel 
constructs (n = 3) were incubated in a 1,100 U/mL collagenase (Gibco) solution in MSC 
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expansion medium for 1 hour. Fractions of the media containing the recovered cells (100 
μL for MMM, 200 μL for OMO and AMA, and 300 μL for OMA; volumes determined in 
order to seed approximately the same number of cells for each construct type) were 
plated into 15-cm tissue culture dishes (Corning) containing 20 mL of MSC expansion 
medium. Media was changed 1 day after seeding and cells were then fed every 3 days for 
14 days of culture. Clonogenicity was evaluated by counting colonies > 2 mm (stained 
with 3% crystal violet (Sigma-Aldrich), 100% methanol (BDH)) after 14 days.  
3.2.6 Histological Analysis 
For histological analysis, all culture configurations under both normal and high 
glucose conditions were infiltrated by graded concentrations of sucrose in PBS followed 
by graded concentrations of optimal cutting temperature compound (OCT; Sakura 
Finetek), frozen in liquid nitrogen, and stored at -80°C until sectioning.  Embedded gel 
constructs were serially cryosectioned at a 20 µm thickness (Microm HM 560 Cryostat; 
Thermo Scientific) and mounted on Superfrost Plus slides (Fisher). Sections were stained 
either for lipids (10 µg Nile Red/mL in 1% acetone) or alkaline phosphatase (ALP) 
activity according to the manufacturer’s protocol (Vector Red Alkaline Phosphatase 
Substrate Kit; Vector Labs). In both cases, sections were counterstained with Hoechst 
33258 (0.25 mg/mL in PBS for 5 min; Molecular Probes). Sections were visualized with 
epifluorescence microscopy under FITC filters for Nile Red, Texas Red Filters for ALP, 
and DAPI filters for Hoechst.  
3.2.7 mRNA Isolation and qPCR 
Hydrogel constructs (n = 5) were rinsed in PBS and blocks containing individual 
cell populations were separated from each other using a scalpel for gene expression 
 68 
analysis by qPCR after 1 and 7 days in mono-, co-, or tri-culture. Gel blocks containing 
the same cell type were pooled from 2 co-culture constructs or 3 tri-culture constructs of 
the same culture configuration and glucose condition to provide sufficient and equivalent 
amounts of mRNA for quantification. Pooled blocks were homogenized in 
microcentrifuge tubes with pellet grinders and mRNA was extracted using a QIAshredder 
tissue homogenizer and RNeasy kit with DNase I digestion (Qiagen).  cDNA was 
generated using SuperScript III Reverse Transcriptase (Invitrogen) with Oligo(dT)15 
primers and dNTPs (Promega). Gene expression was analyzed with quantitative PCR 
amplification performed on a StepOnePlus
TM
 Real-Time PCR System (Applied 
Biosystems) in the presence of SYBR Green/ROX master mix (Applied Biosystems). In 
addition to endogenous controls (40S ribosomal protein S18 (RPS18) and beta-actin), 
gene expression was measured for genes indicating osteogenesis (runt-related 
transcription factor 2 (RUNX2), Osteocalcin (OCN), and Osteoprotegerin (OPG)); 
adipogenesis (peroxisome proliferator-activated receptor γ (PPARγ2), CCAAT/enhancer-
binding protein beta (CEBPB), Leptin (LEP), and adiponectin (ADIPOQ)); and glucose-
responsive transcription factors (activating transcription factor 2 (ATF2), forkhead box 
protein O1 (FOX01), c-jun (JUN), and nuclear factor kappa B (NFKB1)). Sequences for 
custom-designed primers (Invitrogen) can be found in Table 3.1.  
Table 3.1 National Library of Medicine accession number and primer sequences for 
target genes in qPCR. 











































To analyze PCR amplification data, the raw fluorescence data was processed 
using LinRegPCR (v12.11; http://www.hartfaalcentrum.nl). Starting amplicon number 
(No) was calculated based on mean efficiencies (E) and cycle threshold (Ct) using the 
formula No = Nt/E
Ct
, where Nt is the amplicon number at the cycle threshold. No for each 
target gene were normalized to a geometric mean of the starting amplicon numbers of the 
endogenous controls to obtain relative expression values.  
3.2.8 Univariate Statistical Analysis of Cell Viability and Colony Formation 
Viability and CFU-F results are depicted as mean ± standard deviation. Prior to 
statistical analysis, all data were transformed with a Box-Cox transformation. Where 
significant factors and interactions were identified by ANOVA, Tukey’s post hoc test 
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(significance level p < 0.05) was used to generate pairwise comparisons between means 
of individual sample groups and determine statistically significant differences. 
3.2.9 Multivariate Models of Gene Expression 
Statistical modeling was performed using SIMCA-P+ software (version 12.0.1.0, 
Umetrics) on gene expression results. All Box-Cox-transformed data were mean-centered 
and scaled to unit variance prior to analysis as a means of normalization to allow all 
variables to be considered equally scaled in the principal components or latent variables 
[291]. For PCA, N x K X-matrices were generated of N culture condition observations 
and K time-variant gene expression responses. PCA was conducted to determine the 
source of maximum variation in the dataset, resulting in clusters of similar observations 
separated across one or more principal components. Based on clustering, partial least 
squares discriminate analysis (PLS-DA) was performed to find LV that served as 
discriminating factors to best separate observations [32,294]. For PLS-DA, N x M Y-
matrices were generated of N culture condition observations and M responses, which 
were based on assigned classes (culture configuration or glucose level). To optimize 
model quality, pruning processes were performed to remove observations that lied 
outside of the 95% confidence interval and variables that were not influential in model 





Y (PLS-DA) provide a measure of the extent that the model explains the 
variation in data matrices and indicates a goodness of fit; and Q
2
 provides a measure of 
the extent to which the variation of a future experimental data set may be predicted by the 
model and indicates a goodness of prediction [294]. For further model quality 
assessment, model validation based on permutation testing was performed in SIMCA-P. 
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In brief, this technique randomly shuffles the positions of variables in the Y-block and 









 values of the new models 




, the model is valid [295].  
3.3 Results 
3.3.1 Adipocyte Response to Culture Conditions and Glucose Levels 
 Adipocytes were cultured under normal and high glucose conditions in three 
different culture configurations: mono-culture with only adipocytes (AAA), co-culture 
with MSCs (AMA), or tri-culture with MSCs and osteoblasts (OMA), where the 
underlined letter represents the cell type being discussed from a particular culture 
configuration (Figure 3.1). Lipid deposition was observed using Nile Red staining at all 
time-points and experimental conditions (Figure 3.2A). Lipid deposition was constant 
throughout the duration of culture and no changes in lipid deposits were observed 
regardless of time, glucose level, or culture configuration (data not shown). 
Expression levels for a variety of genes that act as markers of adipogenesis and 
energy metabolism (Table 3.1) were measured for each condition using qPCR. Using this 
data, Principal Component Analysis (PCA) was conducted to model adipocyte gene 
expression data that included all experimental conditions (Figure E.1A, Appendix E). 
Based on observed clustering patterns in PCA, Partial Least Squares Discriminate 
Analysis (PLS-DA) was used to build a model for adipocytes assigned to classes by 
culture configuration (Figure 3.2B). The PLS-DA model yielded two latent variables 




= 0.92). The 
first LV discriminates OMA (or osteoblast-containing cultures) from AAA and AMA (or 
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non-osteoblast-containing cultures). The second LV discriminates AMA from AAA. The 
weight plot showed significant correlation of osteocalcin (OCN), leptin (LEP), 
adiponectin (ADIPOQ), and ATF2 with OMA cultures; peroxisome proliferator-activated 
receptor γ (PPARγ2), ADIPOQ, and osteoprotegrin (OPG) with AMA cultures; and JUN, 
NFKB1, CEBPB, and RUNX2 with AAA cultures. Then, the dataset was further divided 
and sub-models of gene expression data from AAA, AMA, and OMA cultures were used 
in PCA (Figure E.1B, Appendix E). In the case of the AAA culture configuration, 
observations clustered by glucose level and classes assigned by normal and high glucose 
levels were further discriminated using PLS-DA (Figure 3.2C; Figure E.1C, Appendix 
E).  
 
Figure 3.2. Adipocytes were assessed for response to culture conditions. (A) 
Representative images of adipocytes stained with Nile Red, specific for lipids (green) and 
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counterstained with Hoechst, specific for nuclei (blue).  (B) PLS-DA was used to build 
models for adipocytes assigned to classes by culture configuration. Models yielded two 





0.92).  (C) For AAA culture, classes based on normal and high glucose levels were 
discriminated using PLS-DA (AAA: R
2
Y= 0.79 and Q
2
= 0.70). The corresponding weight 
plot can be found in the supplementary information (Figure E.1C). In all models, dashed 
lines represent the 95% confidence limit of the distribution of weights. 
 
Confocal microscopy was used to image hydrogel blocks of adipocytes stained 
with LIVE/DEAD reagents in each culture condition at each time point (representative 
images in Figure E.2A, Appendix E). Numbers of live and dead cells were quantified and 
the fraction of viable cells is reported normalized to day 1, normal glucose (Figure 3.3). 
Adipocytes maintained viability across the entire experiment, and no statistically 
significant differences were observed within each culture configuration.  
 
Figure 3.3. Viability of adipocytes was assessed in each culture configuration at normal 
and high glucose levels. Fraction viable cells (via LIVE/DEAD staining) for each culture 
condition is presented (n = 3 for AAA, AMA; n >2 for OMA; no statistically significant 
differences were seen, p < 0.05). 
 
3.3.2 Osteoblast Response to Culture Conditions and Glucose Levels 
Osteoblasts were cultured under normal and high glucose conditions in three 
different culture configurations:  mono-culture (OOO), co-culture with MSCs (OMO), or 
tri-culture with MSCs and adipocytes (OMA) (Figure 3.1). Alkaline phosphatase (ALP) 
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activity was evaluated using ALP substrate stain in all experimental conditions across all 
time points. Similar levels of production were seen for normal and high glucose 
conditions (data not shown) and representative images from each culture configuration at 
both time points are presented (Figure 3.4A). Low production was seen throughout the 
duration of the culture and a transiently higher amount of ALP production was seen in 
osteoblasts from OMA cultures at day 1 (Figure 3.4A). 
Expression levels for a variety of genes that act as markers of osteogenesis and 
energy metabolism (Table 3.1) were measured for each condition using qPCR. Using this 
data, PCA was conducted to model osteoblast gene expression data that included all 
experimental conditions (Figure 3.4B). The PCA yielded two principal components 
(R
2
X= 0.81 and Q
2
= 0.56). The first component indicates presence of random variance 
that can be attributed neither to culture configuration nor to glucose condition, possibly 
due to the genes measured in the experiment. However, the second component separates 
OMA cultures from OOO and OMO cultures. Further, three separate PCA models were 
built within each osteoblast culture configuration (Figure E.3A, Appendix E). In cases 
that the majority of observations clustered by glucose level in PCA (OOO and OMA 
cultures), classes based on normal and high glucose levels were further discriminated 
using PLS-DA (Figure 3.4C; Figure E.3B, Appendix E). Notably, a different set of genes 
served to separate glucose classes in OOO and OMA cultures configurations. PCA for 
osteoblasts in the OMO culture configuration indicated that primary variance in gene 
expression was not due to glucose level and did not warrant further discrimination using 
PLS-DA (Figure E.3A, Appendix E). 
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Figure 3.4. Osteoblasts were assessed for response to culture conditions. (A) 
Representative images of osteoblasts stained for ALP, a marker of osteogenic 
differentiation (red), and counterstained with Hoechst for nuclei (blue). Noticeably higher 
amount of ALP production was seen in osteoblasts from OMA cultures at day 1.  (B) 
PCA was applied to the gene expression data of the global osteoblast population, yielding 
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two principal components (R
2
X= 0.81 and Q
2
= 0.56). (C) For OOO and OMA cultures, 
classes based on normal and high glucose levels were discriminated using PLS-DA 
(OOO: R
2
Y= 0.5 and Q
2




= 0.55). The corresponding 
weight plots can be found in the supplementary information (Figure E.3B). In all models, 
dashed lines represent the 95% confidence limit of the distribution of scores. 
 
Numbers of live and dead osteoblasts were quantified from confocal microscope 
images, as described above (Figure E.2B, Appendix E). Viability decreased for both 
OOO and OMA cultures in normal glucose at Day 7, while viability was maintained in 
the OMO cultures (Figure 3.5).  
 
Figure 3.5. Osteoblast viability was measured in response to culture conditions. Fraction 
viable cells (via LIVE/DEAD staining) for each culture condition is presented (n = 3 for 
OOO, OMO; n >2 for OMA;* = Significantly different from same culture configuration 
and glucose condition on Day 1; p < 0.05). 
 
3.3.3 MSC Response to Culture Conditions and Glucose Levels  
MSCs were cultured under normal and high glucose conditions in four different 
culture configurations:  mono-culture (MMM), co-culture with osteoblasts (OMO), co-
culture with adipocytes (AMA), or tri-culture with osteoblasts and adipocytes (OMA) 
(Figure 3.1). Expression levels for a variety of genes that act as markers of osteogenesis, 
adipogenesis, and energy metabolism (Table 3.1) were measured for each condition using 
 77 
qPCR. Using this data, PCA was conducted to build a model of MSC gene expression 
data that included all experimental conditions (Figure E.4, Appendix E). Based on 
observed clustering patterns, a PLS-DA model was built for MSCs assigned to classes by 





= 0.63). The first LV discriminates MMM and 
AMA, the second discriminates MMM and OMA, and the third discriminates OMA and 
OMO. Then, four separate PCA models were built for each MSC culture configuration 
(Figure E.5, Appendix E). In the cases of OMO and AMA, observations clustered by 
glucose level in PCA and classes based on normal and high glucose levels were further 
discriminated using PLS-DA (Figure E.6, Appendix E). Similarly to osteoblast cultures 
that could be discriminated by glucose level, a different set of genes acted to separate 




Figure 3.6. MSCs were assessed for gene expression changes response to culture 
conditions. PLS-DA models were constructed for MSCs assigned to classes by culture 





= 0.63). In all models, dashed lines represent the 95% 
confidence limit of the distribution of weights. 
 
After 7 days of culture in normal and high glucose conditions, the degradable 
MSC block in each culture configuration was exposed to collagenase and degraded. Live 
cells were recovered and colony forming ability was assessed after 14 days of growth 
(Figure 3.7A). Significantly fewer colonies were seen in MMM and OMO cultures in 
high glucose conditions as compared to normal glucose, but number of colonies were 
similar regardless of glucose level in in AMA and OMA cultures.  
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Numbers of live and dead MSCs were quantified from confocal microscope 
images, as described above (Figure E.2C, Appendix E). Decreases in viability were seen 
for MSCs in both high and normal glucose MMM cultures at Day 7 and also in normal 
glucose OMO cultures at Day 7 (Figure 3.7B).   
 
Figure 3.7. MSC clonogenicity was measured post-culture using colony forming assays 
(A) Number of colony-forming units greater than 2 mm in diameter per dish (n = 3) (* = 
Significantly different from same culture configuration; p < 0.05). (B) MSC viability was 
measured in response to culture conditions. Fraction viable cells (via LIVE/DEAD 
staining) for each culture condition is presented (n = 3 for MMM, OMO, AMA; n >2 for 
OMA; * = Significantly different from same culture configuration and glucose condition 
on Day 1; p < 0.05). 
 
3.4 Discussion 
As stem cell microenvironments have been observed to undergo changes that 
affect resident stem cells in disease states [281], the correlation between diabetes and 
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osteoporosis may be better explained by understanding the MSC response to the 
environmental changes inherent to diabetes. Thus, we were interested to characterize how 
MSCs are affected by soluble factors secreted by osteoblasts and adipocytes in 
hyperglycemic conditions. As experimental models available to date have not been 
satisfactory in addressing this technical need, we expanded upon a model system of the 
MSC microenvironment previously developed in our laboratory to include a degradable 
polymer for live-cell retrieval [32,287]. In this model system, we focused on decoupling 
the effects of paracrine signals from other types of signaling that may occur in the bone 
marrow niche.  Within the bone marrow microenvironment, information is thought to be 
transmitted over relatively short length scales (on the order of hundreds of microns) given 
the well-defined, compact architecture [296,297], we believe the geometry of our tri-
culture system sufficiently mimics this aspect of the structure of the bone marrow while 
allowing for separation of cell types post-culture.  From this system, we analyzed gene 
expression, histological markers, cell viability, and MSC colony forming ability after 7 
days of culture in normal or high glucose conditions.     
3.4.1 Encapsulated Cells Maintain Viability and Phenotype 
Previous experiments provided evidence that our culture platform was suitable for 
at least 18 days of culture [32]. In the experiments presented here, cell viability was 
generally maintained for the duration of the experiment in all cell types (Figure 3.3, 3.5, 
and 3.7B). However, osteoblasts in OOO and OMA culture configurations under normal 
glucose conditions exhibited significantly lower viability by day 7. The decreased 
viability observed in the mono- and tri-culture conditions remains unclear, but is possibly 
due to interactions with neighboring cell types.  MSCs may have promoted osteoblast 
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viability in the co-culture, but these effects could have been interrupted by the presence 
of adipoctyes in the tri-culture.  Clinically, osteoblast turnover is thought to occur on the 
order of days [298], suggesting that osteoblasts need constant replenishment from the 
stem cell compartment. While soluble signals from stem cells are present in this system, 
direct replenishment via differentiation is impossible. Thus, the maintenance of viability 
observed in OMO cultures might be a result of communication with MSCs that 
encouraged osteoblast survival. Further refinement of our culture platform could improve 
osteoblast viability by including more soluble signals known to contribute to normal 
osteoblast function in vivo. 
Osteoblast production of ALP, a marker for osteogenic phenotype, persisted at 
generally low levels throughout the duration of culture time (Figure 3.4A). Similarly, 
adipocyte lipid deposition was evident in adipocytes throughout the duration of culture in 
all experimental conditions (Figure 3.2A). Taken together, the maintenance of viability 
and cell type-specific markers indicate that the culture system is a valid platform for 
analysis of interactions between these three cell types, even under hyperglycemic 
conditions.  
3.4.2 Multivariate Models Allow Discrimination by Neighboring Cell Type and 
Glucose Level  
Multivariate statistical modeling was used to better understand maximum sources 
of variance within the gene expression of each cell type as well as to inform future co-
culture experimental design. In global multivariate models for all cell types, the 
maximum source of variance originated from differences in neighboring cell types, 
referred to as culture configuration (i.e. mono-, co-, or tri-culture), as determined by 
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clustering patterns and discrimination across principal components and latent variables 
(Figure 3.2B, 3.4B, and 3.6). In adipocyte global models, the first LV discriminated 
osteoblast containing cultures from non-osteoblast containing cultures. From this, we 
know that the presence of osteoblasts influences adipocyte behavior, an important 
consideration in designing future co-culture studies that aim to understand adipocyte 
behavior within the bone marrow microenvironment. Osteoblast models showed less 
distinct clustering patterns, possibly indicating a large amount of random variance in the 
system. Alternatively, these results may be indicative of osteoblast stability regardless of 
neighboring cell type. Overall, future co-culture experiments may need to analyze 
different genes or other output measures to gain a better understanding osteoblast 
behavior. Finally, MSC global models discriminated each culture type from the other 
except for MMM and OMO culture configurations. This suggests that interactions with 
adipocytes significantly influence MSCs, as was evident in other analyses and will be 
discussed further. As osteoblast presence did not seem to impact MSCs as strongly, at 
least based on gene expression data, future co-culture studies could aim to gain a deeper 
understanding of MSC and adipocyte communication and the mechanisms in which this 
communication influences MSC behavior.  
Clustering by glucose level was not often observed in global models, indicating 
that neighboring cell types had a greater influence on gene expression than glucose 
conditions. However, this may have been partially due to the genes analyzed in this 
study, and by including more genes, discrimination by glucose in global models may 
have been possible.  When sub-groups of the dataset were modeled to understand primary 
variance within each culture configuration, it was found that in several cases 
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discrimination by glucose level could be achieved (Figure 3.2C and 3.4C; Figure E.6, 
Appendix E). In other cases, it was more difficult to definitively determine if culture 
configurations could be separated by glucose level, and whether this is due to the choice 
of genes analyzed or the influence of the culture configuration on cellular response to 
glucose remains unclear. Overall, it was evident that the response of individual cell type 
to glucose level was unique to each culture configuration and thus interactions with 
neighboring cell types. This provides further incentive to probe cellular response to 
pathological conditions within a co-culture setting, as it better represents the 
simultaneous cell response to neighbors and environment that occurs in vivo. 
The fact that correlations in the multivariate models were seen primarily based on 
type of neighboring cells strongly supports the idea that traditional monoculture 
platforms are not able to mimic/reproduce important features of systems-level cell-cell 
communication that occurs in disease states. Other indirect (no cell-cell contact) co-
culture studies with bone marrow cells also report that cellular behavior changes when in 
communication with other orthopaedic-derived cells. Increased osteoblast death has been 
observed in response to diabetic bone marrow cells [283] and reduced MSC hypertrophy 
and mineralization was achieved when in co-culture with chondrocytes [299]. These 
studies and the work presented here provide strong motivation to include multiple cell 
types in in vitro studies of the bone marrow microenvironment in order to gain more 
relevant biological insights for diseases affecting the entire tissue. Thus, our culture 
platform provides a novel technology that is well-suited for future studies in which 
multiple co-cultured cell types responding both to each other and to environmental 
changes may be required to adequately recapitulate a complex in vivo disease state.  
 84 
3.4.3 Adipocyte Co- and Tri-culture Conditions Correlate with Genes Related to 
Energy Metabolism and Adipogenesis 
Multivariate models were also used to understand the correlations between gene 
expression and culture configuration. In the adipocyte-only model, markers of 
adipogenesis and energy metabolism (OCN, LEP, ADIPOQ, PPARγ2, OPG) showed 
statistically significant correlation with AMA and OMA  cultures while markers of 
inflammation and oxidative stress (JUN, NFKB1, CEBPB) showed correlation with AAA 
cultures (Figure 3.2B). This suggests that presence of MSCs may promote adipocytes to 
up-regulate genes related to adipogenesis and energy metabolism.  Interestingly, these 
differences in gene expression did not manifest in adipocyte viability data or levels of 
lipid deposition, as both were constant in all conditions (Figure 3.2A and 3.3). It is 
possible that adipocytes were robust to environmental changes, or that gene expression 
data provided an early view of adipocyte response to neighboring cells that may manifest 
in viability differences or changes in lipid at a later time. These results are consistent with 
experiments that have been done previously, in which adipocytes have been observed to 
secrete markers of inflammation and to undergo hypertrophy rather than apoptosis under 
hyperglycemic conditions [300]. Overall, these results indicate the presence of cross-talk 
between adipocytes and MSCs, which was further confirmed in additional studies 
discussed below. 
3.4.4 MSCs Modulate Osteoblast Response to Glucose 
Cell viability and MSC clonogenicity studies suggested that MSCs exert 
modulatory effects on osteoblasts at the expense of their own viability and clonogenicity, 
trends that were not seen when MSCs were co-cultured with adipocytes. MSCs in OMO 
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and MMM cultures demonstrated decreased viability and clonogenicity after 7 days of 
culture, while both viability and clonogenicity were maintained in AMA and OMA 
cultures (Figure 3.7). Similar to MSCs in OMO and MMM cultures, previous work has 
also shown reduction of MSC clonogenicity and viability under hyperglycemic 
conditions [86]. Osteoblast viability, on the other hand, was unlike that of MSCs, as only 
osteoblasts in the OMO cultures showed constant cell viability for the duration of culture 
(Figure 3.5), whereas MSCs from OMO cultures showed decreased viability over time in 
high glucose conditions (Figure 3.7B). These opposing trends were also seen in gene 
expression data, where MSCs from OMO cultures were seen to cluster by glucose level 
in the global multivariate model and culture configuration sub-model (Figure 3.6; Figure 
E.6, Appendix E) while osteoblasts from  the OMO culture configuration could not be 
discriminated by glucose level (Figure E.3A, Appendix E). This complementing 
relationship may indicate that MSCs somehow act to modulate the response of 
osteoblasts to glucose in a way that changed their own behavior. As MSCs are known to 
secrete therapeutic soluble factors [301]. This work further suggests that the secretion of 
soluble factors in hyperglycemic conditions may have had positive effects on osteoblasts 
but was detrimental to some MSC functions. However, this does not appear to be a 
universal consequence of MSC co-cultured with differentiated cells, as these detrimental 





3.4.5 Adipocytes Promote MSC Viability and Clonogenicity and Early Osteoblast 
ALP Activity 
Unlike MSCs in monoculture or co-culture with osteoblasts, MSCs in co-culture 
with adipocytes showed maintenance of viability and clonogenicity in high glucose 
conditions. Changes in adipocyte gene expression in the presence of MSCs also provides 
evidence that interactions between MSCs and adipocytes occurred, possibly due to an 
increase in expression of LEP and ADPIQ by adipocytes , which  is known to act upon 
other cell types [300]. Furthermore, it appears that adipocytes also modulated osteoblast 
behavior, especially in regards to ALP production (Figure 3.4A).  As ALP is a marker for 
osteogenesis, higher levels in osteoblasts co-cultured with adipocytes after one day may 
indicate that interactions with adipocytes promoted their activity, although high ALP 
staining was not observed by day 7 for any sample types. Thus, it appears that adipocytes 
may “buffer” MSCs from the reduction of clonogenicity and viability induced by 
hyperglycemic conditions. Analyzing these results alongside gene expression data, the 
ability of adipocytes to influence other cell types may correlate with upregulation of 
genes for adipogenesis and energy metabolism in adipocytes.   
The idea that adipocytes may act to modulate MSC response to glucose has not, to 
our knowledge, been reported in other experiments. It is well known that adipocytes and 
osteoblasts co-exist in the bone marrow microenvironment, and that the ratio of 
adipocytes to osteoblasts increases with age [74,78]. It also has been observed that an 
increase of adipocytes in the marrow coincides with the onset of disease like osteoporosis 
and anorexia nervosa, but the direct impact of higher numbers of adipocytes on disease 
progression has yet to be determined [74,302]. It has been hypothesized that increased 
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marrow fat may be a compensatory mechanism in times of disease [302], or be a direct 
cause of reduced MSC osteoblastogenesis [302,303]. Our results suggest it is possible 
that, under hyperglycemic conditions, an increased number of adipocytes in the bone 
marrow may exert compensatory mechanisms to maintain MSC function and possibly 
delay the onset of osteoporosis. Thus, our system provides important insight into a 
complex biological system that has not been achieved through other mono- and co-
culture experiments and highlights the interconnected nature of these three cell types in 
pathological conditions.  
3.5 Conclusion 
As a whole, the study presented illustrates a platform that facilitated elucidation 
of non-intuitive cellular behavior in a model of hyperglycemia. This tri-culture platform 
permitted the study of reciprocal cellular interactions, often impossible in other in vitro 
culture systems. Specifically, the tri-culture allows simultaneous analysis of cellular 
response to both pathological conditions and neighboring cell types. Also unique to our 
culture platform is the ability for on-demand retrieval of live cells, allowing for further 
analysis of individual cell response to their environment. In our model of the 
hyperglycemic bone marrow microenvironment, it was observed that neighboring cell 
type was the primary source of variance in our system and that disease-relevant 
environmental alterations can best be understood within the context of multi-cell systems. 
It was also found that while MSC clonogenicity and viability decreased when in culture 
with osteoblasts, both were maintained when in culture with adipocytes, regardless of the 
presence of osteoblasts. One possible explanation for this can be derived from adipocyte 
gene expression data, which indicates that cross-talk between adipocytes and MSCs 
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resulted in an altered reaction to high glucose levels, at least at early stages of 
hyperglycemia.  
These results provide specific avenues of study that can follow. Further studies to 
understand mechanistic reasons for why MSC viability and colony forming ability is 
decreased in the presence of osteoblasts but not adipocytes could inform future therapies 
aimed to target diseases like osteoporosis. Also, as increased marrow adipocyte levels 
coincide with osteoporosis [74], it would be interesting to further investigate if the 
relative quantities of osteoblasts and adipocytes change MSC response to culture 
conditions. The culture system described here could be used to investigate these 
questions and to generate further hypotheses that could be studied in vivo. Overall, the 
technological innovations in our in vitro tri-culture platform permitted a deeper 
understating of cellular response to hyperglycemic conditions that may be used to direct 
future research into cell-based therapies for diabetes and its secondary pathologies. 
After employing hydrogels to interrogate cell behavior, we were interested in 
using hydrogels to modulate cell behavior. However, to understand how our hydrogel-
based materials affected cell behavior, a defined cell system was required. Thus, we 
transitioned away from the MSC, osteoblast, and adipocyte co-culture model and began 
using a well-defined model system of cellular differentiation to modulate cell behavior 
with heparin-based materials.  
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CHAPTER 4 
HEPARIN MPS TO MODULATE CELL DIFFERENTIATION IN AN 
IN VITRO MODEL SYSTEM OF ENDOCHONDRAL 
OSSIFICATION 
4.1 Introduction 
 Heparin is a highly sulfated GAG known to bind a variety of proteins involved in 
cellular differentiation, including BMPs, IHH, FGFs, Wnts, and TGFβs [25]. While 
heparin has often been used in controlled-delivery vehicles for enhanced protein affinity 
[53], recent studies have also shown its utility in sequestering cell-secreted protein for 
subsequent analysis or to modulate cell differentiation. For example, heparin cross-linked 
into hydrogels has been shown to enhance cardiac progenitor cell differentiation, 
osteogenesis, and chondrogenesis, and while the mechanism is still unknown, evidence 
points toward endogenous protein sequestration [38,40,41,198]. For example, in heparin 
hydrogels seeded with MSCs in co-culture with osteoblasts, enhanced markers for 
osteogenesis were observed in MSCs as heparin content increased, possibly due to 
increased growth factor sequestration [40]. In addition, hyaluronic acid and heparin-based 
hydrogels were degraded after acting as a scaffold for cardiac progenitor cells, and 
analysis of released proteins revealed higher concentrations of cell-secreted angiogenic 
factors in heparin-containing gels, which likely contributed to enhanced neovascular 
differentiation [41]. These studies indicate the ability of heparin to sequester endogenous 
protein to modulate differentiation, which could eliminate the need to deliver 
recombinant proteins in tissue regeneration applications [3]. Still, little is known about 
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the ability of heparin alone to modulate differentiation processes, especially in a 
temporally controlled manner. Thus, in this work, the ability of heparin to modulate 
differentiation in an in vitro model system of endochondral ossification was investigated.  
Endochondral ossification is the process by which cartilage is converted into bone 
during skeletal development in vertebrates [23,106]. In this process, mesenchymal cells 
condense and differentiate into proliferative chondrocytes [23,106]. Eventually, these 
chondrocytes undergo hypertrophy and apoptosis, at which point they direct 
vascularization, mineralization, and osteoblast invasion of the tissue, converting the 
cartilage analgen into bone [23,106]. This process is tightly regulated by both systemic 
and local signaling by proteins such as FGFs, BMPs, TGFβs, IHH, PTHrP, Wnts, and 
IGFs [23,107,186]. In the growth plate, endochondral ossification continues through 
puberty and is required for normal bone elongation and growth [23,106]. Unfortunately, 
bone fractures that affect the growth plate can interrupt this process, and depending upon 
the severity of the injury, can result in limb length disparities, angular deformations in the 
bone, and possibly growth arrest in the limb [111,112]. Recently, tissue engineering 
strategies have been investigated to facilitate regeneration of the growth plate cartilage 
tissue using cell-seeded scaffolds, but only limited success has been observed [111,113–
118]. Because heparin is known to bind a variety of proteins implicated in endochondral 
ossification, it is possible that heparin materials could be used to modulate the 
differentiation process through cell-secreted protein sequestration. In the future, such a 
technique could be employed to modulate the timing of endochondral ossification and 
possibly improve growth plate cartilage regeneration strategies.  
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  The chondrogenic ATDC5 cell line was employed as a model cell system for 
these studies. Derived from the murine teratocarcinoma stem cell line AT805, ATDC5 
cells are known to undergo the stages of endochondral ossification in vitro [304–307]. In 
the presence of insulin and often β-glycerophosphate and ascorbic acid, these cells show 
increases in gene expression for such as collagen II, aggrecan, BMPs, FGFs, IHH, and 
Pthr1; staining for GAGs, collagen II, and aggrecan in the cell matrix; and production of 
proteins such as BMP-2 and TGF-β1 within 10-20 days of monolayer culture 
[304,305,308–313]. Thus, in these studies the ATDC5 cell line was chosen to enable 
large-scale experiments to investigate the effect of heparin MPs on endochondral 
ossification in a reproducible manner.  
 Often, in vitro models of cellular differentiation are carried out in pellet culture 
[36]. Dense cell aggregates better mimic the in vivo cellular microenvironment of 
cartilage and bone tissue, as aggregates provide extensive opportunity for cell-cell and 
cell-matrix interactions  [36,314]. One challenge to using cell aggregates is diffusion 
limitations of soluble factors through the dense cell matrix [315,316]. To overcome this 
challenge, protein loaded microparticles have recently been incorporated into cell 
aggregates to achieve more uniform protein delivery [256,258,260,261,263,264,317]. 
Using a similar argument, sequestration of cell-secreted proteins must occur uniformly 
throughout the aggregate. Therefore in these studies, heparin was incorporated into 
ATDC5 cell aggregates in microparticle format to ensure uniform sequestration of cell-
secreted proteins. Besides being advantageous for incorporation into cell aggregates, MPs 
are also advantageous over bulk hydrogels due to their high surface area to volume ratio, 
which improves protein binding and release [211]. Previously, heparin MPs were 
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fabricated and shown to have a high binding capacity for BMP-2 [59], suggesting that 
heparin MPs will have the ability to sequester large quantities of protein in ATDC5 cell 
aggregate culture. 
Herein, we present a model system using ATDC5 cells upon which to test the 
ability of heparin MPs to modulate cellular differentiation, specifically endochondral 
ossification, via sequestration of soluble factors. Heparin or PEG MPs, a low-binding 
material control, were incorporated into ATDC5 cell aggregates (spheroids) to evaluate 
the effect of heparin MPs on differentiation. Cell spheroids were cultured for 18 days and 
then assessed for viability, general morphology, GAG deposition, collagen deposition, 
and gene expression markers for chondrogenesis and hypertrophy. In addition, ATDC5 
cells were cultured in monolayer transwell culture with heparin or PEG MPs to evaluate 
the mechanism of action behind heparin MP mediated changes in differentiation. Finally, 
growth factor sequestration studies were conducted to better understanding heparin MP 
protein binding. Overall, these studies indicate that heparin MPs can modulate cell 
differentiation, likely through the sequestration of soluble protein.  
4.2 Materials and Methods 
4.2.1 Material Synthesis 
Heparin was functionalized with methacrylamide according to previous methods 
[40]. Briefly, the reaction was carried out in a phosphate buffer of pH 5 with 20 mg/mL 
heparin, 83 mM N-Hydroxysulfosuccinimide sodium salt (Sigma-Aldrich),  100 mM N-
(3-aminopropyl) methacrylamide hydrochloride (Polysciences), and 78 mM (N-3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) (Sigma-Alrich) for 2 
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hours on ice. An additional round of EDC was added, resulting in a final molarity of 156 
mM. After 4 more hours, solution was dialyzed for 2-3 days and lyophilized. PEG-
diacrylate (PEG-DA) (MW=8 and 3.4 kDa) was synthesized by combining acryloyl 
chloride (Sigma-Aldrich) and PEG (Sigma-Aldrich) according to previous methods 
[148]. All polymers were stored at -20°C prior to use. 
4.2.2 Microparticle Fabrication and Protein Pull-Down Studies 
Heparin methacrylamide MPs were formed according to previous methods [59]. 
Briefly, an aqueous phase of 10% heparin methacrylamide (wt%), 18 mM ammonium 
persulfate (Sigma-Alrich), and 18 mM N,N,N′,N′-Tetramethylethylenediamine (Sigma) 
was emulsified against corn oil with 1.67% (v/v) Tween-20 (polysorbate 20; BDH) at a 
1:120 ratio aqueous:oil phase. MPs were cross-linked under nitrogen purge at 60°C for 
30 minutes (see Figure 4.1A for cross-linked structure), then washed with acetone and 
water. PEG MPs for spheroid studies and BMP-2 pull-down studies were fabricated via 
water-in-water emulsion between a 1:4 PEG-DA-rich phase (150 mg/mL 8 kDa PEG-
DA, 2 mg/mL Poly-L-Lysine (PLL) (Sigma-Aldrich), 0.05% (w/v) Irgacure D2959 in 
PBS) to dextran phase (50% (w/v) 70 kDa dextran (Sigma-Alrich), 2 mg/mL (PLL) in 
PBS). Vortexing (30 seconds) was used to form an emulsion between the two phases and 
the resulting emulsion was ultrasonicated at 21 mW energy for 1 minute to reduce 
particle size. Then, the emulsion cross-linked under UV light at an intensity of 17 mW/m
2
 
and washed twice in PBS buffer pH 7.4 containing 1% Pluronic F127 (Sigma-Aldrich). 
PEG MPs for transwell and media sequestration studies were fabricated by homogenizing 
an aqueous phase containing 16 wt% PEG-DA (3.4 kDa), 0.05 wt% Irgacure 2959 
Photoinitiator (Ciba), and 2 mg/mL poly-l-lysine (PLL, Sigma-Aldrich) against a mineral 
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oil phase (light, white; Ameresco) with 1.3% (v/v) Span-80 (sorbitan monooleate; TCI) at 
a 1:16.7 ratio aqueous:oil phase. MPs were then nitrogen purged for 1 minute, cross-
linked under UV light (approximately 10.5 mW/cm
2
) in a 35x10 mm petri dish for 10 
minutes, and washed in water.  
MPs were sized using phase microscopy images and ImageJ. For BMP-2 
sequestration studies, 0.1 mg heparin and PEG MPs were incubated with 0.1 µg BMP-2 
overnight in 0.5 mL 0.1% BSA in PBS. Concentration of BMP-2 was assessed by ELISA 
(R&D Systems). For cell studies, MPs were sterilized by incubating in 70% ethanol for 
30 minutes followed by three 30 minute PBS washes. 
4.2.3 ATDC5 Cell Culture, Spheroid Culture, and Transwell Culture 
ATDC5 cells were expanded in maintenance media (DMEM/F-12 with L-
glutamine (Life Technologies), 5% FBS (Atlanta biologics), 100 IU Penicillin 
(Mediatech), 100 ug/mL Streptomycin (Mediatech), 0.25ug/mL Amphotericin B1 
(Mediatech), 30 nM Sodium Selenite (Sigma-Alrich), and 10 µg/mL transferrin (Life 
Technologies)) and experiments were conducted mineralization media (maintenance 
media plus 10 µg/mL insulin (Sigma-Alrich), 10 mM sodium β-glycerophosphate 
pentahydrate (Alfa Aesar), and 50 µg/mL L-ascorbic acid-2-phosphate 
sequimmagnesium salt hydrate (Sigma-Aldrich)). For spheroid studies, cells and MPs 
were combined at a 3:1 and 1:3 MP cell ratio and spheroids were formed via forced 
aggregation of the cell-MP solution into 400 µm agarose wells (Figure 4.2A). After about 
18 hours, spheroids were removed from agarose wells with a wide-bore pipette tip and 
placed in non-stick dishes (6000 spheroids/plate; BD Biosciences, 10 cm diameter) on 
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rotary culture at 65 RPM. Media was changed every 3 days. For transwell studies, 
ATDC5 cells were plated at a 6500 cells/cm
2
 in 12-well plates and cultured in 
maintenance media until confluent (3-5 days). Once confluent, media was changed to 
mineralization media and treatment groups in transwell inserts were added. For MP 
groups, a high or low (3.28 and 0.328 mg MPs, respectively) were added to the transwell 
insert. This mass was chosen to match, by mass, the high and low ratios used in the 
spheroid studies. Media was changed daily.  
For spheroid studies, MP incorporation efficiency was determined incorporating 
MPs into ATDC5 spheroids at 1:3, 1:1, and 3:1 MP:cell ratios. After 6 hour, a portion of 
the spheroids was taken for counting, and the other portion was treated with 0.25% 
trypsin for 1 hour, followed by an overnight treatment with 5% sodium dodecyl sulfate 
(SDS) (Sigm-Aldrich). The number of MPs from dissociated spheroids were counted and 
incorporation efficiency was calculated by comparing MP number to number of 
spheroids and actual number of MPs expected (actual ratio/expected ratio). For each set 
of samples, incorporation efficiency was normalized to the 1:3 MP:Cell ratio.  
4.2.4 qPCR and DNA Analysis 
Spheroids were rinsed in PBS and subject to lysis buffer for an hour at 4°C before 
mRNA was extracted using a QIAshredder tissue homogenizer and RNeasy kit with 
DNase I digestion (Qiagen). For monolayer cells, cells were lifted with 0.05% trypsin and 
washed once in PBS, then incubated in lysis buffer for 15 minutes. cDNA was generated 
using SuperScript III Reverse Transcriptase (Invitrogen) with Oligo(dT)15 primers and 
dNTPs (Promega). Gene expression was analyzed using quantitative PCR amplification 
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performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) in the 
presence of SYBR Green/ROX master mix (Applied Biosystems). Sequences for custom-
designed primers (Invitrogen) are listed in Table 4.1. 
Table 4.1. National Library of Medicine accession number and primer sequences 
(F=forward, R=reverse) for target genes used in qPCR.  










Collagen X NM_009925 
F- TGCCCGTGTCTGCTTTTACTGTCA 
R- TCAAATGGGATGGGGGCACCTACT 
To analyze PCR amplification data, the raw fluorescence data were processed 
using LinRegPCR (v12.11; http://www.hartfaalcentrum.nl). The starting amplicon 
number (No) was calculated based on mean efficiencies (E) and cycle threshold (Ct) using 
the formula No = Nt/E
Ct
,where Nt is the amplicon number at the cycle threshold. No for 
each target gene were normalized the starting amplicon numbers of the endogenous 
controls and then further normalized to no MP controls at each timepoint. 
 For DNA was extraction, cells were washed twice with PBS. DdH2O was added 
to cells for 20 minutes and then cells were subjected to a freeze-thaw cycle. Cells were 
then scraped from the 96 well plate and cell lysate solution was transferred to 1.7 mL 
tube. Cell lysate was sonicated for 20 minutes, then subjected to another freeze-thaw 
cycle. This was repeated once, then samples were spun down and supernatant was used 




4.2.5 Histological Analysis and Stain Extraction 
For histological analysis of ATDC5 spheroids, spheroids were imbedded in 
histogel, sectioned at 10 µm sections and stained with Safranin-O or H&E according to 
standard protocols. Immunostaining for ECM deposition was performed using primary 
antibodies for collagen type II (Abcam).  Antigen retrieval was performed by incubating 
in 20 μg/ml proteinase K (Sigma-Aldrich) for 10 minutes at 37°C, blocked with 1.5% 
goat serum (Fisher Scientific), and incubated with the primary antibodies at a 1:20 
dilution overnight at 4°C. Secondary antibody binding with Alexa Fluor 488-conjugated 
goat polyclonal anti-mouse immunoglobulin G (IgG, Molecular Probes) was performed 
at room temperature for 1 hour. Samples were counterstained with Hoechst (Sigma-
Aldrich) to visualize the nuclei.  
For histological analysis of ATDC5 monolayer cells, cells were rinsed in ddH2O 
and then fixed in 95% ice cold methanol for 30 minutes. Cells were stained with either 
1% Alcian blue 8GX (Sigma-Aldrich) or 2% Alizarin red (Sigma-Aldrich) pH 4.2 in 0.1 
M HCl for 1 hour. Cells were then rinsed with ddH2O and imaged. Stain was extracted by 
incubating Alcian Blue stained cells with 6 M guanidine-HCl (Sigma-Aldrich) and 
Alizarin Red stained cells with 0.5M HCl and 5% SDS for 6 hours. Absorbance was 
measured at 630 and 405 nm for Alcian Blue and Alizarin Red extractions, respectively.  
A LIVE/DEAD staining kit (Life Technologies) was used to assess cell viability 
via confocal microscopy. Stacks with slices every 2 μm were flattened using the Z-
project function on Image-J. 
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4.2.6 Protein Analysis Experiments 
 For BMP-2 sequestration studies in conditioned media, 0.01, 0.2, and 1 mg of 
Heparin and PEG MPs were incubated in ATDC5 cell-conditioned media with 500 pg of 
BMP-2 overnight at 4°C on rotary. Supernatant was then analyzed using an ELISA 
(R&D Systems). For SDS-PAGE studies, heparin or PEG MPs were cultured in transwell 
with ATDC5 cells or media only, then isolated and washed once with PBS. MPs were 
combined with a loading buffer (63 mM  Tris-HCl pH 6.8, 350 mM SDS, 6.84 M 
glycerol, 0.75 mM Bromophenol Blue, 1.78 M β-mercaptoethanol) at a 4:1 MP:buffer 
ratio, then heated to 90°C for 5 minutes. MPs and a protein ladder (BioRad) were loaded 
onto a 12% polyacrylamide gel (BioRad) and ran at 200 V for 30-60 minutes.  The gel 
was stained with Silver Stain Plus (BioRad) according to the manufacturer’s protocol.  
4.2.7 Statistical Analysis 
All results are depicted as mean + standard deviation. ANOVA was used to 
identify significant factors and interactions, then Tukey’s post hoc test (significance level 
p < 0.05) was used to generate pairwise comparisons between means of individual sample 
groups and determine statistically significant differences (Minitab 15 Statistical 
Software). 
4.3 Results 
4.3.1 Microparticle Fabrication, Characterization and Incorporation in Spheroids 
 Heparin-MAm and PEG-DA MPs had similar diameters, 5.0±3.1 and 4.9±3.9 μm, 
respectively (Figure 4.1B,C). In BMP-2 loading studies, heparin MPs loaded nearly 
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100% of the BMP-2 in solution, while PEG MPs loaded almost no BMP-2 (Figure 4.1D). 
These studies provided rationale for using the PEG MPs as a low-binding material 
control for the remainder of this work.  
 
Figure 4.1. Similarly sized heparin and PEG MPs were fabricated. (A) Heparin MAm 
was cross-linked via free-radical initiated polymerization (B) Phase microscopy images 
of heparin (stained with alcian Blue) and PEG MPs. (C) Heparin MPs and PEG MPs had 
average diameters of 5.0±3.1 and 4.9±3.9 μm, respectively. (D) Percent BMP-2 loaded 
on heparin MPs vs. PEG MPs normalized to total BMP-2 in soluble control 
(*=significantly different than heparin MP group; p<0.05). 
 MPs could be incorporated into ATDC5 spheroids at several different ratios: 3:1, 
1:1, and 1:3 MP:cell, as shown in sections of spheroids stained with Safranin-O and Fast 
Green (Figure 4.2B). Incorporation efficiency was similar for both heparin and PEG 
MPs, but decreased with increasing amounts of MPs (Figure 4.2C). The 3:1 MP:cell ratio 
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was used for the remainder of the studies, but when taking the incorporation efficiency 
into account, effectively becomes a 2:1 MP:cell ratio. 
 
Figure 4.2. Heparin and PEG MPs can be incorporated into ATDC5 cell spheroids at 
similar efficiencies. (A) Heparin or PEG MPs are incorporated in spheroids via forced 
aggregation. (B) Heparin and PEG MPs (heparin MPs shown here in red, stained with 
Safranin-O) can be incorporated at a 1:3, 1:1, and 3:1 MP:cell ratio. (C) Heparin and PEG 
MPs can be incorporated into 700 cell ATDC5 spheroids with similar incorporation 
efficiency (no significant differences between heparin and PEG at each ratio, p<0.05).  
4.3.2 Morphology and Viability of MP-Containing ATDC5 Spheroids 
700 cell ATDC5 spheroids with high and low doses (3:1 and 1:3 MP:cell ratios, 
respectively) of heparin and PEG MPs were formed (Figure 4.3A). Spheroids were 
cultured for 18 days and timepoints were taken on days 1, 6, 12, and 18 to assess overall 
morphology, cell viability, GAG and collagen II deposition, and gene expression (Figure 
4.3A). All spheroids were observed to grow over time and developed a dense cell border 
(Figure 4.3B). Heparin MPs stained a light purple with H&E staining, while PEG MPs 
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were dehydrated and either appeared as small purple spheres or were lost during 
histological processing, leaving behind holes in the matrix. No differences in spheroid 
viability were observed in any of the groups at day 18 (Figure 4.4).  
 
Figure 4.3. (A) Heparin and PEG MPs were incorporated at high and low ratios and 
cultured for 18 days on rotary culture. Gene expression and histological analyses were 
conducted at days 1, 6, 12, and 18, and viability analysis at day 18. (B) No MP control 
and heparin (reds) and PEG MP (blues) containing spheroids over the course of 18 days, 
stained with H&E. Groups are listed at the top of each set of images. PEG MPs appear as 




Figure 4.4. LIVE/DEAD staining for heparin MP and PEG MP groups at day 18. 
Confocal microscopy was used to image spheroids and stacks were z-projected after 
green (live) and red (dead) channels were merged. 
4.3.3 Heparin MP-Mediated Modulation of ATDC5 Cell Spheroid Differentiation 
 Gene expression markers of chondrocytic differentiation were analyzed at days 1, 
6, 12, and 18. Overall, it was observed that heparin MPs caused greater reductions in 
gene expression than PEG MPs (Figure 4.5). For collagen II, high heparin and PEG MP 
groups showed significantly lower gene expression than the cell control at day 6, but the 
magnitude was much greater for the heparin MP group (7.4±1.8- and 1.8±0.2-fold 
decreased for heparin and PEG, respectively). In addition, the low MP group was 
significantly decreased as compared to the cell control in the heparin group, while no 
differences were observed in the PEG group (Figure 4.5A).  For aggrecan, the magnitude 
of gene expression decrease for heparin MPs as compared to PEG MPs was also much 
greater at day 6 (16.5+6.2- and 2.9+0.2-fold decrease for heparin and PEG, respectively). 
Furthermore, the decreased expression for aggrecan persisted through day 18 for the 
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heparin MP group, while only increases were observed in PEG MPs groups at later 
timepoints (Figure 4.5B). No differences in collagen X expression were observed for 
heparin MP groups, and PEG MP groups showed slight upregulation by days 12 and 18 
(Figure 4.5C).  
 
Figure 4.5. Chondrocytic gene expression for heparin and PEG MPs groups at high and 
low MP ratio for (A) collagen II, (B) aggrecan, and (C) collagen X. Fold change 
normalized to the no MP control is reported (*=significantly different than no MP on 
same TP; #=significantly different than low MP on same TP; p<0.05). 
 IHC for collagen II was assessed for heparin and PEG MP groups on days 12 and 
18. At day 12, less staining for collagen II deposition was observed in the low and high 
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heparin MP groups as compared to the PEG MP groups (Figure 4.6A). By day 18, levels 
of staining appeared to be similar, though possibly still slightly lower in the high heparin 
MP group compared to all other groups (Figure 4.6B).  
 
Figure 4.6. IHC for collagen II (green) at (A) day 12 and (B) day 18 for heparin and PEG 
groups with low and high MPs. Nuclei are shown in blue. 
GAG deposition was assessed at days 1, 6, 12, and 18. Little staining for GAG 
deposition was observed at days 1 and 6 (data not shown), but substantial staining for 
GAG deposition was observed at days 12 and 18 in PEG and no MP groups (Figure 4.7). 
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In contrast, very little staining for GAG deposition was observed in heparin MP groups at 
both 12 and 18 days. High magnification images indicate staining for pericellular GAG 
deposition in all groups but the high heparin MP group (Figure 4.7, arrows in high mag 
images). As heparin MPs stain with safranin-O, they also appear stained red in the matrix 
(Figure 4.7, arrowheads in high mag images), but look distinctly different from the 
endogenous pericelluar GAG deposition.  
 
Figure 4.7. Safranin-O staining for GAG deposition (red) in heparin and PEG groups 
with low and high MPs. Heparin MPs appear dark red and PEG MPs appear clear or light 
purple. Inset boxes on day 18 are shown at high mag below original image. Staining for 
GAG deposited by cells appears pericellularly (arrows with tail) while GAG MPs appear 
round (arrows without tail) (scale bars = 50 µm). 
4.3.4 Heparin MP-Mediated Modulation of ATDC5 Cells in Transwell Culture 
ATDC5 cells were cultured in transwell with heparin and PEG MPs (low and high 
dose for heparin MPs, high dose only for PEG MPs), allowing for exchange of soluble 
factors but no physical contact between cells and MPs. Gene expression was measured at 
day 6 and 12 and GAG and mineral deposition was assessed at day 12 (Figure 4.8). At 
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day 6, significant down regulation was observed in the high heparin MP group for 
chondrocytic markers collagen II and aggrecan as compared to the low and no MP 
groups. In contrast, no differences were observed between PEG MP groups and the no 
MP control group at day 6. No differences in gene expression were observed between any 
groups at day 12 (Figure 4.8A). At day 12, cells were stained for GAG (alcian blue) and 
mineral deposition (alizarin red), and reduced staining was observed in the heparin MP 
groups compared to the PEG and no MP group. The stain was extracted and quantified, 
which confirmed that the heparin MP groups showed significantly less staining than the 
PEG MP and no MP control groups (Figure 4.8B and C).  
 
Figure 4.8 ATDC5 cells were cultured in transwell with heparin and PEG MPs. (A) Gene 
expression for chondrocytic markers collagen II, aggrecan, and collagen X at day 6 is 
reported as fold change normalized to the no MP group (*=significantly different than no 
MP group; p<0.05). (B) Representative images of GAG (alcian blue) and (C) mineral 
(alizarin red) deposition. Graphs show quantification of stain extraction (#=significantly 
different than cell only group; *=significantly different than indicated group, p<0.05). 
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Finally, DNA content was measured for both heparin and PEG MP groups to assess 
difference in cell number. Heparin MP groups showed significantly more DNA than the 
cell control group, while the PEG MP showed no significant differences (Figure 4.9).  
 
Figure 4.9 DNA content for heparin and PEG MP groups normalized to no cell control 
(#=significantly different than cell only group, p<0.05).  
4.3.5 Protein Sequestration and Analysis 
SDS-PAGE gels showed more proteins at greater intensity for heparin MPs as 
compared to PEG MPs incubated with ATDC5 cells for two and four days (Figure 
4.10A). In addition, heparin MPs were able to sequester BMP-2 in conditioned media 
while PEG MPs did not sequester BMP-2 (Figure 4.10B). This held true for MPs/protein 
ratios at least as low as 500 pg BMP-2/0.01 mg MPs, or 0.05 µg BMP-2/mg MP. Finally, 
when run on SDS-PAGE, an additional band at approximately 16-17 kDa was observed 




Figure 4.10. Analysis of heparin and PEG MP protein sequestration (A) SDS-PAGE for 
Heparin and PEG MPs in transwell with ATDC5 cells for 2 or 4 days. (B) Heparin and 
PEG MP sequestration of BMP-2 in ATDC5 conditioned media (*=significantly different 
than indicated group, p<0.05). (C) SDS-PAGE for Heparin MPs incubated overnight in 
transwell with cells (right, “Media + Cell Incubation”) or with media alone (left, “Media 
Incubation”). Red box indicates a band observed only in MPs incubated with cells, 
approximately 16-17 kDa. 
4.4 Discussion 
 In these studies, heparin and PEG MPs were cultured with ATDC5 cells in 
spheroid and monolayer culture, and in both formats heparin MPs were able to delay or 
decrease differentiation, likely through soluble factor sequestration. Overall, the objective 
of this study was to modulate endochondral ossification through presentation of heparin 
materials, as heparin is known to bind an abundance of growth factors implicated in 
differentiation, including BMP-2, IHH, FGF-2, WNT, and TGF-β [25]. Thus, heparin 
MPs were incorporated into ATDC5 spheroids to evaluate their effect in a three-
dimensional environment, which better mimics the cell-cell and cell-matrix interactions 
important for chondrocytic and osteogenic differentiation  [36,314]. However, when 
integrated in spheroids, it is possible that these MPs would exert not only an effect on the 
concentration of growth factors in the matrix, but also on the number of cell-cell 
interactions that could form, which are often implicated in differentiation and cell 
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behavior [316]. To ensure that observed results were due to protein binding and not due 
to the physical presence of MPs in the matrix, PEG MPs were used as a low-binding 
material control [28,318–320]. Thus, heparin and PEG MPs of similar diameter were 
formed (Figure 4.1 B,C) and protein sequestration studies indicated that while heparin 
MPs loaded nearly 100% of BMP-2, PEG MPs loaded very little of this protein. Then, 
heparin and PEG MPs were incorporated into ATDC5 spheroids at several different ratios 
with varying efficiencies (Figure 4.2B, C). A final ratio of 3:1 MP:cell (2:1 MP:cell ratio 
if efficiency is accounted for) was selected as the high MP dose because previous results 
indicated that this ratio can present a large amount of material in the ECM without 
compromising spheroid formation [259]. A ten-fold lower ratio (1:3 MP:Cell) was chosen 
for the low MP ratio in these experiments to evaluate if the influence of heparin MPs was 
dose-dependent.  
While there are many examples of successful incorporation of positively and 
negatively charged MPs into cell spheroids [232,233,259,263], we and others have been 
unable to incorporate unmodified PEG materials into dense cell aggregates [220]. 
Previously, the fibronectin cell-adhesive sequence RGD has been incorporated into PEG 
MPs to promote incorporation into spheroids [220], but MPs functionalized with the 
RGD peptide have been found to enhance chondrocytic differentiation when integrated 
into cell aggregates [220,254], which would be counterproductive in the PEG control 
group. It has been suggested that the negatively charged cell glycocalyx causes cells to be 
attracted to positive surfaces, and poly-l-lysine (PLL) has been used previously to 
promote cell binding on PEG-based surfaces [258]. Thus, in an effort to confer a slight 
positive charge on the MP surface and allow for incorporation into spheroids without 
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changing the low protein-binding properties of PEG, PLL was encapsulated into PEG 
MPs during MP fabrication. The addition of PLL allowed PEG MPs to be incorporated 
into the ATDC5 spheroids without affecting the low-binding capacity of PEG MPs 
(Figures 4.1C and 4.10A,B). More so, as PLL can be toxic at high levels [321], 
LIVE/DEAD staining indicated that the concentration of PLL used in the PEG MPs was 
not cytotoxic (Figure 4.4). 
 Heparin and PEG MPs were incorporated into ATDC5 spheroids for 18 days to 
assess the influence of heparin MPs on endochondral ossification, a time period found to 
be sufficient for ATDC5 cells to produce chondrocytic and osteogenic gene expression 
markers and matrix proteins when cultured in mineralization media [304,305,308–313]. 
General spheroid morphology was assessed over the course of culture, and spheroids 
were found to grow larger over time, consistent with the high proliferative capacity 
observed for ATDC5 cell in vitro culture in previous work [306,322], and to form a dense 
cell border on the spheroid surface (Figure 4.3B). Such dense cell borders have also been 
observed in spheroids composed of other cell types [220,233,259,323], and may be a 
result of cell reorganization due to nutrient availability or differentiation state. MPs 
remained in the matrix over the course of 18 days; however, due to sectioning and the 
solvents used in the staining process, PEG MPs often shrunk or fell out of the matrix 
during histological processing, leaving behind what appear as holes in the spheroid 
matrix (Figure 4.3B).  Finally, no differences in LIVE/DEAD staining were observed 
among any of the culture conditions, indicating that viability was not negatively impacted 
by incorporation of MPs into ATDC5 cell aggregates (Figure 4.4). Thus,  general 
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morphology and viability staining validated this platform for further evaluation of the 
influence of heparin MPs on endochondral ossification.  
 Cellular differentiation was delayed or reduced in groups with heparin MPs as 
compared to PEG MP and no MP control groups, as shown by gene expression and stains 
for matrix molecules. In the presence of a high dose of heparin MPs, gene expression for 
chondrocytic markers was downregulated as compared to no MP and PEG MP controls, 
indicating that heparin MPs delayed chondrocytic differentiation. As only subtle 
differences were observed for the low heparin MP group, the observed delay may have 
been dose-dependent. Interestingly, gene expression for the high heparin MP group was 
similar to that of the no MP control by later time points, suggesting that the effect of 
heparin MPs also might have been transient (Figure 4.5). Decreased staining for collagen 
II and GAG was observed in the high heparin MP group as compared to PEG MP and no 
MP control groups, confirming trends observed in gene expression data (Figures 4.6 and 
4.7). Taken as a whole, these results indicate that heparin MPs transiently delay or reduce 
endochondral ossification in a dose-dependent manner.  
 To further confirm that changes in differentiation observed were due to the 
presence of heparin and not simply due to MPs in the aggregate matrix, heparin and PEG 
MPs were cultured in transwell culture with monolayer ATDC5 cells, allowing exchange 
of soluble factors between cells and MPs without physical contact. Similar to what was 
observed in spheroid culture, heparin MPs decreased/delayed chondrocytic differentiation 
in ATDC5 cell transwell culture, which also appeared to be dose-dependent and transient 
(Figure 4.8). DNA content analysis indicated that observed affects were not due to 
decreases in cell numbers in the heparin MP group, as DNA content was higher in this 
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group than cell controls (Figure 4.9). In addition, proteins bound by heparin and PEG 
MPs from days 2 and 4 in transwell culture were run on SDS-PAGE gels, and observed 
protein profiles showed that PEG MPs bound fewer proteins than heparin MPs days 2 and 
4 (Figure 4.10A). Finally, gels also showed few differences between the protein profiles 
of the heparin MP groups at days 2 and 4 (Figure 4.10A). This may indicate that heparin 
MPs become saturated with protein quickly, and while exchange of protein may occur 
initially, eventually high affinity proteins may cover the MP, preventing further binding. 
The “saturation” of heparin MPs could possibly explain why a transient delay in 
differentiation is observed and why the response is dose-dependent. Overall, as heparin is 
known to be a potent binder of many growth factors involved in endochondral 
ossification [25,106], from these results it was hypothesized that sequestration of soluble 
factors was the mechanism behind heparin MP-mediated modulation in differentiation. 
In ATDC5 cell culture, two types of proteins could potentially be sequestered by 
heparin MPs: 1) cell-secreted proteins and 2) proteins found in FBS, as ATDC5 cell 
culture is carried out in serum. ATDC5 cells produce a variety of heparin-binding growth 
factors that could affect differentiation, including IGF-2, TGFβ-2, WNT, BMP-2, IHH, 
FGF-9 and FGF-18 [25,308,309,324,325]. Furthermore, many heparin-binding proteins 
are also present in serum, including but not limited to fibronectin, fibrinogen, kininogen, 
plasminogen, vitronectin, haptglobin, and lipoproteins [326–332]. Serum can also contain 
heparin-binding growth factors, but generally at a very low concentrations compared to 
the high abundant proteins listed above [326,327]. Thus, to evaluate if heparin MPs could 
still bind small growth factors in the presence of cell-conditioned, serum-containing 
media, sequestration of BMP-2 that had been spiked into ATDC5 conditioned media was 
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assessed. Results indicate that heparin MPs can still bind BMP-2 in the presence of cell-
conditioned media containing serum, while PEG MPs did not show any BMP-2 binding 
(Figure 4.10B). This suggests that heparin MPs have the potential to sequester cell-
secreted protein in ATDC5 culture, and to further investigate this possibility, heparin 
MPs incubated in transwell with cells or in FBS-containing media alone were run on 
SDS-PAGE. Resulting protein profiles indicated that heparin MPs incubated with cells 
bound additional proteins in comparison to heparin MPs incubated in media alone (Figure 
4.10C). These additional proteins had a MW of approximately 17 kDa, which suggests 
that these proteins could be one or more of several ATDC5 produced growth factors. 
Overall, these results indicate that heparin-mediated delays in differentiation were likely 
a result of the binding of both cell-secreted and serum proteins. 
Future experiments could help elucidate the mechanisms behind observed 
changes in differentiation. To determine if saturation of heparin MPs is responsible for 
transient delays in differentiation, heparin MPs previously cultured with ATDC5 cells for 
12 days could be incubated with a second population of ATDC5 cells. If MPs truly do 
become saturated, then no changes in differentiation would be observed in the second 
population. In addition, to determine if the response is dose-dependent on heparin and not 
the total amount of MPs, heparin MPs with varying amounts of heparin could be 
employed. Heparin MPs with different amounts of heparin have different protein binding 
capacities (see Chapter 6 and Figure 6.5B), allowing control of heparin dosage while 
maintaining equal MP number. Finally, to identify the protein(s) comprising the 17 kDa 
band observed for heparin MPs incubated with cells, mass spectrometry or western blots 
for proteins implicated in endochondral ossification, mentioned above, could be 
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performed. If particular proteins are able to be identified, these proteins could be dosed 
back into ATDC5 cell cultures containing heparin MPs. If normal differentiation was 
restored when the protein dose overwhelmed the binding capacity of heparin MPs, this 
would provide more evidence that this phenomenon is mediated by protein sequestration.  
 Employing heparin materials to delay differentiation has the potential to be 
beneficial for growth plate injury repair and several other applications. Currently, the 
gold standard for growth plate defect repair is to fill the defect with an inert substances, 
such as fat, muscle, bone wax, or silicone to prevent bony bridge formation [112]. These 
materials cannot stimulate regeneration of the damaged growth plate tissue, which has 
motivated the development of biomaterial-based strategies [112,113]. In general, 
therapeutic cell types such as MSCs or chondrocytes are seeded into hydrogel-based 
scaffolds and implanted into the defect. This technique has been met with varying levels 
of success, but directing regeneration of the tissue by native or delivered cells has not 
been achieved [111,113–118]. Thus, the use of heparin-based materials could be explored 
to modulate cellular differentiation through sequestration of cell-secreted proteins, 
possibly delaying or preventing undesirable ossification. Additionally, heparin-based 
materials could be useful in craniosynostosis, which involves premature fusion of cranial 
bones and can lead to craniofacial deformities and neurological complications if left 
untreated [207,208,333]. The current treatment involves surgery to separate and reshape 
fused cranial bones, but resynostosis, or refusing of the bones, is common due to high 
osteogenic potential in the tissue [207]. Biomaterial-based strategies to prevent 
resynostosis include delivery of antibodies against osteogenic proteins such as BMPs and 
TFGβs, but the short half-life of antibodies decreases the efficacy of these therapies 
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[209,210,334]. However, heparin materials, which unlike antibodies do not undergo rapid 
degradation in vivo, could be employed to sequester osteogenic proteins to prevent 
resynostosis. Finally, for in vitro differentiation of MSCs in chondrogenic applications, 
cells often undergo hypertrophic differentiation rather than maintaining a chondrocytic 
phenotype [37]. Current strategies to promote a chondrocytic phenotype revolve around 
achieving the proper milieu of growth factors, either by adding exogenous growth factors 
to the culture [37,129,130] or by relying on proteins secreted during MSC-chondrocyte 
co-culture [128,131–135]. It may be possible that application of heparin MPs would help 
prevent or delay hypertrophic differentiation through growth factor sequestration. Thus, 
the therapeutic potential of heparin-mediated delays in differentiation could be explored 
in variety of tissue engineering applications that require modulation of the differentiation 
timeline.  
 In these studies, heparin was selected due to its ability to bind many proteins 
involved in differentiation [25], enabling the material to make a significant impact on the 
cellular microenvironment. This could be beneficial over other systems that allow for 
specific sequestration of single proteins, as multiple growth factors are generally required 
for cellular differentiation and such systems tend to be expensive. In addition, as cell 
phenotype and consequential protein release profile evolve with time, a material with 
specific-sequestration abilities would only be relevant at certain stages during 
differentiation, while heparin could continue to bind an assortment of proteins throughout 
the entire course of differentiation. Still, sequestration of proteins in a non-discriminate 
manner is not always advantageous, as two heparin-binding growth factors might have 
opposing affects in a differentiation process, such as BMPs and FGFs in endochondral 
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ossification [23,106].  In such cases, single-protein affinity systems could be beneficial. 
Some of these systems, such as antibody-based sequestration platforms, have short half-
lives [209,210]. Other systems have utilized peptide sequences that sequester specific 
proteins, such as VEGF, TNFα, and FGF [43,46,335], to increase the stability of the 
sequestering system. As analyses techniques for heparin-sequestered proteins improve, 
heparin MPs could be used as a “first pass” to understand how protein sequestration 
affects a system of interest, and analysis of sequestered protein could inform design of 
future, protein-specific sequestration systems to enhance control of differentiation. Thus, 
the ability of heparin to sequester a variety of growth factors involved in differentiation 
enables the employment of heparin MPs as tools to modulate cellular differentiation and 
investigate sequestered proteins.  
4.5 Conclusion 
 In this work, heparin MPs delayed chondrocytic differentiation in the ATDC5 cell 
line in both spheroid and transwell culture as assessed by chondrocytic gene expression 
and matrix molecule deposition. In contrast, PEG MPs did not have a strong effect on 
differentiation, suggesting that protein sequestration was possibly responsible for the 
affects observed. SDS-PAGE supported this hypothesis, indicating that after culture with 
ATDC5 cells, more proteins were bound to heparin MPs than PEG MPs, and that heparin 
MPs may have been able to sequester cell-secreted proteins in the ~17 kDa size range. 
Overall, the studies presented here act as a proof-of-concept for GAG-based modulation 
of endogenous growth factors to control cell behavior. The ability harness the potential of 
endogenous growth factors within the cellular microenvironment is an emerging theme in 
the field of regenerative medicine, as it eliminates the need for exogenous protein, thus 
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reducing cost, requirements for FDA approval, and concerns about recombinant protein 
potency [3]. Thus, heparin materials have the potential to be used to sequester proteins 
toward the applications of modulating cell behavior, a valuable technique in tissue 
engineering and regenerative medicine. 
 Once we observed the ability of heparin MPs to modulate cellular differentiation, 
we set out to design heparin-based technologies that enabled enhanced temporal control 
over protein sequestration and subsequent re-presentation. In addition, we were interested 
in designing degradable heparin-based MPs to allow release and subsequent analysis of 
sequestered proteins. Thus, we developed core-shell heparin-PEG and degradable 




CORE-SHELL MICROPARTICLES FOR PROTEIN 





Tissue regeneration is a complex process that involves intricate coordination of 
cellular events, many of which are modulated by proteins [3]. The concentration of these 
proteins, often growth factors or cytokines, must be spatially and temporally controlled to 
ensure proper tissue growth [175]. While biomaterial-based controlled delivery systems 
have traditionally been used to deliver single growth factors [10,42], tissue regeneration 
may require more complex temporal control over growth factor presentation and cell 
signaling [3]. Of particular interest, cell-secreted proteins have the potential to be 
captured and manipulated to enhance tissue regeneration and repair [3,336]. For example, 
a protein might be locally sequestered by a biomaterial and its effect thus amplified 
during tissue repair [40,43–45]; alternatively, an undesirable protein might be captured 
and eliminated from the cellular microenvironment [46]. Combining these two ideas, a 
protein undesirable at one point in time might be captured and temporarily eliminated 
from the microenvironment until it is released at a second point in time, when its 
expression is desirable for tissue regeneration [3]. Thus, development of dynamic 
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biomaterials that can sequester and temporarily isolate cell-secreted proteins prior to a 
triggered release may achieve the level of temporal control needed to more fully regulate 
tissue regeneration and repair.   
Core-shell microparticle (MP) technologies are a particularly attractive 
technology for temporally modulating protein presentation in the cellular 
microenvironment [237,245]. Traditionally, core-shell MPs have either been used to 
prolong release and activity of cargo in an inner core by manipulating the degradation 
prolife of an outer shell [51,52] or to sequester and concentrate various biomarkers from 
bodily fluids, such as plasma or urine, for diagnostic tests [48–50]. To date, only a 
handful of core-shell MP systems have been used to deliver proteins [52,245–247]. In 
these studies, core-shell MPs were advantageous because either 1) burst release of the 
protein encapsulated in the core was significantly reduced due to the protective shell 
[52,245,247], or 2) the shell significantly prolonged protein bioactivity [246]. Similarly, 
only a few studies have shown the ability of core-shell MPs to sequester protein [48–50]. 
In contrast to core-shell MPs used for controlled release, core-shell MPs for biomarker 
sequestration are designed with an outer shell of small mesh size to exclude large proteins 
such as albumin, but to allow passage of smaller biomolecules, which remain trapped in 
the protein-binding core until retrieved for further analysis [48–50]. The two core-shell 
MP applications discussed above, protein delivery and biomarker sequestration, do not 
fully address the need for technologies able to sequester, isolate, and release cell-secreted 
proteins. However, taking inspiration from these technologies, it may be possible to 
create core-shell MPs not only to sequester proteins of interest, but also redeliver them at 
a user-defined time. Thus, in this work, we set out to develop a multifunctional heparin-
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poly(ethylene-glycol) (PEG) core-shell MP that 1) preserves protein bioactivity, 2) 
delivers protein in a temporally controlled manner with minimal burst release and 3) 
sequesters and re-delivers protein on a user-defined timescale.   
A non-degradable heparin MP was used as a protein-sequestering core due to its 
high affinity for growth factors and ability to preserve protein bioactivity. Heparin is a 
highly sulfated glycosaminoglycan, often used in tissue engineering scaffolds due to its 
ability to bind positively charged proteins [11,42,58,59,196,337]. Importantly, heparin 
can bind many growth factors involved in tissue formation, including bone 
morphogenetic protein-2 (BMP-2), Indian hedgehog (IHH), basic fibroblast growth factor 
(FGF-2), WNT, and transforming growth factor-β (TGF-β) [25]. Previous studies with 
these heparin MPs have shown high BMP-2 loading capacity and have suggested that 
BMP-2 is bioactive and can interact with cells while still bound to the MP [59]. 
Furthermore, heparin can protect proteins from denaturation, as it has been well 
documented that it protects FGF-2  from thermal and proteolytic degradation [338] and 
recently found that it can protect BMP-2 from degradation by heat and in aqueous 
solutions at physiological pH [58,339]. Thus, use of heparin MPs as a sequestering core 
could minimize burst release, present protein to cells only when the protein-loaded core is 
in contact with cells, and prevent protein denaturation. 
PEG-diacryate (PEG-DA) was used for the degradable shell, as PEG can be 
chemically modified with a variety of functional groups and PEG hydrogels permit 
protein diffusion [27,28]. To achieve user-defined shell degradation, dithiothreitol (DTT) 
was integrated into the PEG-DA  network, which enhances hydrolytic degradation of the 
polymer network [60]. Thus, use of a PEG-DA-based shell enables protein diffusion into 
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the heparin MP core, which then remains physically separated from cells until shell 
degradation.  
In this work, we developed heparin-PEG core-shell MPs for potential applications 
in protein sequestration and subsequent re-delivery. A re-emulsification method was 
established to encapsulate pre-formed heparin MPs in a degradable PEG-based shell. 
Then, a proof-of-principle experiment was conducted to demonstrate that BMP-2-laden 
heparin MPs can be delivered in a temporally controlled manner to cells from core-shell 
MPs with a hydrolytically-degradable shell. Subsequently, it was shown that BMP-2 
could be sequestered through the PEG-based shell onto the heparin core, and the BMP-2-
laden heparin core could then be released to stimulate a cell response, thus demonstrating 
that the core-shell MPs provide enhanced temporal control over protein sequestration and 
release for potential applications in tissue regeneration and repair. 
5.2. Materials and Methods 
5.2.1 Polymer Synthesis 
PEG-DA was synthesized according to previous methods [148]. Briefly, PEG 
(Sigma-Aldrich; Mn = 3.4 kDa) was reacted with acryoloyl chloride (Sigma-Aldrich) in 
100% molar excess in methylene chloride (Fisher Scientific), with trimethylamine 
(Sigma-Aldrich) acting as a catalyst at a 1:1 molar ratio with PEG. The reaction was 
allowed to proceed under nitrogen purge overnight, at which point the aqueous and 
organic phases were separated and PEG was precipitated from the organic phase using 
diethyl ether (EDM Millipore) and dried. Heparin was functionalized with 
methacrylamide according to previous methods [40]. Briefly, the reaction was carried out 
in a phosphate buffer of pH 5 with 20 mg/mL heparin, 83 mM N-
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hydroxysulfosuccinimide sodium salt (Sigma-Aldrich),  100 mM N-(3-aminopropyl) 
methacrylamide hydrochloride (Polysciences), and 78 mM (N-3-Dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDC) (Sigma-Alrich) for 2 hours on ice. An 
additional round of EDC was added, resulting in a final molarity of 156 mM. After 4 
more hours, solution was dialyzed for 2-3 days and lyophilized. All polymers were stored 
at -20°C prior to use. To fluorescently tag heparin, heparin methacrylamide was 
dissolved at 10 mg/mL in 0.1 M Na2HPO4, pH 6 and reacted with Alexa-Flour (AF) 633 
Hydrazide (Invitrogen) at 5.7 μM concentration with 0.1 M EDC for 1 hour. The solution 
was dialyzed for 2 days and lyophilized. Proton NMR (
1
H NMR) was used to determine 
the percent functionalization of heparin methacrylamide as previously described [59]. 
Briefly, Heparin was dissolved at 10 mg/mL in deuterated water and run on a Bruker 
Avance III 400 spectrometer. The percent of carboxyl groups substituted with 
methacrylamide groups was determined by comparing the integration regions of N-(3-
aminopropyl) methacrylamide hydrochloride and unmodified heparin.  
5.2.2 Microparticle Fabrication  
For Heparin MP fabrication, Heparin methacrylamide MPs were formed 
according to previous methods [59]. Briefly, an aqueous phase of 10% heparin 
methacrylamide (wt%), 18 mM ammonium persulfate (Sigma-Alrich), and 18 mM 
N,N,N′,N′-Tetramethylethylenediamine (Sigma) were emulsified against corn oil with 
1.67% (v/v) Tween-20 (polysorbate 20; BDH) at a 1:120 ratio aqueous:oil phase. MPs 
were cross-linked under nitrogen purge at 60°C for 30 minutes, then washed with acetone 
and water. Heparin MPs were filtered using a size extrusion device (Lipex Thermoline 
extruder, Northern Lipids) against a 12 μm nucleopore membrane to ensure MPs were all 
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less than12 μm in diameter. For AF633 tagged heparin MPs, the same procedure was 
followed but tagged heparin was included at 70 wt% total polymer content.  
Core-shell MPs were formed by suspending pre-formed heparin MPs in a 
precursor aqueous phase containing 16 wt% PEG-DA, 0.05 wt% Irgacure 2959 
Photoinitiator (Ciba), 2 mg/mL poly-L-lysine (PLL, Sigma-Aldrich), 45 mM DTT 
(degradable MPs only) and 0.33 mg/mL FITC-PEG-SH (1 kDa; NANOCS; for 
fluorescently tagged MPs only). For MPs with FITC-PEG or DTT, the aqueous phase 
was allowed to incubate for 1 hour at 37°C to allow for a click reaction to occur between 
the thiolated FITC molecule or DTT and the acrylate group on the PEG molecules. The 
aqueous phase was then emulsified with a homogenizer against a mineral oil phase (light, 
white; Ameresco) with 0.3-1.3% (v/v) Span-80 (sorbitan monooleate; TCI) at a 1:16.7 
ratio aqueous:oil phase, nitrogen purged for 1 minute, then cross-linked under UV light 
(approximately 10.5 mW/cm
2
) in a 35x10 mm petri dish for 10 minutes. Core-shell MPs 
were then washed with water and filtered using the size extrusion device against a 12 μm 
filter to remove any remaining free heparin MPs. PEG-based MPs were made in a similar 
fashion to the core-shell MPs, but without heparin MPs in the aqueous phase. 
PEG-based MPs were made in a similar fashion to the core-shell MPs, but without 
heparin MPs in the aqueous phase. Dithiothreitol (DTT) was added to the aqueous phase 
at a 40 or 45 mM concentrations, corresponding to a PEG:DTT molar ratio of 1.42:1 or 
1.21:1 , for the slow- and fast-degrading MPs, respectively.  For sizing studies, 0.07, 1.3, 




5.2.3 Microparticle Characterization 
To characterize core-shell MPs, fluorescent core-shell MPs were imaged via 
confocal microscopy. Heparin methacrylamide tagged with Alexa Flour (AF) 633 was 
used to fabricate the heparin MP core and FITC-PEG-SH was included in the aqueous 
PEG phase. Confocal microscopy (20x objective, LSM 700; Zeiss) was used to image 
stacks of MPs at 2 μm intervals. To immobilize MPs for imaging studies, core-shell MPs 
were suspended in a 10 wt% PEG-DA (8kDa) phase with 0.05% D2959  and cross-linked 
under UV light (approximately 10.5 mW/cm
2
) in PTFE (Teflon) wells for 10 minutes to 
form MP-containing hydrogels discs of approximately 6 mm in diameter and 1 mm thick. 
This kept MPs from drifting while confocal stacks were being taken. Stacks were then z-
projected and orthogonal views were used to confirm complete encapsulation of heparin 
MPs within the PEG-based shell.  
To quantify number of heparin MPs/core-shell MP, ImageJ was used to z-project 
and split stacks into FITC (green, PEG-based shell) and AF633 (red, heparin core) 
channels. Then, each PEG-based shell was defined as a Regions of Interest (ROI) through 
thresholding and particle analysis of the FITC channel. Next, the number of heparin MPs 
in each ROI was counted using thresholding and particle analysis of the AF633 channel. 
Finally, number of heparin MPs per each core-shell MP was graphed against its cross-
sectional area (CSA; μm
2
). Linear correlations were obtained for masses of 0.1, 0.25, 0.5. 
0.75, and 1 mg heparin MPs suspended in precursor PEG phase and each mass was tested 
in three separate MP batches (n=3 batches, 50-100 MPs analyzed/batch).  
In all subsequent studies, a mass of 1 mg heparin MPs was used. For each batch 
of core-shell MPs used for protein pull-down studies and cell studies, core-shell MPs 
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were sized and a histogram of core-shell CSA was constructed with binning at every 40 
μm
2
. The average slope of the lines of the linear correlations obtained for a mass of 1 mg 
was then used to determine an average number of heparin MPs/core-shell MP based on 
average number of core-shell MPs per each bin. With this information, the correct 
number of core-shell MPs could be used to match the mass of heparin in the core-shell 
MPs to the mass of the heparin MP controls. 
For core-shell and PEG-based MP degradation studies, MPs were counted with a 
hemocytometer and 1 million MPs/mL of PBS were incubated at 37°C on a shaker plate 
at 65 RPM (Barnstead Lab-Line, Multipurpose Rotor). 30 μL aliquots of MP solution 
was taken every 2-3 days and imaged using phase microscopy. Core-shell MPs were 
determined to be degraded when few (less than10 MPs) or no core-shell MPs were 
visible. Slow- and fast-degrading PEG-based MPs were treated in a similar fashion. 
For PEG-based MP sizing studies, PEG-based MPs with 0.07, 1.3, and 2.0 wt% 
Span-80 were fabricated. MPs were sized by using ImageJ to manually measure MP 
diameter from phase microscopy images (n=3 MP batches for each Span-80 
concentration; 150 MPs analyzed for each batch). 
5.2.4 Protein Loading and Release 
Degradable core-shell MPs and PEG-based MPs (45 mM DTT) were prepared. 
The mass of heparin MPs was 0.02 mg for both the degradable core-shell MPs and the 
heparin MPs. The number of degradable PEG-based MPs was matched to the number of 
degradable core-shell MPs. 90 ng of recombinant human BMP-2 or stromal cell-derived 
factor-α (SDF-1α) (R&D Systems) was loaded onto the MPs in a 0.1% bovine serum 
albumin (BSA) PBS solution in low-binding tubes, resulting in 4.5 μg protein/mg heparin 
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MP. MPs were incubated at 4°C on rotary for 2 or 24 hours, at which point they were 
centrifuged and the supernatant was analyzed using an enzyme-linked immunosorbent 
assay (ELISA; R&D Systems).  
Two techniques were used for loading core-shell MPs. In the first technique, 
heparin MPs were loaded with protein prior to encapsulation into the PEG shell (“pre-
fabrication load”; Figure 5.5A). In the second technique, core-shell MPs were formed and 
then loaded with protein (“post-fabrication load”; Figure 5.7A). Because small proteins 
are able to diffuse through PEG-DA networks [27], it was hypothesized that encapsulated 
heparin MPs would still be able to sequester protein, which was confirmed in pull-down 
studies. For “pre-fabrication load” studies, 1 mg heparin MPs were loaded at a 
concentration of 1.5 µg BMP-2/mg MP in a 0.1% BSA solution in low-binding tubes at 
4°C on rotary overnight. MPs were centrifuged and supernatant was removed and 
analyzed using an ELISA (R&D Systems) to calculate total BMP-2 loaded. Then, loaded 
heparin MPs were used to form degradable and non-degradable core-shell MPs. 
Degradable core-shell MP, core-shell MP, and heparin MP groups all contained 0.02 mg 
heparin MPs and were incubated in a 0.1% BSA solution in PBS at 37°C for seven days 
on a shaker plate. At days 1, 4, and 7, MPs were centrifuged and supernatant was 
removed for analysis and replaced with fresh 0.1% BSA solution. Supernatant was 
analyzed using an ELISA (R&D Systems). 
 For “post-fabrication load” studies, degradable core-shell and PEG-based MPs 
were fabricated. Degradable core-shell MP contained 0.02 mg heparin MPs. The number 
of PEG-based MP and core-shell MPs were matched. All MPs were loaded at a 
concentration of 4.5 µg BMP-2/mg MP in a 0.1% BSA PBS solution in low-binding 
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tubes at 4°C on rotary overnight. MPs were centrifuged and supernatant was removed 
and analyzed using an ELISA (R&D Systems) to calculate total BMP-2 loaded. 
Supernatant was replaced with a fresh 0.1% BSA solution in PBS and MPs were 
incubated at 37°C for seven days on a shaker plate. At days 1, 4, and 7, MPs were 
centrifuged and supernatant was removed for analysis and replaced with a fresh 0.1% 
BSA solution. Supernatant was analyzed using an ELISA (R&D Systems). 
5.2.5 ALP Activity Assays 
The C2C12 cell line was used to evaluate the ability of core-shell MPs to delivery 
bioactive BMP-2 after shell degradation, as C2C12 cells produce ALP in response to 
BMP-2 [340]. C2C12 cells were cultured at 37°C, 5% CO2 in DMEM with 4.5 g/L 
glucose, fetal bovine serum (FBS) (10% for growth media, 1% for assay media; 
Hyclone), 2 mM L-glutamine, 50 IU Penicillin and 50 μg/mL Streptomycin. For assays, 
cells were plated at 62,500 cells/cm
2
 in 96 well plates and were incubated for 6 hours to 
allow adherence before the assay was started. 
Microparticles were prepared for pre- or post-fabrication load experiments as 
described above and were sterilized by washing with 70% ethanol for 30 minutes, 
followed by 3 washes with PBS for 30 minutes each. For pre-fabrication studies, groups 
included pre-fabrication loaded and non-loaded degradable core-shell MPs, pre-
fabrication loaded and non-loaded core-shell MPs, and a soluble BMP-2 and a no BMP-2 
media control (Figure 5.5A). For post-fabrication studies, groups included post-
fabrication loaded and non-loaded degradable core-shell microparticles, loaded and non-
loaded degradable PEG-based MPs, and a soluble BMP-2 and no BMP-2 control (Figure 
5.7A). All MPs were incubated for 2.5 days prior to being added to cells for pre-
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degradation. This allowed MP shell degradation to occur during the three day cell assay 
(while degradation occurs throughout the entire time course, the majority of the PEG-
based MP degradation occurred between days 3-6 for these MPs; Figure 5.1C). All core-
shell and heparin MP groups had 0.02 mg of heparin and the degradable PEG-based 
control group had the same number of MPs as the core-shell group. Cells were cultured 
for 3 days and then media/MPs were removed.  
After media and MP removal, cells were washed twice with PBS. DdH2O was 
added to cells for 20 minutes and then cells subjected to a freeze-thaw cycle. Cells were 
then scraped from the 96-well plate and cell lysate solution was transferred to 1.7 mL 
tube. Cell lysate was sonicated for 20 minutes, then subjected to another freeze-thaw 
cycle. This was repeated once, then samples were centrifuged at 10,000 RCF for 5 
minutes and supernatant was used for analysis. For ALP activity, 50 μL sample was 
combined with 50 μL 1.5M 2-amino-2-methyl-1-propanol (Sigma-Aldrich), 50 μL 10 
mM magnesium chloride, and 50 μL 20 mM p-nitrophenol phosphate disodium salt 
hexahydrate (Sigma-Aldrich). For standards, p-nitrophenol (Sigma-Aldrich) was used. 
Samples were allowed to incubate for 2 hours and absorbance was read at 405 nm. DNA 
content was assessed with the CyQUANT Assay following the manufacturer’s 
instructions and using bacteriophage λ DNA to create a standard curve (ThermoFisher 
Scientific). The assay was read at excitation/emission of 480/520. 
5.2.6 Statistical Analysis 
All results are depicted as mean ± standard deviation. Analysis of Variance 
(ANOVA) was used to identify significant factors and interactions, then Tukey’s post hoc 
test (significance level p ≤ 0.05) was used to generate pairwise comparisons between 
 129 
means of individual sample groups and determine statistically significant differences 
(Minitab 15 Statistical Software). 
5.3 Results 
5.3.1 PEG Shell Fabrication and Characterization  
At 0.7% Span-80, non- (no DTT), slow- (40 mM DTT), and fast- (45 mM DTT) 
degrading MPs had average diameters of 18.3±15.8, 70.0±49.0, and 44.6±36.1 µm, 
respectively, a range of about 52 µm. At 1.3 wt% Span-80, non-, slow-, and fast-
degrading MPs had average diameters of 11.1±7.3, 31.5±28.1, and 15.3±12.7 µm, a range 
of 20 µm. At 2.0 wt% Span-80, non-, slow-, and fast-degrading MPs had average 
diameters of 9.2±4.8, 13.4±11.0, and 23.2±22.3 µm, a range of 14 µm (Figure 5.1A).  
For degradation studies, DTT was incorporated into the network via Michael-
Type addition to accelerate hydrolytic degradation (Figure 5.1B). Slow-degrading MPs 
were observed to degrade in about 23 days, while fast-degrading MPs degraded in about 
8 days (Figure 5.1C). MPs were determined to have degraded if few (less than 10) or no 
MPs were visible via phase microscopy. 
 
Figure 5.1. PEG-based MPs with tunable size and degradation profiles. (A) PEG-based 
MPs of 0mM, 40mM, and 45mM DTT concentrations were fabricated with varying Span-
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80 surfactant  concentrations (*=significantly different than other groups with same DTT 
concentration; p<0.05, n=3 batches of MPs). (B) Cross-linking schematic for PEG-DA 
and DTT. DTT clicks into the PEG-DA via Michael-Type addition at the acrylate bonds, 
and accelerates hydrolysis of the ester bond and thus degradation of the network. (C) 
Degradation time course for slow- and fast-degrading MPs (40 and 45 mM DTT, 
respectively). Slow-degrading MPs degraded by day 23 and fast-degrading MPs degraded 
by day 8. Arrows indicate MPs (n=3 batches of MPs, scale bar = 100 μm). 
 
5.3.2 Core-Shell MP Fabrication and Characterization 
Core-shell MPs were fabricated by suspending heparin MPs (15-27% 
methacrylamide functionalization) of known mass in a precursor aqueous PEG-DA phase 
that was emulsified against mineral oil and then cross-linked via free radical initiated 
polymerization (Figure 5.2A). The size of core-shell MPs could be controlled by varying 
the concentration of Span-80 in the oil phase (Figure 5.1A). Heparin MPs appeared 
encapsulated inside PEG-based shell in phase microscopy images (Figure 5.2B) and 
encapsulation was confirmed using orthogonal views of three-dimensional image stacks 
from confocal microscopy (Figure 5.2C).  
 
Figure 5.2. (A) Core-shell MPs were formed via a water-in-oil emulsion. (B) Phase 
images of core-shell MPs. Arrows and arrowheads indicate the PEG-based shell and 
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heparin core, respectively. (C) Orthogonal view from 3D confocal image stacks 
confirmed encapsulation of heparin core (red, arrow) into PEG-based shell (green) (scale 
bar = 25 µm). 
 
As multiple heparin MPs are encapsulated in each PEG-based shell in this 
fabrication process, the number of heparin MPs per core-shell MP was determined in 
order to achieve known heparin dosages for subsequent cell studies. Using ImageJ, the 
number of heparin MPs per core-shell MP was determined and a linear correlation was 
found between the number of heparin MPs and the CSA of each core-shell MP (Figure 
5.3A). As the CSA of the core-shell MP increased, the number of heparin MPs increased 
(Figure 5.3A and B). The ratio of the number of heparin MPs:core-shell CSA also 
increased as the mass of heparin MPs in the pre-cursor was increased, evidenced by the 
increasing slope in graphs of heparin MPs vs. core-shell CSA (Figure 5.3A). A second 
linear correlation was found between mass of heparin MPs in precursor PEG phase and 
the ratio of heparin MPs:core-shell CSA (Figure 5.3C). Thus, for similarly sized core-
shell MPs, the number of heparin MPs increases as the mass of heparin MPs in the pre-
cursor PEG phase increases (Figure 5.3C and D).  
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Figure 5.3. The heparin content in core-shell MP is correlated to MP size and  mass of 
heparin MPs in the precursor PEG solution. (A) Number of heparin MPs correlated 
linearly with core-shell MP cross-sectional area for five masses of heparin tested. Note 
axes are different in 0.75 and 1 mg groups due to increases in MP size (n=3 batches of 
MPs for each mass). (B) Representative images of MPs fabricated with 1 mg of heparin 
ranging from 35-125 μm in diameter, noted above each image and pointed out by white 
arrows if more than one MP/image (PEG in green, heparin in red ; scale bar = 25 μm). 
(C) The ratio of heparin MPs/core-shell size increases as the mass of heparin MPs in 
precursor PEG phase is increased (n=3 batches of MPs for each mass). (D) 
Representative images of 0.1, 0.5, and 1 mg heparin MP encapsulated in PEG shell (scale 
bar = 25 μm).  
 
5.3.3 Core-Shell MP Degradation 
 Hydrolytic degradation of PEG-DA MPs can be accelerated by adding DTT into 
the network, which enhances the susceptibility to hydrolysis of the ester bond [60]. By 
varying the concentration of DTT, degradation rate of PEG-based MPs could be 
temporally modulated, allowing a range of degradation time between 8 and 23 days 
(Figure 5.1C). For core-shell MPs, DTT was incorporated into the PEG-DA network at a 
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45 mM concentration (corresponding to a molar ratio of 1.21:1 PEG-DA:DTT) and the 
shell of the core-shell MPs were observed to degrade in approximately six days using 
phase microscopy. In addition, the non-degradable heparin MP core was released and 
present after shell degradation (Figure 5.4).  
 
Figure 5.4. Degradation of PEG-based shell and release of heparin MP core from core-
shell MPs.  Core-shell MPs are present through day 5 (days 1-5, arrows), at which point 
they begin to degrade and release heparin MPs (days 5 and 7, arrowheads). Core-shell 
MPs are fully degraded by day 7. 
 
5.3.4 Pre-Fabrication Load Bioactivity Studies 
 For pre-fabrication load studies, heparin MPs loaded 98.0+0.1 % of BMP-2. 
Degradable and non-degradable core-shell MPs were fabricated with loaded heparin MPs 
and release of BMP-2 was monitored over seven days. As BMP-2 binds tightly to heparin 
MPs, very little BMP-2 was released over the course of seven days (5.8+3.2%, 7.9+4.3%, 
and 2.5+1.7% for degradable core-shell, core-shell, and heparin MPs, respectively; 
Figure 5.5B). Degradable core-shell microparticles induced similar C2C12 ALP activity 
as the soluble control, while core-shell microparticles induced significantly lower activity 
after three days (85.4+19% vs. 9.0+4.8% of soluble control, respectively; Figure 5.5C). 
No signal was observed for groups without BMP-2, and an elevated DNA content was 
observed in all groups subjected to BMP-2 as compared to those without BMP-2. No 
trends in DNA content were observed between groups. 
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Figure 5.5. Degradable (Deg) core-shell MPs modulate loaded heparin MP delivery to 
cells. (A)  Experimental set-up for pre-fabrication loaded core-shell MPs. (B) Cumulative 
percent released of loaded BMP-2 for deg core-shell, core-shell, and heparin MP groups 
(&=significantly different from heparin MP group, p<0.05, n≥3). (C) Normalized ALP 
activity for deg core-shell, core-shell, and soluble BMP-2 groups (non-loaded groups 
showed no signal; *=significantly different from core-shell MP group, p<0.05, n=4). 
 
5.3.5 Post-Fabrication Load Protein Sequestration Studies 
  When degradable core-shell MPs were loaded with BMP-2 and SDF-1α, 
sequestration of proteins was temporally delayed. At two hours, significantly more SDF-
1α remained in solution after incubation with core-shell MPs than with heparin MPs 
(26.8+7.1% and 2.3+1.8%, respectively). However, by twenty-four hours similar 
amounts of protein were found for each group (6.0+0.7% and 1.2+0.4%, respectively; 
Figure 5.6A). BMP-2 behaved similarly, with significant differences in sequestration 
observed at 2 hours (47.8+2.4% and 15.2+4.6% remaining for core-shell and heparin 
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MPs, respectively) but similar levels of sequestration by twenty-four hours (10.7+1.4% 
and 9.0+1.2% remaining for core-shell MPs and heparin MPs, respectively; Figure 5.6B). 
In both cases, no protein sequestration was observed in the PEG-based shell group. All 
results are normalized to the soluble control group. These studies indicate that it is 
possible to sequester protein through the PEG-based shell of core-shell MPs, but that 
sequestration is temporally delayed. Thus, for all post-fabrication loading cell studies, a 
24 hour loading time was used. 
 
Figure 5.6. Core-shell MPs temporally modulate protein sequestration. Protein pull-down 
studies with growth factors (A) SDF-1α and (B) BMP-2. Graphs show percent of protein 
remaining in solution (i.e. percentage of protein not sequestered by MPs) normalized to 
soluble protein controls. (*=significantly different from heparin MP group, 
**=significantly different from degradable core-shell; p<0.05, n≥3). 
 
5.3.6 Post-Fabrication Load Bioactivity Studies 
 Loading studies indicated that degradable core-shell MPs loaded 93.5+1.0% of 
BMP-2 while degradable PEG MPs loaded only 11.5+14.6% as compared to the soluble 
control (Figure 5.7B). Core-shell MPs released only 2.7+1.6% of loaded BMP-2 over 
seven days (Figure 5.7C). Degradable core-shell MPs induced ~7-fold higher C2C12 
ALP activity than the soluble control, while no detectable signal was observed for the 
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loaded degradable PEG-based MP group (Figure 5.7D). No signal was observed for 
groups without BMP-2.  
 
 
Figure 5.7. Post-fabrication loading allows for delivery of loaded heparin MPs. (A) 
Experimental set-up for post-fabrication loaded MPs. (B) Post-fabrication loading 
resulted in nearly 100% loading in deg core-shell MP group and less than 10% loading in 
deg PEG-based MP group. (C) Cumulative mass of BMP-2 released for deg core-shell 
and deg PEG-based MPs for seven days. (D) Normalized ALP activity for deg core-shell 
MP, deg PEG-based MP, and soluble groups. “ND” indicates not detectable (non-loaded 




In these studies, core-shell MPs were designed to sequester, isolate and protect, 
and deliver protein on a user-defined timescale.  First, a hydrolytically degradable PEG-
based shell was required in order to release the protein-laden heparin core. Thus, DTT 
was incorporated into the PEG-DA aqueous phase via a click reaction, as DTT can 
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enhance the susceptibility of the resulting ester bond to hydrolytic degradation [60].  
Slow- and fast-degrading MPs were formed by varying the concentration of DTT in the 
PEG-DA network. Because DTT links two PEG-DA chains via their acrylate groups, 
these acrylates are then no longer available for cross-linking in free radical initiated 
polymerization, which can result in longer chain lengths and thus larger mesh size 
(Figure 5.1B). This was likely the cause of larger MPs observed in previous work that 
utilized this technique, as it was shown that increasing the concentration of DTT resulted 
in increased MP size [221]. While those studies employed a water-in-water emulsion 
technique [221], a water-in-oil emulsion technique was used in these studies, as MP size 
could be modulated independently of DTT content by varying surfactant concentration 
(Figure 5.1A). First, for each type of MP (non-, slow-, and fast-degrading), increasing 
amounts of Span-80 resulted in a smaller MP diameter. Additionally, as Span-80 
concentration was increased, the range in average MP diameter between the three types 
of MPs tightened. With the lowest amount of Span-80 (0.7% wt%), the diameter of non- 
and fast-degrading MPs was the most variable (a range of 52 µm) and showed similar 
trends to previous work [221], with increasing sizes observed with increasing DTT 
concentration. As Span-80 increased, however, MP size could be controlled with less 
dependence on DTT concentration, as diameter ranges dropped to 20 and 15 µm for 
higher concentrations of Span-80. These results indicated not only that Span-80 could be 
used to tune MP size within one DTT concentration, but also that concentration of Span-
80 could be used to modulate MP size independently of DTT concentration (especially at 
higher wt%). Thus, non-, slow-, and fast-degrading PEG-based MPs of different sizes 
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could be formed by varying Span-80 concentrations, allowing size to be controlled 
independently of DTT concentration. 
Degradation studies showed that slow- and fast-degrading MPs degraded at 8 and 
23 days, respectively (Figure 5.1C). This indicates that by varying the DTT concentration 
in the MPs, the degradation rate could be varied, providing ample room for fine-tuning 
these concentrations to achieve MPs that degraded between 8-23 days or after 23 days. 
As DTT reacts with functional acrylate groups in the PEG-DA network, there is a limit to 
the amount of DTT, dependent upon the mass of PEG-DA, that can be incorporated into 
the PEG-DA network before MPs can no longer be formed (data not shown). In these 
studies, the fast-degrading PEG MPs contained the maximum amount of DTT that could 
be added to the network and still be crosslinked, indicating that the mass of PEG-DA 
would have to be adjusted in order to add more DTT and achieve faster degradation rates. 
However, within these limits, PEG-based MPs with tunable size and degradation profiles 
were developed, and the fast-degrading MPs with 2.0% Span-were used for the shell of 
core-shell MPs. Overall, a degradable PEG-based shell was designed to degrade over 
time in aqueous conditions, allowing shell degradation to occur after delivery to a 
biological system. 
Previously, a variety of fabrication techniques have been employed to make core-
shell MPs, including double-emulsion and layer-by-layer coating. While the double 
emulsion fabrication technique is a convenient, one-batch reaction, it requires two 
immiscible phases [238,239,242,341], restricting the chemical properties of the materials 
that can be used. Layer-by-layer coating can provide control over shell size, but requires 
layers to interact with each other through electrostatic interactions [246], again narrowing 
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material choice to those with positive or negative charges. Because the heparin-PEG 
core-shell MPs presented here required use of specific materials, each having a separate 
function, a fabrication technique that permitted greater flexibility in material choices was 
required. Thus, a re-emulsification technique was chosen [241] for core-shell MP 
fabrication to allow use of heparin and PEG-based materials. In this method, pre-formed 
heparin MPs were re-emulsified in a precursor PEG phase (Figure 5.2), a process mild 
enough to maintain protein bioactivity when protein was loaded onto heparin MPs pre-
fabrication (loading of heparin MPs prior to re-emulsification; Figure 5.5C).  
Core-shell MP characterization revealed that the number of heparin MPs was 
linearly correlated to the CSA of core-shell MPs, and that increasing the mass of heparin 
in the precursor PEG phase increased the number of heparin MPs encapsulated (Figure 
5.3). Thus, although a heterogeneously-sized population of MPs was formed in each 
batch, the number of heparin MPs per core-shell MP was tunable and predictable. If more 
homogenously-sized MPs per batch are required for future experiments, this re-emulsion 
technique could be translated to a microfluidic device to increase core-shell MP size 
homogeneity [242], as a PEG-based MPs have previously been fabricated on microfluidic 
devices with a variety of cross-linking techniques [342–344].  
 Recently, it has been shown that hydrolytic degradation can be enhanced in PEG-
DA hydrogels by integrating DTT into the polymeric network [60].  In this work, slow- 
and fast-degrading MPs were developed by varying the amount of DTT added to the 
aqueous PEG phase (Figure 5.1C). Previously, DTT has been incorporated into PEG-DA 
MPs using a water-in-water emulsion technique, but it was shown that increasing the 
concentration of DTT resulted in increased MP size, likely due to increased chain length 
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and consequently, a larger mesh size [221]. To overcome this limitation, a water-in-oil 
emulsion technique was used, as MP size could be modulated independently of DTT 
content by varying surfactant concentration (Figure 5.1A).  Thus, tunable degradation and 
controllable size of the PEG-based MP shells was achieved, which was then applied to 
core-shell MPs to enable shell degradation in approximately six days (Figure 5.4).  
 In these experiments, core-shell MPs were loaded using two different techniques.  
In the first, a “pre-fabrication loading” technique (Figure 5.5A), heparin MPs were 
loaded with BMP-2 prior to encapsulation into the PEG-based shell. Using the pre-
fabrication loading technique may be advantageous because the core-shell fabrication 
technique does not require use of solvents and heparin can protect proteins from 
denaturation [58,338,339], thus promoting maintenance of bioactivity of loaded proteins. 
Furthermore, pre-fabrication loading could allow for loading of proteins in both the 
heparin core and PEG-based shell in future experiments for dual-release applications. 
When core-shell MPs were pre-fabrication loaded with BMP-2, degradable and non-
degradable core-shell MPs released very little protein over the course of seven days 
(5.8+3.2%, 7.9+4.3%, and 2.5+1.7% for degradable core-shell, core-shell, and heparin 
MPs, respectively; Figure 5.5B). These results are comparable to what has been seen in 
previous studies when heparin MPs loaded with 1000 ng BMP-2/mg heparin MPs 
showed less than 10% release of BMP-2 after 30 days [59]. 
Because so little protein is released from the core-shell MPs, only degradation of 
the PEG-based shell and release of the protein-laden heparin core would be able to 
initiate a response from C2C12 cells. This necessitates the ability of protein to interact 
with cell receptors while still bound to heparin. Here and in past studies [59], it was 
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evident that BMP-2 could interact with cells while bound to the heparin MPs (Figure 
5.5C and 5.7D), possibly with greater efficiency, as ALP activity was higher in groups 
with BMP-2 loaded on core-shell MPs than soluble BMP-2 (Figure 5.7D). In addition, 
evidence from in vivo and in vitro studies indicates that many other proteins, such as 
IHH,  FGF, and WNT can also interact with their cell surface receptor while bound to 
heparin or heparan sulfate, potentially with enhanced affinity [175,182], indicating that 
this core-shell technology is versatile and can be used for delivery of a variety of heparin-
binding proteins. 
Pre-fabrication loaded degradable core-shell MPs were able to initiate a cell 
response that was similar to the response initiated by the soluble control, unlike the non-
degradable control group, which demonstrated limited cellular response (Figure 5.5C). 
This is distinctly different than many other delivery systems, which generally have an 
unavoidable burst release prior to more sustained delivery of protein [52,234,237]. Here, 
protein release from a loaded vehicle was prevented for over three days in the non-
degradable group, strongly supporting the idea that in this system, the majority of protein 
presentation can only occur after shell degradation and release of the protein laden core. 
Additionally, when core-shell MPs were allowed only a two day pre-degradation period 
(rather than the three days allotted for the experiment above) prior to placement on cells, 
the response initiated by the degradable core-shell MPs was lower than the soluble 
control, indicating that the degradation state of the shell does temporally control cell 
response (Figure E.9).  
By tuning the degradation rate of the PEG-based shell, it would be possible to 
further adjust the delay period between MP delivery and protein presentation, beneficial 
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for applications that require delivery of different proteins at different points in time. 
Specifically, optimization of cellular differentiation processes such as chondrogenesis for 
cartilage regeneration [37] or myogenesis for muscle regeneration [345] may benefit 
from such a technology that promotes complex temporal coordination of protein 
presentation. In addition, tissue repair processes such as wound healing and 
vascularization could benefit from release vehicles with tight temporal control over 
protein release [3]. 
 For the second loading technique employed with these core-shell MPs, “post-
fabrication loading,” core-shell MPs were formed and then loaded with BMP-2 by 
diffusion through the outer shell (Figure 5.7A). First, protein sequestration studies were 
conducted to determine if protein diffusion through the PEG-based shell could occur, 
using two different model proteins, SDF-1α and BMP-2, chosen because they possess 
molecular weights (~7-16 kDa) that represent small to average size for many growth 
factors, including but not limited to BMP-2, IHH, FGF-2, and TGFβ-1 (molecular 
weights ranging from 12-20 kDa, R&D Systems website [346]). Interestingly, a slight 
temporal delay in sequestration of both proteins was observed in the core-shell MP 
groups as compared to the heparin MP control, indicating that the PEG-based shell 
delayed diffusion of these proteins. These findings are similar to previous studies that 
have shown that protein diffusion is slowed but not inhibited by a PEG-DA hydrogel 
network [27,347,348]. For example, one study found that myglobin (17 kDa, similar in 
size to the proteins used in this study) was able to diffuse through both 2 and 10 kDa PEG 
networks, but at a slower rate in the 2 kDa network [27]. (NB: Because PEG may protect 
protein from denaturation in aqueous solution [238], protein levels were observed to be 
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greater than 100% of soluble control (Figure 5.6)). Thus, for the rest of post-fabrication 
load studies, core-shell MPs were incubated with protein for 24 hours to ensure complete 
protein loading.  
After loading with BMP-2, very little release was observed in post-fabrication 
loaded core-shell MPs over the course of 7 days (2.7+1.6% of loaded BMP-2), similar to 
what was seen in pre-fabrication loading release studies. In a proof-of-principle study, 
when incubated with C2C12 cells, post-fabrication loaded degradable core-shell MPs 
induced ~7-fold higher C2C12 ALP activity than the soluble control (Figure 5.7D), 
indicating that these MPs can effectively sequester and then re-present growth factors to 
cells. The degradable PEG-based MP control, in which no signal was detected, was used 
to ensure that cell response was not due to free BMP-2 caught in the PEG network during 
loading. Several studies have shown the potential for heparin-based materials to sequester 
endogenous proteins [40,44,45,349,350], but none of these have included a temporal 
control over re-presentation. Previously, core-shell MPs have been used to selectively 
sequester proteins through a size-exclusive shell to concentrate biomarkers [47–50], but 
few, if any, technologies can sequester, physically isolate, and then re-release protein to 
the external environment. As the core-shell MPs presented in this work has the potential 
to achieve this, it is possible that this technology can enhance temporal control over 
protein presentation in the cellular microenvironment for future tissue engineering 
applications.  
The core-shell MPs in this work were designed to degrade in approximately 6 
days, which is an appropriate timeframe for several different applications involving the 
ATDC5 cells used in Chapter 4. In both monolayer and spheroid culture, ATDC5 cells 
 144 
began strongly expressing differentiation markers at days 4-12 [309] (Figures E.7 and 8). 
In order to sequester and re-deliver cell-secreted protein to ATDC5 cells, two different 
scenarios were envisioned. In the first, core-shell MPs would be incubated with ATDC5 
cells for approximately three days (shell would be intact) to sequester cell-secreted 
proteins. The three day period would be chosen to achieve maximum binding of desired 
proteins, and days 6-9 would be used for initial tests as many proteins are likely released 
during this time to encourage cell differentiation based on increased gene expression 
levels. Then, intact and saturated core-shell MPs would be removed and placed on a 
second population of cells, either ATDC5 cells or another cell type, to enhance 
differentiation as the shell degraded between days 3-6 and released protein-laden heparin 
MPs. In the second scenario, core-shell MPs would be used to sequester protein from 
ATDC5 cells at early timepoints (for example, days 3-6) to effectively halt or restrict 
differentiation until shell degradation (days 6-9), at which point protein-laden heparin 
MPs would be re-delivered to accelerate or reinitiate differentiation. Thus, the ~6 day 
degradation timeframe was chosen specifically for ATDC5 cell differentiation, but could 
be modified for other applications (Figure 5.1).  
In this system, degradable core-shell MPs enabled triggered or temporally off-set 
release of protein-laden heparin MPs through hydrolytic degradation. While a 
hydrolytically degradable system is advantageous because it permits a user-defined 
degradation rate and release of cargo that is initiated simply by the presence of water (and 
not an external stimuli), it is limited by its inability to respond to conditions in the 
cellular microenvironment or a user-defined stimuli. Other systems can overcome these 
limitations. For example, hydrogels can be engineered to degrade or deform via enzymes, 
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light exposure, change in pH, ultrasound exposure, temperature changes, or magnetic 
fields [351–354]. Materials that degrade due to enzymes, pH changes, or temperature 
changes can be useful due to their responsiveness to the cellular microenvironment. For 
example, as the concentration of a specific enzyme controls the release profile of 
encapsulated cargo in an enzymatically degradable hydrogel, release only occurs under 
particular conditions [353]. While beneficial for specific applications, these types of 
systems would not have widespread applicability. Ultrasound, light-mediated, and 
magnetic-mediated release are beneficial because they allow user-defined controlled 
release that can be varied in time and modified throughout the course of delivery. 
Ultrasound degradation usually functions by temporarily breaking reversible bonds; light-
mediated degradation by directing UV, visible, or IR light in specific spatial locations on 
a hydrogel to break photolabile bonds; and magnetic-mediated release by applying a 
magnetic force to cause a deformation leading to increased water movement through the 
gel [351–354]. Negative aspects of these techniques are the requirements for light or 
magnetic field penetration (not always possible for in vivo applications), the need for 
specialized equipment, and the dependence of the system on an outside user. Still, in the 
future many of these techniques could be applied to enhance control over shell 
degradation in the core-shell MPs presented in this work.  
5.5 Conclusions 
In these experiments, heparin-PEG core-shell MPs were fabricated using a re-
emulsification technique to encapsulate pre-formed heparin MPs within a degradable 
PEG-based shell, thus creating MPs with tunable amounts of encapsulated heparin. In 
pre-fabrication load studies with BMP-2, degradable core-shell MPs initiated enhanced 
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ALP activity as compared to non-degradable core-shell MPs, indicating these MPs can be 
used to temporally modulate protein presentation to cells. In addition, post-fabrication 
loading studies demonstrated that core-shell MPs were able to sequester BMP-2 through 
the PEG shell and then re-present that protein to cells to initiate enhanced ALP activity. 
Thus, the goals of developing a dynamic core-shell MP technology that preserved protein 
bioactivity, delivered cargo in a temporally controlled manner with no burst release, and 
sequestered and re-delivered proteins were achieved in this system.  In the future, 
because the post-fabrication loading technique allows fully fabricated core-shell MPs to 
sequester protein, it could be extended to sequestration and release of cell-secreted 
proteins.  Overall, the multifunctional core-shell technology presented here has the 
potential to temporally modulate the presentation of growth factors in the local cellular 
microenvironment and is therefore a unique tool to explore the emerging area of cell-
secreted protein manipulation for enhancement of tissue regeneration. 
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CHAPTER 6 
DEGRADABLE HEPARIN-PEG-BASED MPS FOR PROTEIN 
SEQUESTRATION AND RELEASE 
6.1 Introduction 
 Heparin has frequently been integrated into controlled delivery bulk hydrogel 
systems due to its ability to attract and protect protein [9,174,338,339]. Integration of 
heparin into microparticle (MP)-based delivery systems could be particularly beneficial, 
as MPs are injectable and have a high surface area to volume ratio that can assist in 
efficient protein release [211], and several techniques have been explored. A common 
method includes layer-by-layer coating of heparin onto pre-formed MPs [222–225]. 
While this method has been used to deliver proteins like TGFβs and BMPs to 
successfully enhance cell differentiation [222–225], the layer-by-layer approach requires 
alternating layers of positively and negatively charged materials, which can limit the 
choices of materials used to fabricate MPs and thereby limit user-defined control over 
other MP properties, such as size and degradability. In addition, as electrostatic 
interactions are the only forces responsible for maintaining heparin in the delivery 
vehicle, premature release of heparin into the cellular microenvironment could occur. To 
combat these problems, heparin has been functionalized with methacrylamide and 
covalently cross-linked into MPs [59]. While these non-degradable MPs showed high 
loading efficiency of BMP-2, very little release (~10-15% of loaded BMP-2) was 
observed over the course of 30 days [59]. Thus, development of heparin-based MPs with 
controlled and tunable protein release remains a challenge.  
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 Protein release can be more precisely tuned in degradable MPs, as degradation 
rate can be user-controlled, eliminating reliance solely on diffusion as the main 
mechanism of protein release [10]. In addition, degradable materials are preferable for in 
vivo applications, as they do not require surgical removal [10]. Recently, our lab 
developed heparin-PEG-based MPs using 4-arm PEG acrylate, thiolated heparin, and 
DTT [58]. The MPs were cross-linked via Michael Type addition, and DTT was included 
to enhance MP degradability by accelerating hydrolytic degradation of the ester bond in 
the acrylate group [58,60]. This method enabled MP degradation and a higher percent 
release of loaded BMP-2 as compared to what was observed previously for non-
degradable, covalently cross-linked heparin MPs [58,59]. However, as these MPs were 
only cross-linked via Michael-Type addition of DTT and heparin, both of which 
accelerated MP degradation, an increase of heparin content increased degradation rate of 
the MPs [58].  
 Thus, this work presents an alternative strategy to fabricate degradable heparin-
PEG-based MPs with enhanced control over degradation rate and incorporation of higher 
concentrations of heparin. Degradable MPs were fabricated by integrating DTT into a 
PEG-DA and heparin MAm network that was subsequently cross-linked via free-radical 
initiated polymerization. MPs were characterized to assess heparin content and 
degradation rate, and loading and release studies were conducted with histone, a 
positively charged protein. Finally, MPs were cultured with ATDC5 cells to investigate 
1) sequestration and release of cell-secreted protein and 2) degradation of MPs within 
dense cell aggregates. Overall, these studies indicate that degradable heparin-PEG MPs 
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have the potential to be used for protein loading and release in tissue engineering 
applications.   
6.2 Materials and Methods 
6.2.1 Materials 
Heparin MAm and 3.4 kDa PEG-DA were fabricated as described in Section 4.2.1. 
6.2.2 MP Fabrication and Degradation Studies 
For heparin-PEG-based MPs, an aqueous phase of PEG-DA was incubated with 
DTT (Sigma-Aldrich) in PBS for 30 minutes at 37°C to allow a click reaction between 
DTT and the acrylate groups on PEG-DA. Then, heparin was added to the aqueous phase 
for an additional 30 minute incubation. For MPs without heparin, called PEG-based MPs, 
PEG-DA and DTT were incubated for 1 hour. The amounts of heparin and PEG added 
for each MP formulation resulted in a total polymer content of 12 wt% and are listed in 
Table 6.1. DTT concentrations for each formulation are also listed in Table 6.1. After 
incubations, Irgacure 2959 Photoinitiator (Ciba) was added to the aqueous phase to 
achieve a final concentration of 0.05 wt%. The aqueous phase was then emulsified with a 
homogenizer against a mineral oil phase (light, white; Ameresco) with 0.3-1.3% (v/v) 
Span-80 (sorbitan monooleate; TCI) at a 1:16.7 ratio aqueous:oil phase, nitrogen purged 
for 1 minute, then cross-linked under UV light (approximately 10.5 mW/cm
2
) in a 35x10 
mm petri dish for 10 minutes. MPs were washed with water. 100% heparin MPs were 
prepared as described in Section 4.2.2.  
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Table 6.1. Amounts of heparin, PEG and DTT for each MP formulation.  










PEG-based MPs 0 42.4 0 32.5 
10% Heparin MPs 10 38.1 4.2 30 
20% Heparin MPs 20 33.9 8.5 27 
30% Heparin MPs 30 29.7 12.7 23.5 
40% Heparin MPs 40 25.4 17.0 20 
For PEG-based MPs used for ATDC5 aggregate incorporation, MPs were formed 
as described in Section 5.2.2. MPs had 0 (non-degrading), 40 (slow-degrading) or 45 
(fast-degrading) mM DTT.  
For MP degradation studies in aqueous solutions, 0.1 mg/mL of MPs was 
incubated in 1 mL PBS unless another concentration is noted. MPs were incubated on 
rotary (65 RPM; Barnstead Lab-Line, Multipurpose Rotor) at 37°C. 30 μL aliquots of MP 
solution was taken every 2-3 days and imaged using phase microscopy. MPs were 
determined to be degraded when few (less than10 MPs) or no MPs were visible. 
6.2.3 Alcian Blue Staining and Surfen Assay 
 PEG-based MPs and 10, 20, 30, and 40% heparin MPs were stained with 1% 
alcian blue 8GX (Sigma-Aldrich) in 0.1 M HCl for 30 minutes. Then, MPs were 
centrifuged at 10,000 RCF and stain was removed. MPs were resuspended in PBS, 
centrifuged again, and PBS was removed. This was repeated until the supernatant was 
clear. MPs were then imaged on phase microscopy.  
 For surfen studies, 0.025 mg/mL PEG-based MPs and 10, 20, 30, 40 and 100% 
heparin MPs were incubated with 10 µM surfen in PBS. 100 uL of the MP-surfen 
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solution was added to a 96 well plate, and an area-scan fluorescence reading was taken at 
excitation/emission 320/460 after 3 hours.  
6.2.4 Histone Loading and Release Studies 
 10% heparin MPs were used for maximum loading studies. 0.1 mg MPs were 
incubated with 6, 8, 10, 15, 30, 60, 150, and 200 µg histone (Sigma-Aldrich) overnight 
on rotary at 4°C. MPs were then centrifuged and supernatant was analyzed using a Pierce 
BCA protein assay according to the manufacturer’s instructions (ThermoFisher 
Scientific). BSA protein was used to construct the standard curve and absorbance was 
read at 562 nm. For loading and release studies, 0.1 mg PEG-based MPs and 10, 20, 30, 
and 40% heparin MPs were loaded with 20 µg of histone overnight on rotary at 4°C. MPs 
were then centrifuged at 10,000 RCF and supernatant was analyzed to determine loading 
efficiency. Fresh PBS was added to the MPs and MPs were incubated on a shaker plate 
(65 RPM; Barnstead Lab-Line, Multipurpose Rotor) at 37°C for 7 days, with timepoints 
taken at days 1, 4, and 7. For each timepoint, MPs were centrifuged, supernatant was 
collected for analysis, and fresh PBS was added to the MPs. Supernatant was analyzed 
using a Pierce Coomassie protein assay according to the manufaturer’s protocol 
(ThermoFisher Scientific). A standard curve was constructed with histone and 
absorbance was read at 595 nm. 
6.2.5 Transwell MP Studies 
 ATDC5 cells were expanded and prepared for transwell culture as described in 
Section 4.2.3. Mineralization media was used for all studies (composition described in 
Section 4.2.3). At day 6 in transwell culture, transwells with 0.1, 1, and 3 mg 10% 
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heparin or PEG-based MPs were added to either well plates with cells or well plates with 
media only. After an overnight incubation in a cell culture incubator (37°C, 5% CO2), 
MPs were removed from the transwell inserts, transferred to low-binding microcentrifuge 
tubes, centrifuged at 10,000 RCF, and supernatant was removed. MPs were rinsed once 
with PBS, then incubated at 37°C on a shaker plate (65 RPM; Barnstead Lab-Line, 
Multipurpose Rotor) for 2 days. MPs were then centrifuged at 10,000 RCF, and 
supernatant was analyzed using a Coomassie Protein assay (see Section 6.2.4).  
6.2.6 Incorporation of PEG-based MPs into ATDC5 Spheroids 
 ATDC5 cells were prepared for spheroid culture and MPs were incorporated into 
spheroids as described in Section 4.2.3. Non-, slow-, and fast-degrading PEG-based MPs 
were incorporated into ATDC spheroids at a 3:1 MP:cell ratio and cultured on rotary 
culture in mineralization media for 21 days. At days 1, 7, 14, and 21, spheroids were 
collected for histological analysis. Spheroids were sectioned, stained with H&E, and 
imaged as described in Section 4.2.5.   
6.3 Results 
6.3.1 Heparin Content in Heparin-PEG-based MPs 




Figure 6.1. Cross-linking scheme for polymeric network in heparin-PEG-based MP 
fabrication. DTT is clicked into the PEG-DA network at the acrylate bond (blue circle), 
and heparin MAm and PEG-DA are cross-linked via free-radical initiated polymerization 
(green circle).  
To validate that heparin had been cross-linked into the polymer network, MPs were 
stained with alcian blue, a stain specific for GAGs. All MPs fabricated with heparin 
stained blue, while PEG-based MPs did not (Figure 6.2A). Surfen, a small molecule that 
when bound to heparin emits a fluorescent signal [355] (see Appendix A), was incubated 
with PEG-based MPs and 10, 20, 30, 40, and 100% heparin MPs and fluorescence 
intensity increased as heparin content increased for 10, 20, and 30% heparin MPs, then 
plateaued for 40 and 100% heparin MPs. PEG MPs showed little fluorescent signal 
(Figure 6.2B).  
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Figure 6.2. Heparin-PEG-based MPs can be fabricated with varying amounts of heparin. 
(A) 10, 20, 30, and 40% heparin MPs and PEG-based MPs (from left to right) were 
stained with Alcian Blue (scale bar = 50 µm). (B) Fluorescence intensity after incubation 
with surfen for MPs of varying amounts of heparin.  
6.3.2 Degradation of Heparin-PEG-Based MPs 
 Heparin-PEG-based MPs were formed with the maximum amount of DTT that 
still permitted MP fabrication (Table 6.2). MPs degraded within 7-19 days,  
Table 6.2. DTT concentration and degradation rate for varying heparin contents in 






0 1.3 14-17 
10 1.3 7-9 
20 1.2 7-9 
30 1.2 17-19 
40 1.2 17-19 
depending on the amount of heparin and DTT in the polymeric network (Table 6.1, 
Figure 6.3). 10% heparin MPs were incubated at 0.1, 1, and 3 mg/mL, and degradation 
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was dependent on initial MP concentration. MPs at 0.1 mg/mL degraded between 4-6 
days, at 1 mg/mL between 11-14 days, and at 3 mg/mL between 14-17 days (Figure 6.4).  
 
Figure 6.3. Degradation of PEG-based MPs and 10, 20, 30, and 40% heparin MPs. 10 and 
20% heparin MPs degraded between days 7-9, 30-40% heparin MPs between days 17-19, 
and PEG-based MPs between days 14-17. White arrows point out MPs in each image. In 
images with many MPs, only a few are pointed out as examples (scale bar 100 µm). 
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Figure 6.4. Degradation of 10% heparin MPs at 0.1, 1 or 3 mg MPs/mL initial 
concentration. MPs at 0.1 mg/mL degraded between 4-6 days, MPs at 1 mg/mL between 
11-14 days, and MPs at 3 mg/mL between 14-17 days.  
6.3.3 Loading and Release of Histone from Heparin-PEG-Based MPs 
 As 10% heparin MPs were loaded with increasing amounts of histone, a plateau 
was reached at 35 µg histone/0.1mg MP (Figure 6.5A). This corresponds to a max 
loading of 3500 µg histone/mg heparin. PEG-based MPs and 10, 20, 30, and 40% heparin 
MPs were loaded with histone at a 100 µg histone/0.1 mg MP ratio, or 10,000 µg 
histone/mg heparin. Less histone remained in solution, indicating that more histone was 
bound to MPs, as heparin content in the MP increased (Figure 6.5B). 
 
Figure 6.5. Heparin-PEG MP loading of histone. (A) 0.1 mg of 10% heparin MPs showed 
a max loading of 35 µg histone. (B) 10, 20, 30, and 40% heparin MPs show increasing 
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binding capacity as heparin content increases (*=significantly different than 10% heparin 
and PEG-based MP groups, p<0.05). 
 PEG-based MPs and 10, 20, 30, and 40% heparin MPs were loaded with 20 µg 
histone/0.1 mg MP and subsequent histone release was monitored for seven days. All 
MPs that contained heparin loaded about 80% of histone in solution, while PEG-based 
MPs only loaded about 10% (Figure 6.6A). All heparin containing MPs released protein 
over the course of seven days, and the majority of release occurred between days 1-3. By 
day 7, cumulative histone release was 33±1.2% for 10% heparin MPs, 26±3% for 20% 
heparin MPs, 8.1±3.4% for 30% heparin MPs, and 12±2% for 40% heparin MPs (Figure 
6.6B). 
Figure 6.6. Heparin-PEG MP loading and release of histone. (A) Percentage of histone 
loaded onto 10, 20, 30, and 40% heparin MPs and PEG-based MPs, normalized to a 
soluble histone control. (B) Release of histone reported as the percentage of histone 
release relative to what was loaded over the course of seven days (*=significantly 
different from all other groups, p<0.05). 
6.3.4 Sequestration and Release of Proteins in ATDC5 Transwell Studies 
 10% heparin MPs or PEG-based MPs incubated with ATDC5 cells or in media 
alone released protein in a mass-dependent manner. For 0.1 mg of MPs, about 3 mg 
protein was released, for 1 mg MPs, 5-8 mg of protein was released, and for 3 mg MPs, 
8-10 mg of protein was released (Figure 6.7).  
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Figure 6.7. Total release of protein from varying masses of 10% Heparin and PEG-based 
MPs incubated with ATDC5 cells or in media alone after two days of MP incubation in 
PBS. 
6.3.5 Incorporation of Degradable PEG-Based MPs into ATDC5 Spheroids 
 As a proof-of-principle study, fast- (45 mM DTT), slow- (40 mM DTT) and non- 
(0 mM DTT) degrading PEG-based MPs were incorporated into ATDC5 spheroids and 
degradation was monitored.  During histological processing, PEG MPs fall out of the 
spheroid matrix and leave behind holes (arrows, Figure 6.8). From images, it was 
observed that fast-degrading MPs degraded in 1-7 days, slow-degrading MPs degraded in 
7-14 days, and non-degrading MPs did not degrade throughout the course of culture 
(Figure 6.8).  
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Figure 6.8. Degradation of PEG-based MPs in ATDC5 spheroids. Fast-degrading MPs 
(45 mM DTT) appeared to degrade between days 1-7and slow-degrading MPs (40 mM 
DTT) between days 7-14. Non-degrading MPs (0 mM DTT) did not appear to degrade. 
MPs appear as light purple spheres, or as holes in spheroid matrix due to removal during 
histological processing. Arrows point out holes left by MPs (scale bar 100 µm). 
6.4 Discussion 
 Overall, these studies demonstrate the ability to fabricate degradable heparin-PEG 
MPs for protein loading and release, and provide examples of possible future applications 
in sequestering and releasing cell-secreted protein or delivering protein to cell aggregates. 
To characterize these MPs, alcian blue staining validated that heparin was successfully 
cross-linked into the polymeric network, and the staining appeared a deeper blue in 
heparin MPs with higher heparin content (Figure 6.2A). In addition, studies with surfen, 
previously shown to fluoresce upon binding to heparin (see Appendix A) [355], indicated 
that in solutions of equal masses of MPs, a higher fluorescence intensity was observed as 
the heparin content in MPs increased for 10, 20, and 30% heparin MPs. Then, 
fluorescence intensity appeared to plateau or even decrease slightly for 40 and 100% 
heparin MPs. While the reason for the plateau/decrease is unknown, it is possible that as 
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heparin content increased, steric hindrance between surfen molecules prevented further 
binding. To our knowledge, this and the data found in Appendix A are the first reports of 
utilizing surfen to assess heparin content in a hydrogel material.  
 To promote degradation of heparin-PEG-based MPs, DTT was incorporated into 
the polymeric network [60]. For all MPs, regardless of heparin content, the maximum 
molar ratio between PEG-DA and DTT that still allowed MP fabrication was between 
1.2:1 and 1.3:1 moles PEG-DA:DTT. This was similar to previous work that found a 
maximum ratio of 1:25:1 PEG-DA:DTT in degradable MPs fabricated with 3.4 kDa 
PEG-DA [221]. As the heparin content in MPs was increased, the amount of PEG-DA 
was decreased to keep the total polymer content constant for each MP formulation, which 
also decreased the total amount of DTT that could be added. This particular limitation is 
inherent to this method of MP fabrication; thus, the degradation rates reported here are 
the maximum rates possible for each of MP formulations. With the maximum amount of 
DTT, MPs degraded between 1-2.5 weeks, with 10 and 20% heparin MPs degrading the 
fastest (7-9 days) and PEG-based MPs and 30 and 40% heparin MPs degrading slower 
(14-19 days) (Figure 6.4). This indicates that degradation rate was dependent on the total 
amount of DTT in the network, as 10 and 20% heparin MPs degraded before 30 and 40% 
heparin MPs, but also dependent on heparin content, as PEG-based MPs had higher DTT 
content than 10 and 20% heparin MPs but still degraded more slowly. This is similar to 
the previous set of studies that utilized heparin-PEG MPs, which showed that increasing 
heparin content increased degradation rate, possibly due to heparin’s ability to attract 
more water into the network and accelerate hydrolysis of the ester linkages in the PEG-
DA network [58,356]. Finally, it was observed that as MP concentration increased, 
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degradation rate decreased (Figure 6.4). This was likely due to decreased water 
availability in the more concentrated groups, as the MPs tend to pellet during incubation. 
These observations should be kept in mind for in vivo studies, and in vitro studies should 
aim to mimic the concentration that MPs would experience in future in vivo applications. 
 Histone was used as a model protein to evaluate the ability of heparin-PEG-based 
MPs to load and release protein. Histone is positively charged at physiological pH and 
similar in size to many growth factors (11-21 kDa).  In studies to determine the maximum 
histone loading of 10% heparin MPs, a plateau region was found at about 35 µg 
histone/0.1 mg MPs, or 350 µg histone/mg MP (Figure 6.5A). On a per heparin basis, this 
corresponds to a max loading of 3500 µg histone/mg heparin. In previous studies with 
100% non-degradable heparin MAm MPs, the maximum loading for BMP-2 was 
observed to be approximately 10 times lower than this, about 300 µg BMP-2/mg heparin 
[59]. This difference may be due to the different proteins used, as parts of the histone 
protein have a flexible structure [357] and may allow for more compact binding as 
compared to BMP-2. It also may be due to the relative concentration of heparin within 
the network. Recently, it has been suggested that the ECM can act as an “electrostatic 
bandpass”, and it was shown that charged biomolecules are selectively filtered by ECM 
components like heparan sulfate [358]. In addition, a recent experiment with heparin 
hydrogels showed that as heparin content increased, depth of diffusion of histone into the 
gel decreased, indicating that heparin can affect diffusion of proteins through a hydrogel 
network [40]. Thus, the differences in loading capacity observed between the 10% 
heparin MPs in these studies and the 100% heparin MPs in previous studies [59] may be 
due to diffusion limitation imposed on the protein by higher heparin concentrations.  
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Finally, when loaded with a mass of protein that exceeded the loading capacity of 
10% heparin MPs (100 µg histone/0.1 mg MPs), it was observed that 20, 30, and 40% 
heparin MPs bound more histone than 10% heparin MPs, as indicated by less histone 
remaining in the supernatant (Figure 6.5B). This suggests that increasing the heparin 
content in the heparin-PEG MPs can increase MP loading capacity to a certain point, but 
as no differences were observed between 20-40% heparin MPs, it is possible that 
diffusion limitations also arise in these MPs as heparin content is increased.  
 The rate of protein release from delivery systems is important to consider for 
tissue engineering applications [211]. Loading studies indicated that at a mass of protein 
below the maximum loading capacity of the MPs (20µg histone/0.1 mg MP), all MPs 
formulations loaded about 80% of histone in solution (Figure 6.6A). This is similar to 
what was observed in previous studies with heparin-PEG MPs, where similar amounts of 
BMP-2 were loaded into all MP formulations regardless of heparin content  [58]. For 10 
and 20% heparin MPs, the majority of histone release was observed between days 1-3, 
likely due to the faster degradation rate of these MPs. Release rate for 30 and 40% 
heparin MPs was more linear and had not yet plateaued by day 7, likely because either 
these MPs had not degraded at this timepoint or because the higher heparin content of 
these MPs trapped histone in the network, preventing release (Figure 6.6B). Overall, the 
maximum amount of histone released by any formulation was only about 30% of the total 
histone loaded, either indicating that histone was lost due to binding to plastic surfaces or 
that histone remained trapped in the MP network. Thus, these studies suggest that heparin 
content and degradation rate are likely both contributing factors to protein release rate, 
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and that these MPs can be tuned to achieve a desirable release profile as required for 
specific applications.  
 Previous work has highlighted the utility of employing heparin hydrogels to 
sequester cell-secreted protein to either modulate cell behavior or for analysis [40,41]. As 
heparin has a high affinity for proteins released by ATDC5 cells during differentiation 
[304,309,311,322,331], 10% heparin MPs were incubated with ATDC5 cells in a proof-
of-principle study to demonstrate the ability of MPs to sequester and then release cell-
secreted proteins for further analysis.  MPs were incubated overnight with ATDC5 cells 
that had undergone six days of monolayer culture, as ATDC5 cells are seen to upregulate 
chondrocytic gene expression markers around this time, indicating that protein 
production may also be increased [309] (Appendix E.2). MPs were transferred to PBS to 
allow degradation and after 2 days, about 3-10 µg of protein was released, depending on 
the mass of MPs used (Figure 6.7). For each mass of MPs used, the same amount of 
protein was released from 10% heparin MPs and PEG-based MPs incubated with cells or 
in media alone. Thus, it was unclear if 1) protein sequestration was due to specific 
interactions with heparin and 2) the protein sequestered was secreted by cells or was from 
the FBS in the cell culture media. Studies discussed in prior chapters of this thesis 
indicate that heparin MPs bind more protein than PEG-based MPs and that heparin MPs 
incubated with cells bind additional proteins compared to those incubated in media alone 
(Chapter 4, Figure 4.10). This suggests that even if equal amounts of protein were 
sequestered in each group, the identity of those proteins may have been different.  
To validate the hypothesis that released proteins in each MP groups were 
different, additional assays, such as ELISAs or mass spectrometry would need to be 
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conducted. Unfortunately, cell-secreted proteins would likely only be detectable if the 
amount of total protein released from MPs was at least 20 µg, based on assumptions 
described in Appendix F.1.The reasons for the low protein release observed in this study 
are unclear, but assuming each MP group bound the maximum amount of protein 
possible (Figure 6.5), 0.1, 1, and 3 mg MP groups should have theoretically loaded 35, 
350, and 1050 µg protein, respectively. As only 2-10 µg protein was released, it is 
evident that the majority of the sequestered protein either was lost to plastic surfaces or 
remained bound to the heparin MPs. This may have been due to the short degradation 
time (2 days), chosen to maximize MP degradation and reduce the risk for protein 
denaturation. Thus, more work to optimize protein release needs to be conducted prior to 
further analyses are conducted to identify proteins.  
Previously, MPs have been integrated into dense cell aggregates to achieve more 
uniform delivery of soluble biomolecules [253,255,256,258,260,261,263,264]. While 
biodegradable MPs have been incorporated into aggregates, including PLGA and CS 
MPs [253,255,264], modulating degradation rate of MPs within cell spheroids has yet to 
be achieved. Here, by tuning the concentration of DTT in the polymeric network, 
degradation of PEG-based MPs in cell aggregates was achieved in 7 days for fast-
degrading MPs and 14 days for slow-degrading MPs (Figure 6.8). Degradation of MPs in 
spheroids could enhance release of biomolecules and could also be beneficial in cases 
where aggregates are injected in vivo. In the future, degradable heparin-PEG MPs could 
be integrated into spheroids to more finely tune protein release.  
As mentioned, the fastest degradation rate for each MP formulation was used for 
these studies. Thus, if these degradation times are too long for a particular application, or 
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result in denaturation of sequestered proteins in studies aiming to capture and deliver 
cell-secreted proteins, other degradation techniques could be applied. First, as DTT 
accelerates the hydrolysis of the ester bond within the acrylate group of PEG-DA, 
employing 4- or 8-arm PEG-acrylate could enable more linkages between DTT and 
acrylate groups, increasing the number of sites susceptible to rapid degradation. In 
addition, incorporation of enzymatically degradable peptide sequences, such as MMP or 
plasmin-sensitive peptides [28,29], could aid in increasing degradation rate, as the 
concentration of the enzyme responsible for degradation could be controlled during in 
vitro experiments. For example, a recent study with PEG-DA MPs indicated that 
integration of a collagenase-sensitive sequence into the PEG network allowed 
degradation within 24 hours when MPs were incubated with collagenase [221]. Finally, 
degradability has been achieved in PEG materials via co-polymerization of degradable 
synthetic and natural polymers such as poly(lactic acid) [28,359], collagen [360], and 
hyaluronic acid [361]. While all of these options would require significant adjustment to 
the system described, they could be investigated in future work aiming to more tightly 
control degradation of PEG-based MPs.   
6.5 Conclusion 
 Heparin-PEG MPs with tunable degradation rates and heparin content were 
developed. MP degradation occurred between 7-19 days and was dependent on the 
concentration of MPs in solution. In histone loading studies, it was observed that the 
maximum loading capacity of these MPs was about 3500 µg/mg heparin, and that 
increasing the amount of heparin increased loading capacity. MPs released histone over 
the course of seven days in a manner dependent likely on both degradation rate and 
heparin content. Finally, heparin-PEG-based MPs were used to sequester and release 
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proteins present in ATDC5 cell cultures and degradable PEG-based MPs were observed 
to degrade in ATDC5 cell aggregates between 7-14 days. Overall, these degradable 




CONCLUSION AND FUTURE DIRECTIONS 
7.1 Summary 
 In this work, biomaterial systems were engineered to enable analyses and 
modulation of dynamic cellular processes. Specifically, the changes in cell behavior in 
response to both external stimuli and cell-cell communication in disease states are 
difficult to capture in traditional cell culture systems. In addition, modulating cell 
phenotype as it changes in time during differentiation can be challenging with traditional 
methods, such as delivery of single growth factors. Thus, in this work, heparin and PEG-
based biomaterial systems were designed to specifically account for dynamic cell 
behavior. For example, proof-of-concept studies with MSCs, adipocytes, and osteoblasts 
indicated that a PEG-based hydrogel system enabled cell cross-talk in hyperglycemic 
conditions. In addition, incorporation of heparin MPs in ATDC5 cell aggregates 
highlighted the utility of employing GAG-based materials to modulate cellular 
differentiation. With these results in mind, heparin-PEG core-shell MPs and 
hydrolytically degradable heparin-PEG MPs were developed to provide tighter temporal 
over heparin-mediated protein presentation in the cellular microenvironment for future 
applications. These technologies were addressed in detail in the four chapters presented 
in this thesis.  
 In Chapter 3, a PEG-based hydrogel system was used to co-culture MSCs, 
osteoblasts, and adipocytes in normal and high glucose conditions for seven days. Cell 
viability and gene expression for markers adipocyte/osteoblast differentiation and 
glucose-responsiveness were assessed for all three cell types, and clonogenicity was 
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assessed for MSCs. Overall, multivariate models indicated that the primary 
discrimination of gene expression dataset was dependent on neighboring cell type. 
Further discrimination by glucose level was dependent on culture configuration, 
suggesting that neighboring cells influenced cell response to glucose. Reduced 
clonogenicity and viability were observed in MSCs in mono-culture or in co-culture with 
osteoblasts, a trend not observed in MSCs cultured with adipocytes. In addition, 
adipogenic gene expression indicated that cross-talk between adipocytes and MSCs may 
have occurred. Taken together, these results indicate that cell cross-talk affected MSC, 
osteoblast, and adipocyte behavior, and highlights the importance of utilizing biomaterial 
based systems that permit culture and analysis of multiple cell types for in vitro disease 
models. In addition, this study showed the utility in hydrogel-based systems to interrogate 
dynamic cellular communication in response to external stimuli in an in vitro disease 
model. 
 In Chapter 4, heparin MPs were used to modulated differentiation in a model 
system with ATDC5 cells, known to under endochondral ossification in vitro. Heparin 
and PEG MPs were incorporated into ATDC5 spheroids and it was observed that in 
heparin MP groups, chondrocytic differentiation was decreased in a dose-dependent 
manner. This trend was also observed when monolayer ATDC5 cells were cultured in 
transwell with heparin and PEG MPs, indicating that this phenomenon was not dependent 
on physical contact with the MPs. Finally, to further elucidate mechanism behind 
observed decreases in differentiation, heparin MPs were run on SDS-PAGE, which 
indicated that heparin MPs cultured with cells sequestered protein in the 17 kDa range. 
As many growth factors implicated in endochondral ossification, such as IHH, BMPs, 
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and FGFs, fall in this range [346], it is possible that observed changes in differentiation 
were partially due to sequestration of cell-secreted growth factors. Overall, these studies 
indicate that heparin MPs can delay endochondral ossification, likely due to protein 
sequestration. Furthermore, they illustrate the ability of heparin materials to modulate the 
dynamic process of cell differentiation. 
 Having observed the effectiveness of heparin in modulating differentiation in 
ATDC5 cell studies, we aimed to develop heparin-based tools to achieve temporal 
modulation of protein sequestration and release. Thus, in Chapter 5 heparin-PEG core-
shell MPs were developed for protein sequestration and temporally controlled release of a 
protein-laden core. Heparin-PEG core-shell MPs were fabricated using a re-
emulsification technique to encapsulate pre-formed heparin MPs within a degradable 
PEG-based shell, thus creating MPs with tunable amounts of encapsulated heparin. In 
pre-fabrication load studies with BMP-2, degradable core-shell MPs initiated enhanced 
ALP activity as compared to non-degradable core-shell MPs, indicating these MPs can be 
used to temporally modulate protein presentation to cells. In addition, post-fabrication 
loading studies indicated that core-shell MPs were able to sequester BMP-2 through the 
PEG shell and then re-present that protein to cells to initiate enhanced ALP activity. 
Thus, this work developed a core-shell MP technology that utilized heparin to preserve 
protein bioactivity, delivered protein in a temporally controlled manner by employing a 
degradable PEG-based shell, and was able to sequester and re-deliver protein with no 
burst release. Overall, this technology has the potential to assist in further tuning dynamic 
cell behavior via protein sequestration and release. 
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 Finally, in Chapter 6 heparin-PEG-based MPs with tunable hydrolytic degradation 
and heparin content were developed. Alcian blue staining and surfen binding studies 
validated that heparin was cross-linked into the MP network for 10, 20, 30, and 40 wt% 
heparin MPs. Degradation studies showed that MP degradation occurred in 1-2 weeks 
and was dependent DTT and heparin content in the MP as well as the concentration of 
MPs in solution. Loading studies with histone indicated that loading capacity increased 
for MPs with higher heparin content, as compared to 10% heparin MPs, and that histone 
was released from MPs in a manner dependent likely both on heparin content and 
degradation rate. Finally, MPs were used in proof-of-principle studies to show the 
feasibility of sequestration and release of cell-secreted proteins and degradation of MPs 
within ATDC5 cell aggregates. Overall, these studies characterized degradable heparin-
PEG-based MPs and demonstrate their utility for protein loading and release as well as 
integration into cell aggregates for tissue engineering applications. Thus, in the future, 
these MPs can be used as tool to regulate and interrogate dynamic cell processes. 
 As a whole, this work demonstrates that dynamic cellular processes can be both 
studied and regulated using biomaterial-based approaches. In addition, heparin-based MP 
tools can aid in gaining enhanced temporal control over protein sequestration and release. 
Thus, these biomaterial based technologies have the potential to be used in a variety of 
tissue engineering applications. 
7.2 Conclusions 
The research presented in this dissertation highlights the utility of PEG- and 
heparin-based biomaterial technologies to better understand and control dynamic cell 
systems. Aspects of the in vivo microenvironment were captured by co-culturing cells in 
 171 
an in vitro model system and by integrating heparin materials into culture systems and 
microparticle-based tools to modulate protein presentation. The results of this work 
suggest that 1) PEG-based platforms can enable complex analyses of cells in co-culture, 
2) heparin materials can temporally modulate endochondral ossification, and 3) 
utilization of heparin in microparticle technologies can enable tighter temporal control 
over protein sequestration and release. Together, these results validate the use of 
biomaterials to study and modulate complex cellular behavior.  
In Chapter 3, the utility of a laminated PEG-based hydrogel system to culture 
MSCs, osteoblasts, and adipocytes in mon-, co-, and tri-culture in normal and high 
glucose conditions for seven days was explored. PEG-based hydrogels were chosen 
because they have low capacity for protein binding, allow protein diffusion through the 
network , and can be chemically modified with peptide sequences to enhance cell 
attachment and matrix degradation [29,143,144]. Viability data and staining for 
adipocytic and osteoblastic markers (lipid deposition and ALP) indicated that the culture 
system was a valid platform for analysis of the three cell types. This validation was 
important, as both high glucose conditions and co-culture between these cell types has 
been shown to affect, sometimes negatively, cell viability and function [83–93,97–104]. 
In addition, this culture platform permitted MSCs retrieval from enzymatically 
degradable blocks for subsequent clonogenicity studies, and in the future could be 
employed for other functional post-co-culture cell analyses. Finally, gene expression for 
markers of osteogenesis/pro-bone formation, adipogenesis, pro-adipocyte function, 
energy metabolism, and glucose-responsiveness was assessed for all three cell types. In 
global multivariate model for each cell type, the primary source of variance was due to 
 172 
neighboring cell type, indicating that cellular cross-talk occurred in this culture system. 
Discrimination by glucose level was only possible in some culture configurations, 
suggesting that neighboring cell type impacts cell response to glucose. These two 
observations support the use of the co-culture platform presented in this work, as 
traditional monoculture platforms cannot capture system-level cell communication that 
occurs in disease states.  
Multivariate models permitted a deeper understanding of how cells were affected 
in co-culture settings. In the global PLS-DA gene expression model for adipocytes, the 
first latent variable separated osteoblast-containing (OMA) vs. non-osteoblast-containing 
(AMA, AAA) culture conditions, suggesting that osteoblasts, or the communication 
between osteoblasts and MSCs, had an impact on adipocytes. In addition, the adipocytes 
cultured with MSCs (AMA and OMA) showed correlation with markers of adipogenesis 
and energy metabolism, while those cultured without MSCs (AAA) correlated with 
markers of inflammation and oxidative stress, suggesting that MSCs promoted adipocytes 
to upregulate adipogenic and metabolic genes. MSC viability and clonogenicity was 
decreased in osteoblast-containing cultures (OMO), while osteoblast viability was highest 
in MSC-containing cultures (OMO), suggesting that MSCs exerted modulatory effects on 
osteoblasts at the expense of their own viability and clonogenicity. The positive influence 
of MSCs on both cell types may be due to their secretion of therapeutic soluble factors 
[78]. Finally, MSCs in co-culture with adipocytes (AMA and OMA) showed 
maintenance of viability and clonogenicity under high-glucose conditions, a trend not 
observed in other culture configuration (OMO and MMM). Overall, these results indicate 
that MSCs may exert compensatory effects on osteoblasts while adipocytes exert 
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compensatory effects on MSCs, and that adipocytes are affected by neighboring 
osteoblasts. More so, it illustrates the utility of advanced biomaterial-based cell culture 
platforms combined with multivariate modeling to interrogate dynamic cell systems 
implicated in disease. 
In Chapter 4, we transitioned to utilizing heparin-based biomaterials to modulate 
another dynamic process: cell differentiation. In this set of studies, an in vitro model 
system of ATDC5 cell endochondral ossification with was used as a testbed for 
understanding how heparin MPs can modulate differentiation. As endochondral 
ossification is tight regulated by a variety of heparin-binding proteins, such as FGFs, 
BMPs, TGFβs, IHH, and Wnts [23,25,107,186], it is possible that heparin could sequester 
these proteins in a manner that modulates ATDC5 cell differentiation. Thus, heparin and 
PEG MPs, a low-binding material control [28], were integrated in ATDC5 cell aggregates 
(spheroids) at high and low doses and assessed for gene expression and matrix deposition 
markers of differentiation. It was observed that gene expression for collagen II and 
aggrecan were significantly downregulated in high heparin MP groups as compared to 
PEG and no MP groups, a trend that was confirmed by staining for GAG and collagen II 
matrix deposition. Overall, this suggests that heparin MPs can delay or reduce 
differentiation via protein sequestration, as this trend was not observed in PEG MP 
control groups. 
To further assess if this phenomenon was actually due to heparin-mediated 
protein sequestration and not simply due to the presence of MPs in the spheroid matrix, 
heparin and PEG MPs were cultured with ATDC5 cells in monolayer transwell culture, 
allowing exchange of soluble factors without physical contact. Similar to trends observed 
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in spheroid culture, heparin MPs delayed or reduced differentiation as assessed by gene 
expression, staining for GAG and matrix mineralization, and quantification of extracted 
stains. Total DNA analysis confirmed that this phenomenon was not due to a decreased 
cell number in the heparin MP group. In addition, SDS-PAGE analysis of MPs incubated 
in transwell with cells suggested that heparin MPs bound more and different types of 
protein than PEG MPs. Finally, SDS-PAGE showed that while heparin MPs were able to 
bind proteins from the FBS-containing media, when incubated with cells, additional 
proteins of about 17 kDa were also sequestered. The identity of these protein remains 
unknown, but IHH, BMPs, TGFβs, and FGFs are likely candidates, as they all have MWs 
near 17 kDa. Taken together, these studies strongly support the hypothesis that the 
mechanism behind heparin MP-mediated changes in ATDC5 cell differentiation is 
soluble factor sequestration.  
Several other studies have shown the ability of heparin materials to modulate 
cellular differentiation, likely through soluble factor sequestration [40,41]. This suggests 
that heparin-mediated sequestration of soluble factors is translatable to other cell systems. 
For example, heparin-based materials could be used to modulate endochondral 
ossification in injured growth plates, as current therapies under investigation cannot yet 
recapitulate native growth plate cartilage in animal models [111,113–118]. In addition, 
heparin materials could be used in place of antibodies to sequestered undesirable 
osteogenic factors in patients with craniosynostosis [209,210,334]. Finally, chondrocytic 
differentiation of MSCs requires tight control over chondrocytic factors [37], which could 
potentially be modulated by heparin materials. Overall, the studies presented in Chapter 4 
highlight the ability of heparin-based biomaterials to modulate the dynamic process of 
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cellular differentiation, a characteristic of heparin materials that could be used in a variety 
of tissue repair processes.  
Inspired by the potential for heparin MPs to modulate cellular processes via 
sequestration of growth factors, we developed a technology to temporally modulate this 
process in Chapter 5. In this work, heparin-PEG core-shell MPs were developed for 
protein sequestration and temporally modulated release of the protein-laden core. To 
fabricate these MPs, a re-emulsification technique was used to encapsulate previously 
formed heparin MPs with a PEG-DA shell. As this technique resulted in more than one 
heparin MP in each PEG shell, quantification methods were developed to show that 
heparin content in core-shell MPs was predictable and tunable, based on both the amount 
of heparin in the precursor polymer solution and the final core-shell MP cross-sectional 
area. Finally, the hydrolytically degradable PEG-based shell was able to degrade and 
release the heparin core in about 6-7 days by integrating DTT into the PEG-DA network. 
Thus, heparin-PEG core-shell MPs with predictable amounts of heparin and a degradable 
shell were formed.  
Previous worked has indicated that BMP-2 bound to heparin MPs can enhance 
ALP activity in C2C12 cells [59]. Thus, in proof of concept studies, heparin MPs were 
pre-fabrication loaded (i.e. prior to core-shell MP fabrication) with BMP-2 and then 
encapsulated into degradable and non-degradable core shell MPs. Loading and release 
studies showed very little release (3-8% release) of BMP-2 over 7 days, indicating that 
observed cell response in subsequent cell studies would be due to release of the BMP-2 
laden heparin core and not due to release of soluble BMP-2. When incubated with C2C12 
cells, degradable core-shell MPs induced similar ALP activity as compared to the soluble 
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BMP-2 control, while cells cultured with non-degradable core-shell MPs showed 
significantly lower ALP activity. This indicates only degradable core-shell MPs were 
able to release the BMP-2-laden heparin core and initiate a cell response. Overall, these 
results show that core-shell heparin-PEG MPs could be used to gain tighter temporal 
control protein release, as well as reduce burst release, two sought-after characteristics in 
controlled release systems for tissue engineering applications [52,245,247]. 
In addition to pre-fabrication loading, core-shell MPs were post-fabrication 
loaded (i.e. loaded after core-shell MP fabrication) to evaluate the ability of proteins to 
diffuse through the PEG shell, be sequestered onto the heparin core, and then be released 
while bound to the heparin core to initiate a cell response. Loading studies indicated that 
degradable core-shell MPs were able to load almost 100% of the BMP-2 protein in 
solution, and release studies again showed very little protein release over 7 days (<3% 
release). When incubated with C2C12 cells, degradable core-shell MPs were able to 
initiate significantly higher ALP activity than the soluble control, again indicating release 
of the protein-laden heparin core to initiate a cell response. The ability to post-fabrication 
load these core-shell MPs could enable sequestration and temporally modulated re-
delivery of cell-secreted proteins, a technique recently proposed as a means to more 
tightly control dynamic cellular processes [3]. For example, a protein that is undesirable 
at one point in time could be sequestered and effectively eliminated from the 
microenvironment until re-delivery at a point in time at which it is desirable again. Thus, 
studies conducted with the core-shell MPs developed in this work show their utility for 
use in future experiments to carefully tune protein presentation during differentiation or 
other cell processes.  
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Finally, in Chapter 6, degradable heparin-PEG based MPs were developed and 
investigated for future applications involving temporally controlled protein loading and 
release. Previously, control over heparin MP degradation has been a challenge due to 
cross-linking techniques [58,59]. Thus, in this work hydrolytically degradable heparin-
PEG MPs of varying heparin content (10, 20, 30, and 40 wt% total polymer) were 
developed and characterized. Alcian blue staining and incubation with surfen indicated 
that heparin was successfully cross-linked into the network, and suggested that more 
heparin was cross-linked into the network as the amount of heparin in the precursor 
polymer solution was increased. DTT was integrated into the polymeric network, as it is 
known to enhance hydrolytic degradation PEG-DA materials [60]. MP degradation 
occurred between 1-2 weeks and was dependent both on DTT and heparin content in the 
MPs. Thus, degradable heparin-PEG-based MPs with tunable heparin content were 
developed.  
To evaluate the ability of MPs to load protein, histone was used a model protein, 
as it is positively charged and similar in size to a variety of growth factors. The maximum 
loading capacity was evaluated to be about 3500 µg histone/mg heparin for 10% heparin 
MPs, which is about 10 times higher than what was previously observed for BMP-2 
loading in 100% heparin MPs. This difference could be attributed to differences in 
protein binding for the two proteins, or to the ability of higher amounts of heparin to 
restrict diffusion of positively charged proteins into heparin-based hydrogels. Previously, 
it has been observed that heparan sulfate can act to selectively filter biomolecule passage 
through the ECM [358], and that as heparin content was increased in hydrogels, diffusion 
depth of histone was decreased [40]. The next set of studies supported the possibility that 
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increased amounts of heparin prevented protein diffusion, as the binding capacity of 20, 
30, and 40% heparin MPs were not significantly different from each other, though they 
were significantly higher than 10% heparin MPs. Thus, protein loading capacity could be 
increased by increasing heparin content to a certain extent, at which point a plateau was 
reached. Finally, heparin MPs were able to release histone over the course of 7 days at a 
rate dependent likely both on degradation rate and heparin content. Thus, these heparin-
PEG MPs can be tuned to achieve a degradation rate and protein release rate suitable for 
a given tissue engineering application. 
Heparin-PEG MPs and PEG-based MPs were used in two proof-of-principle 
studies to demonstrate potential future applications for this technology. First, 10% 
heparin and PEG based MPs were incubated with ATDC5 cells, retrieved and degraded 
for two days. Analysis of supernatant indicated that no differences in protein release were 
observed between heparin and PEG groups, and that total protein released was lower than 
expected, indicating further optimization of the MPs is required before released cell-
secreted proteins can be analyzed. Second, fast-, slow-, and non-degrading PEG-based 
MPs were incorporated into ATDC5 spheroids and monitored for degradation via 
histological processing. Fast- and slow-degrading MPs degraded in about 7 and 14 days, 
respectively, while non-degradable MPs did not degrade over the 14 day culture period. 
In the future, degradable heparin-PEG-based MPs loaded with protein could be 
incorporated into cell spheroids to affect cell differentiation via protein release. Thus, 
these studies demonstrate the utility of degradable heparin-PEG for future cell studies, 
either for isolation and concentration of cell-secreted proteins for analysis, or for protein 
delivery in dense cell aggregates. Overall, these MPs have the potential to modulate 
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dynamic cellular processes, such as differentiation, by temporally controlling protein 
delivery.  
In these studies, two model systems were used to demonstrate the utility of 
biomaterial-based systems for analysis and regulation of cellular behavior. First, due to 
their implication in the diabetes and osteoporosis, MSCs, adipocytes, and osteoblasts 
were cultured on a co-culture platform that allowed cell-cross talk and subsequent 
analysis of each individual cell type, including live-cell retrieval of MSCs. Multivariate 
analyses indicated that cells were highly dependent on neighboring cell types in the 
culture configurations, validating the need for biomaterials to facilitate co-culture 
experiments. Second, ATDC5 cell endochondral ossification was used as a proof-of-
principle model system to demonstrate the ability of heparin MPs to modulate cellular 
differentiation. These studies highlighted the ability of heparin to act on and modulate 
dynamic cell systems, likely through soluble factor sequestration, and motivated the 
development of two additional technologies to gain tighter control over heparin-mediated 
protein sequestration. Heparin-PEG core-shell MP and heparin-PEG MP technologies 
were developed and demonstrated to temporally control protein sequestration and release. 
Thus, overall this work demonstrates the utility of biomaterial-based technologies for 
studying cell behavior to gain further insight into various pathologies and cellular 
processes, and for modulating cellular differentiation for tissue regeneration and repair. 
7.3 Future Directions 
 The results of this work highlight several technologies that are beneficial for 
understanding and controlling cellular behavior. The PEG-based co-culture system 
presented allowed analysis of complex interactions between MSCs, adipocytes, and 
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osteoblasts, and heparin MPs were able to modulate ATDC5 cell differentiation. Inspired 
by these experiments, heparin-based MP technologies were developed to further enable 
the use of heparin to modulate protein presentation in an effort to control cellular 
differentiation. However, another attractive aspect of these technologies is their flexibility 
and potential to be modified to meet different goals in tissue engineering and regenerative 
medicine. Thus, future work could extend and enhance these technologies for their use in 
a plethora of applications.   
 As the culture platform developed in Chapter 3 allows for post-culture retrieval of 
MSCs, several applications for released live cells could be explored. First, as it is 
hypothesized that increased marrow fat and decreased bone mineral density is due to 
dysregulated lineage allocation in MSCs [17], it would be interesting to conduct 
differentiation assays on MSCs retrieved from cultures with and without high glucose 
levels. If MSC osteoblastic differentiation was restricted in cultures with high glucose or 
if measures of osteoblastic function (such as matrix mineralization) were reduced, this 
would support the hypothesis that MSC differentiation is dysregulated in hyperglycemic 
conditions. Confirmation of this hypothesis could lead to development of drugs and 
therapies to counteract this dysregulation. Second, this platform and release of live cells 
could be extended to other applications in which cells could be “primed” within the 
hydrogel co-culture platform before use in other applications. For example, it has been 
observed that chondrocyte and MSC co-culture promotes the chondrocytic phenotype in 
MSCs [133–135]. This platform provides a 3D environment in which the two cell 
populations can be cultured, interact, and then be released for subsequent cartilage 
 181 
therapy applications. Overall, the ability to retrieve live cells from a co-culture hydrogel 
system could be used in a variety of analysis and cell priming applications. 
 The co-culture platform presented in this work also allows for user-defined, 
dynamic changes to the culture system. For example, to better mimic the conditions 
observed in diabetes, additional adipocyte blocks could be laminated to the tri culture 
system over time. In the same vein, osteoblast blocks could be removed. We have shown 
in previous experiments that it is possible to laminate, separate, and then relaminate two 
cell-laden hydrogel blocks without loss of cell viability (Figure 7.1). Thus, it would be 
possible to 1) laminate additional adipocyte blocks onto the culture system and/or 2) 
remove osteoblast blocks through enzymatic degradation, both without loss of cell 
viability. This could be applied to other model systems in which cellular communication 
is transient or dynamic, such as communication between osteoblasts and chondrocytes 
during endochondral ossification [23] or signaling between inflammatory cells, 
osteoblasts, and chondrocytes in rheumatoid arthritis [362]. Overall, the co-culture 
platform can be tuned to mimic many cellular process that change in space and time. 
 
Figure 7.1 (A) 1.Fabrication, 2. separation via enzymatic degradation, and 3. re-
lamination of hydrogel culture system, PEG-DA gels depicted with blue dye, Acrylate-
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PEG-LGPA glue clear. All gels are acellular. Arrows indicate glue and scale bar = 0.5 
mm. (B) Cell viability was calculated using LIVE/DEAD staining, confocal imaging, and 
ImageJ processing for hydrogels laminated, separated and relaminated (day 4 reglued) or 
control groups that were only originally laminated, all normalized to day 4 control group. 
No significant differences in viability were observed (p<0.05). (C) Representative images 
of LIVE/DEAD staining in each gel, scale bar = 100 µm.  
The use of in vitro models for drug screening can be very beneficial, as human 
cells can be used and animal number is reduced [363]. In the co-culture model system 
presented in Chapter 3, it would be interesting to observe how cellular cross-talk is 
affected by drugs that aid in controlling diabetes, such as insulin. By extending the 
culture timeline and introducing insulin at various points in the experiment, it may be 
possible to gain an understanding of when and how insulin presentation can modulate 
communication between the three cell types. Eventually, this may lead to a better 
understanding of the clinical outcomes in patients with controlled and uncontrolled 
blood-glucose levels. Additionally, utilizing this system to develop and screen drugs or 
other therapeutic biomolecules to enable a return to normal differentiation potential in 
MSCs could allow reduction of diabetes-induced osteoporosis.  
In Chapter 4, heparin MPs were shown to modulate endochondral ossification, 
likely through sequestration of soluble factors. While heparin MPs sequester positively 
charged protein in a rather non-discriminate manner, other affinity matrix systems have 
been developed to present peptide sequences that target and sequester specific proteins, 
such as VEGF, TNFα, and FGF [43,46,335], which would provide more predictable 
control over cellular processes. Specific sequestration would be beneficial in several of 
the applications mentioned in Chapter 4. For example, to modulate growth plate cartilage 
regeneration, it may not be beneficial to indiscriminately bind proteins, as heparin-
binding proteins such as BMP-2 and IHH [25] enhance chondrocyte proliferation, which 
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is important for normal growth plate function [106]. However, the sequestration of 
heparin-binding proteins that suppress proliferation and promote hypertrophy, like FGFs 
and VEGF [25,106], could reduce the risk of bony bridge formation. This could also 
apply to therapies for articular cartilage regeneration and craniosynostosis. Thus, 
designing biomaterials that can specifically sequester proteins of interests could be 
beneficial as a means to more carefully modulate differentiation.  
In addition to utilizing endogenous growth factors to manipulate differentiation, it 
is possible that heparin based materials could be used to sequester and thus concentrate 
proteins in the local cellular microenvironment for later analysis. Recently, it was shown 
that heparin-based materials could be used to identify proteins secreted by encapsulated 
cardiac progenitor cells, even when these growth factors were at a much lower 
concentration in the surrounding media [364]. Thus, by incubating heparin MPs with 
cells undergoing a process of interest, it would be possible to capture some of the proteins 
involved, which could enable a more mechanistic understanding of the process in 
question. One difficulty in analyzing heparin-bound proteins is removal of proteins from 
the MPs in a manner that allows subsequent analyses to be conducted. As proteins are 
electrostatically bound to heparin, disrupting these interactions with a concentrated salt 
solution enables protein release, but also interferes with subsequent assays, such as 
ELISAs. This technique is compatible with mass spectrometry, but low-abundant proteins 
are often masked by high-abundant proteins present in the serum in this analysis 
technique [328,365]. Combining this idea with the core-shell MP technology described in 
Chapter 5 could allow size exclusion by the PEG-based shell for additional filtration of 
proteins of interest, as discussed later on in this section. Separation of proteins from 
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heparin MPs using salt is also the first step for running SDS-PAGE, which when 
combined with western blots, could allow identification of proteins. However, western 
blots are very low throughput and require an idea of which proteins to assay for, resulting 
in a lot of guesswork. Finally, implementing degradable heparin-based MPs like those 
discussed in Chapter 6 could allow release of intact proteins, which could then be 
analyzed on protein arrays. Overall, use of heparin as a tool for concentrating proteins 
could enable identification of low abundant proteins such as biomarkers or growth factors 
that could potentially enable better treatments for disease or tissue regeneration.  
The heparin-PEG core-shell MPs presented in Chapter 5 could be modified in 
several different ways that would provide innovative techniques to modulate protein in 
the cellular microenvironment. In the current design, degradation of the PEG-based shell 
is dependent on hydrolysis, which is controlled by the amount of DTT integrated into the 
PEG network. This preset degradation method is advantageous in well-defined systems, 
in which desirable timing for protein delivery is known, but possibly not as useful in 
poorly understood systems, as it does not allow degradation to be responsive to the local 
cellular microenvironment. Thus, as PEG can be chemically modified with enzymatically 
degradable peptide sequences, a shell designed to be degradable by a specific enzyme in 
the cellular microenvironment could better enable this core-shell MP system to respond 
to cellular behavior. Often, this technique has been employed to develop hydrogels 
responsive to enzymes implicated in inflammation, such as MMPs or human neutrophil 
elastase [366–368], or enzymes implication in cell migration, such as plasmin [369]. PEG 
materials can also be modified to be degradable in a pH-dependent manner [370], which 
could be beneficial in tissues with low pH, such as in tumors or inflammatory 
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environments [12,371]. While such a technique has yet to be developed, having a 
material whose degradation could be triggered by presence of a particular protein, not just 
an enzyme, would be particularly useful. This could be achieved by engineering a 
polymer linkage to break upon encountering said protein, possibly by inclusion of 
something that changed confirmation when it bound the protein (an inhibitor or peptide 
sequence) within the polymeric network. While the particular type of degradation would 
have to be selected for the application at hand, core-shell MPs with degradation 
responsive to cues in the cellular microenvironment could be highly beneficial. 
Recently, ideas have circulated around utilization of biomaterials to modulate 
endogenous, cell-secreted proteins within the cellular microenvironment as a means to 
control dynamic cellular processes, in place of their traditional use in protein delivery or 
as cell scaffolds [3]. However, biomaterials that can engage with cellular 
microenvironment in a temporally controlled manner are only just emerging. Modifying 
the core-shell MPs presented in this work to prevent sequestration prior to shell 
degradation would result in a first of its kind technology for temporally controlled protein 
sequestration. As presented now, the core-shell MPs allow protein diffusion through the 
PEG-based shell, albeit at slightly slower rate. By decreasing the pore size in the shell, it 
would be possible to prevent protein diffusion into the core-shell MP prior to shell 
degradation. In effect, this would become a controlled delivery vehicle for sequestration 
agents (i.e. the heparin MP core). Then, the technology could be used to precisely time 
protein sequestration, beneficial in applications where timing of growth factor 
modulation is critical, such as cellular differentiation. One way to slow protein diffusion 
in PEG materials, especially of larger proteins, is to decrease the MW of the PEG 
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polymers [27,372]. If sufficiently small pore sizes to prevent protein diffusion cannot be 
achieved with PEG materials, other materials could be explored. For example, PLGA is a 
hydrophobic material with degradation kinetics that can be controlled by the MW of the 
polymer as well as the lactide:glycolide ratio [373,374]. On the microparticle size scale 
(<300 µm in diameter), network degradation occurs by bulk erosion due to hydrolysis of 
the ester linkage in the polymeric backbone [373,374]. However, unlike hydrophilic PEG 
materials, the hydrophobicity of PLGA only permits transport of small, hydrophobic 
molecules until  aqueous pores have developed [373,374] . This characteristic may allow 
better control over protein diffusion in PLGA and other hydrophobic materials as 
compared to PEG. Thus, by modifying the shell of these core-shell MPs to prevent 
protein diffusion prior to degradation, it would be possible to develop a delivery vehicle 
that had controlled release of sequestration agents. 
In addition, the shell of core-shell MPs could be tuned to exclude large proteins 
(>40 kDa) while allowing sequestration of smaller growth factors. This could be 
beneficial in any scenario that involves serum, as growth factors have to compete with 
large, heparin-binding serum proteins, such as fibrinogen or fibronectin [326–332], for 
binding sites on the heparin MP. However, if the pore size of the PEG shell was tuned to 
exclude large proteins, higher concentrations of growth factors could be bound. Studies 
utilizing PEG-based materials for cell encapsulation have indicated that PEGs of MWs 
ranging from 2-8 kDa could be used for this purpose [372], indicating that while the 
increases in chain length due to DTT in the network of the PEG-shell would still have to 
be accounted for, the core-shell MPs discussed in this work could be modified to exclude 
larger proteins. This could be beneficial for two different types of applications. First, if 
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these MPs were to be used to sequester endogenous protein in vivo (and even in most in 
vitro applications), serum proteins could interfere with their ability to affect 
differentiation by blocking sequestration of growth factors. Second, as discussed in a 
future direction for the heparin MPs in Chapter 4, using heparin MPs to identify proteins 
secreted during cell culture could of interest. However, as is the case with many 
experiments that attempt to identify low-abundance proteins from serum-containing 
solutions [328,365], a collaborating lab has found that serum proteins that bind to heparin 
MPs can mask the presence of low abundant proteins in mass spectrometry analysis. 
Thus, core-shell MPs with size-exclusive properties could act as a protein filter, 
sequestering and concentrating these proteins for future analysis. Recent studies have 
showed the utility in this by using core-shell MPs to selectively sequester biomarkers 
from blood and urine [48–50], but this technique has yet to be applied for analysis of 
growth factors. Overall, exclusion of large serum-bound proteins by the PEG-shell could 
allow core-shell MPs to bind growth factors at higher concentrations.  
Currently, the core of the core-shell MPs presented is non-degradable. Because 
proteins can interact with cell receptors while bound to heparin [175,182], this is not 
necessarily problematic; however, it does impose spatial limitations on the system, as 
only cells in contact with heparin MPs will be affected by bound proteins. This problem 
could be remedied by making the heparin MP core degradable, so that sequestered 
proteins would eventually be released from the polymeric matrix into the cellular 
environment. Initiation of the heparin MP core degradation would ideally occur after 
shell degradation, so that proteins could be isolated from the cellular microenvironment 
on a timeline controlled solely by the degradation rate of the PEG shell. The heparin-PEG 
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MPs described in Chapter 6 show potential for this application, as higher heparin content 
MPs (30 and 40% heparin MPs) degrade on a longer timescale (17-19 days) than the 
PEG-based shell (6-7 days) and do not show high protein release during the initial 7 days 
of release after loading (<10% release). In addition, the environmentally triggered 
approaches described in the previous paragraph could also be used for the heparin core. 
Enzymatically triggered degradation could be particularly useful if the shell was able to 
exclude enzymes prior to its degradation. Finally, while a technique for this does not 
necessarily exist yet, if the degradation products of the PEG shell initiated degradation of 
the heparin core, the entire system could be responsive to cellular microenvironment, 
eliminating the requirement for preset degradation timelines. Overall, a degradable 
heparin core could aid in more uniform and effective release of sequestered protein in 
core-shell MPs. 
Finally, it could be very interesting to include heparin materials within the co-
culture platform discussed in Chapter 3. First, this could be done toward the goal of 
modulating cellular signaling. For example, in a co-culture system aiming to analyze 
cellular communication between osteoblasts and chondrocytes, integrating heparin into 
the chondrocyte hydrogel block may better mimic the ECM’s natural ability to sequester 
and concentrate growth factors derived from other cell types. This could further our 
understanding of how GAGs are implicated in cellular signaling in a variety of other 
processes, such as maintenance of articular cartilage [108,375] or tumor development and 
maintenance [174]. In addition, integration of heparin into the co-culture platform could 
permit sequestration and subsequent retrieval of cell-secreted protein for analysis. In the 
study present in Chapter 3, this would be particularly beneficial, as secreted proteins 
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could provide another interesting variable to further strengthen multivariate models, and 
provide additional information upon which to build hypotheses and future experiments. 
As these hydrogels are PEG-based, a small amount of heparin could be integrated into 
enzymatically degradable gels, allowing degradation of gels and release of sequestered 
protein. Thus, integration of heparin into the co-culture system presented could aid in 
modulating protein-mediated cellular communication as well as permitting retrieval of 
cell-secreted proteins for further analysis. 
These future possibilities only further highlight the power of the tunable 
biomaterial-based technologies presented in this work to modulate and study cellular 
processes. A variety of cell systems can be studied upon the co-culture platform 
presented, and some of the modifications presented would enable a deeper understanding 
of dynamic cell communication and behavior. In addition, heparin-based materials can be 
further engineered to actively engage with the cellular microenvironment, providing 
researchers even tighter control over and understanding of evolving cell processes like 
differentiation. Thus, this work lays a foundation for future technology development to 




SURFEN INTERACTIONS WITH SOLUBLE HEPARIN AND 
HEPARIN MPS 
A1. Introduction 
 Surfen (bis-2-methyl-4-amino-quinolyl-6- carbamide) is a small molecule that is 
known to bind heparin and other GAGs [355]. While the nature of the surfen-heparin 
interaction is not fully understood, recent work has uncovered that the dimeric 
aminoquinoline moiety is required for surfen to block heparin-protein interactions, 
indicating that the amine groups of surfen likely interact with positively charged sulfate 
groups to neutralize heparin [376].  Recently, surfen has been used to neutralize the 
affinity of heparin for growth factors. For example, surfen prevented heparin from 
activating antithromin and inhibited FGF-2 signaling in CHO cells, likely due to 
interactions with cell-surface heparin sulfate [355]. Furthermore, delivery of surfen 
resulted in ectopic cartilage formation in long bones, similar to results seen in mice 
deficient for a heparin sulfate-synthesizing enzyme, suggesting that surfen prevents 
heparin sulfate from functioning normally [187]. In addition, surfen was able to replace 
BMP-2 on heparin-functionalized agarose beads [187], suggesting it has a higher affinity 
to heparin than growth factors. Thus, we were interesting in using surfen to block heparin 
MPs, with the intent of neutralizing their protein-binding ability in order to act as a 
control in cell studies. 
A2. Materials and Methods 
A2.1 Materials 
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 Surfen (Sigma-Alrich) was resuspended at 30 mM in dimethyl sulfoxide (DMSO) 
in a glass vial, as surfen binds to plastic [355], and stored at -20°C. Heparin MPs and 
AF633-tagged heparin MPs were prepared as described in Section 5.2.2. Histone was 
functionalized with FITC by reacting 4 mg/mL protein with 0.1 mg/mL FITC in DMSO 
and 150 M ammonium chloride in a bicarbonate buffer solution (pH 8.3) for 8 hours at 
4°C.  The product was then dialyzed and stored at -20°C.  
A2.2 Incubating Heparin Materials with Surfen 
 Prior to incubations, all tubes were blocked using a 0.1% BSA solution for at least 
an hour. MPs and soluble heparin were added to a PBS solution and then surfen was 
added and quickly vortexed. A 10 µM surfen concentration was used for all incubations. 
All incubations were carried out at 37°C on a shaker plate.  
A2.3 Surfen-Blocked Heparin MP Imaging and SDS-PAGE Studies 
 For surfen imaging studies, 10 µM surfen was added to AF633 heparin MPs at a 
35 µg/mL concentration overnight at 37°C on a shaker plate. MPs were centrifuged and 
supernatant was removed, and MPs were washed once. 100 µg FITC-Histone/mg MP 
was then added in PBS and incubated overnight at 4°C on a rotary. MPs were then 
encapsulated in a PEG-DA hydrogel for imaging, as described (Section 5.2.3).  
 For surfen sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) studies, 10 µM surfen was added to heparin MPs at a 35 µg/mL concentration 
overnight at 37°C on a shaker plate. 2.4 µg BMP-2/mg heparin MPs was then added in a 
0.1% BSA PBS solution and incubated overnight at 4°C on a rotary. MPs were then 
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rinsed once, loaded onto an agarose gel (0.21 mg MPs, corresponding to about 500 ng 
protein, in each well), and run against a protein ladder. 
A3. Results and Discussion 
A3.1 Surfen Dosage and Incubation Time 
 Previously, it has been observed that soluble heparin interacts with surfen in a 
dose-dependent manner [355]. Similar to previous results, we found that soluble heparin 
also interacts with surfen and plateaus around 10 µg/mL (Figure A.1A). In addition, we 
show that heparin MPs also interact with surfen in a dose-dependent manner (Figure 
A.1B), with a plateau around 100 µg/mL heparin MPs. Converting these numbers into 
molar ratios, soluble heparin and heparin MPs appeared saturated at 18:1 or 1.8:1 moles 
surfen to moles heparin ratio, respectively. The increase in molar ratio suggests that less 
surfen is required to fully block heparin MPs as compared to soluble heparin, which may 
indicate that there are fewer available surfen binding sites on heparin MPs as compared to 
soluble heparin. This could be due to the conformation or functionalization of heparin in 
MPs, discussed further below, and might also suggest that heparin MPs were unable to be 
fully blocked. To overcome this obstacle, we attempted to incubate surfen and MPs in a 
DMSO solution, but even lower fluorescent intensities were observed (data not shown), 
suggesting that it was energetically favorable for surfen to remain in solution rather than 
binding to heparin MPs. Overall, successfully blocking of heparin MPs with surfen 
proved challenging and should be further explored in the future. For example, dissolving 
surfen in a different organic solvent may enhance binding efficiency, or heparin-PEG 
MPs may have an increased mesh size that permits more surfen binding. If optimized, 
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surfen blocked heparin MPs could be an excellent tool for experimental control groups in 
subsequent studies. 
 Soluble heparin and MPs were incubated for up to 18 or 22 days, respectively. It 
was observed that surfen-soluble heparin interactions began to diminish around day 12 
(Figure A.1A), possibly due to increasing amounts of surfen becoming stuck to the 
plastic tube or heparin degradation. In contrast, surfen remained bound to heparin MPs 
for at least 22 days (Figure A.1B), indicating that heparin MPs were better able to protect 
surfen from loss to the plastic tube or that heparin MPs were less likely to degrade. 
Overall, the stability of the surfen-heparin MP interaction indicates that surfen-blocked 
heparin MPs could be used for long experiments.  
 
Figure A.1. Fluorescence intensity increases with mass of heparin in solution until a 
plateau is reached, indicating that surfen is able to bind to (A) heparin MPs and (B) 
soluble heparin until saturated.  
A3.2 Protein Binding for Surfen-Blocked Heparin MPs 
 As evidenced by confocal microscopy, histone, a heparin-binding protein, was 
able to bind surfen-blocked heparin MPs (Figure A.2). From visual inspection, it did not 
appear that there was any decrease in the ability of surfen-blocked heparin MPs to bind 
histone as compared to unblocked MPs. Histone was found to appear rounded, possibly 
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because a rounded conformation was thermodynamically stable for the flexible histone 
protein, or possibly due to artifacts of imaging, as heparin MPs appear to have dark spots 
that do not emit a fluorescence signal. As these MPs are made with 70% AF633 heparin 
MAm, it is possible that the material is not distributed evenly throughout the MP during 
fabrication.  Heparin MPs blocked with surfen appeared to have similar dark spots (data 
not shown). 
 
Figure A.2. Confocal microscopy images of surfen-blocked heparin MPs. Heparin MPs 
either blocked with surfen and incubated with histone, unblocked and incubated with 
histone, or unblocked without protein, as indicated by key below. Surfen does not prevent 
heparin MPs (red) from binding histone (green) (scale bar = 10µm). 
 To confirm the results obtained from confocal microscopy, surfen-blocked 
heparin MPs were incubated with BMP-2 and then run on a polyacrylamide gel. 
Previously, it has been observed that proteins bound to MPs will dissociate from the MPs 
when incubated with the surfactant SDS and subsequently run on the gel while the MPs 
remain stuck in the well, due to large size [377,378]. In this study, we hypothesized that 
surfen-blocked heparin MPs would not allow for BMP-2 binding, thus no BMP-2 band 
would be present on the gel for this group. In contrast to what we expected, we observed 
that even after being blocked by surfen, heparin MPs were able to bind BMP-2, 
evidenced by the BMP-2 band present in the surfen-blocked MP lane (Figure A.3). As the 
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intensity of the band is similar to the unblocked MP control, we concluded that surfen is 
unable to prevent heparin MP protein interactions.  
 
Figure A.3. Surfen-blocked heparin MPs run on SDS-PAGE. For both surfen-blocked 
and unblocked heparin MPs, BMP-2 was observed to run on the gel (dark band at 16 
kDa, corresponding to the MW of BMP-2). For surfen containing samples, surfen can be 
seen as a bright bar below 10 kDa (surfen MW = 372.42 g/mol). 
 As mentioned above, it is possible that heparin MPs are not blocked as efficiently 
by surfen as soluble heparin, evidenced by the decrease in surfen required to reach the 
apparent max binding for surfen MPs (Figure A.1). Assuming that soluble heparin is 
100% blocked by surfen upon reaching the plateau region, only 10% of the surfen-
binding spots are taken on heparin MPs, which could lead to the protein binding we 
observed. More so, it has been observed that slight increases to the linker region between 
the two aminoquinoline dimers in surfen-like molecules enhances its effectiveness, up to 
a certain limit at which point the molecule becomes too hydrophobic [376]. This suggests 
a structure relationship between surfen and heparin, which might be interrupted when 
heparin is 1) functionalized and 2) cross-linked into MPs, thus reducing the effectiveness 
of surfen. Finally, previous work has not been able to confirm that surfen’s mechanism of 
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action is solely to interact with heparin. While it is known to bind heparin avidly, it is 
also known to interact with other proteins and molecules [376], indicating that observed 
results may have been not only from surfen-heparin interactions, but potentially 
interactions with surfen and other proteins. We have observed that protein incubated with 
surfen is no longer detectable using ELISA, further suggesting that surfen effects protein. 
If surfen does affect protein, this would complicate the use of surfen-blocked heparin 
MPs as control groups. Thus, significantly more work would have to be done to 
efficiently block heparin MPs with surfen in order to use surfen-blocked heparin MPs as 
an experimental control group.  
A4. Surfen Assay to Measure Heparin Concentration in Aqueous Solution 
 Although surfen did not function as we had hoped for our experiments, it was 
possible to use surfen to assay masses of soluble heparin in aqueous solution down to the 
µg level. Following is the protocol: 
Surfen Assay Protocol 
Surfen is a small molecule that binds to GAGs. It emits a weak fluorescent signal that 
increases when bound to GAGs, which is proportional to the amount of GAG bounds in 
the 0-10 µg/mL range.  Surfen is not very soluble in water, and must be prepared in 
DMSO prior to addition to aqueous solution. Surfen concentration in aqueous solution 
should not exceed 10 µM. Because surfen binds avidly to plastic, glass or BSA-blocked 








 Surfen: dilute fresh surfen to a 30 mM concentration in DMSO in the glass vial it 
arrives in. Store at -20°C 
 Tubes: Block tubes for at least 1 hour with 1% BSA in PBS. Removes solution prior 
to adding samples, no need to wash.  
Assay: 
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1. Make heparin standard in PBS: make 1 mg/mL stock soln, 100x dilution for 10 




0 0 1000 
1 100 900 
2 200 800 
4 400 600 
6 600 400 
8 800 200 
10 1000 0 
2. Prepare samples 
3. Add surfen to each sample to achieve a final concentration of 10 uM surfen (ex: 0.33 
uL surfen in 1 mL). Vortex immediately after adding. 
4. Incubate for at least 3 hours at 37°C 
5. Pipet 100 uL of each sample into a 96 well plate 
6. Read at 320/460 fluorescence 
A5. Conclusion 
 Surfen has previously been used to neutralize heparin-protein binding [187,355], 
likely due to electrostatic interactions between heparin’s negatively charged sulfate 
groups and the amine groups on surfen’s aminoquinoline groups [376]. For this reason, 
we were interested in using surfen-blocked heparin MPs as a control group in our 
spheroid and transwell studies (Chapter 4), as surfen blocked MPs would have the same 
mechanical properties as unblocked MPs but would not be able to bind protein. We show 
that surfen is able to saturate heparin at a 18:1 or 1.8:1 molar ratio for soluble heparin and 
heparin MPs, and that these interactions last for 12 to at least 22 days, respectively. 
Through two different studies, we show that surfen-blocked heparin MPs cannot prevent 
heparin-protein binding. This is likely due to an inefficient blocking protocol but may 
also be due to conformational changes in heparin when it is cross-linked into MPs. While 
unable to be used for blocking heparin MP-protein interactions, we were able to use 
surfen to assay masses of soluble heparin in aqueous solution down to the µg/mL level. 
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Overall, current strategies do no effectively block heparin MPs with surfen, and further 
investigation would need to be carried out to render this technique viable. 
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APPENDIX B 
THE EFFECT OF HEPARIN CELL COATINGS ON ATDC5 
SPHEROID DIFFERENTIATION 
B1. Introduction 
 In the body, heparan sulfate (HS) is attached to membrane-bound (syndecans, 
glypicans, betaglycans) or ECM associated (perlecan, agrin, collagen XVIII) core 
proteins to form HS proteoglycans [174,175]. On the cell membrane, HS acts to facilitate 
ligand-receptor binding, and in the ECM, HS participates in the development of 
morphogen gradients and is thought to protect growth factors from degradation 
[174,175,177,178]. Thus, the function of HS differs based on its spatial location relative 
to the cell surface: HS can either localize protein near the cell surface and initiating 
signaling, or sequester it far from the cell surface and preventing signaling [174]. In this 
work, we asked if heparin localization relative to the cell surface would influence cell 
differentiation. We hypothesized that heparin cell coatings would enhance differentiation 
by concentrating growth factors near the cell surface, while heparin MPs would inhibit 
differentiation by sequestering growth factors away from the cell surface. As shown and 
discussed in Chapter 5, heparin MPs do delay differentiation in ATDC5 cells. Here, we 
show a similar study conducted with heparin cell coatings. 
 Recently, cell coatings have been investigated as a means to control the cellular 
microenvironment [379–381]. In general, they have potential applications in conferring 
biological function, masking cell-surface antigens to improve cell transplantation, 
promoting interactions between two cell populations with coatings that interact with each 
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other, and controlling stem cell lineage commitment [379]. Of all applications, the 
coating of islet cells to mask surface antigens and thus reduce the blood-mediated 
inflammatory reaction after transplantation has been the most widely investigated 
[380,382–385]. Given its activity as an anticoagulant in the coagulation cascade, coating 
islets with heparin has gained interest as a means to reduce coagulation and the 
inflammatory reaction [383,385]. Furthermore, researchers have shown that heparin 
coatings applied by covalent reactions on the cell-surface have not negatively impacted 
islet function [383,385], and have shown that heparin coatings can attract heparin-binding 
proteins like VEGF [384]. Our lab has shown that heparin coatings on MSCs do not 
reduce cell viability or reduce innate immunomodulatory properties, and additionally can 
interact with growth factors to modulate cell differentiation and proliferation [195,386]. 
Thus, in this study we used heparin cell coatings to better understand how heparin 
presented at the cell surface would affect ATDC5 chondrocytic differentiation.  
B2. Materials and Methods 
For soluble heparin studies, AF633 tagged heparin was mixed with single cells at 
a 5 mg/mL concentration prior to forming spheroids as described in Section 4.2.3. For 
heparin cell coating studies, heparin was biotinylated using EDC/HOBt chemistry as 
previously described [386,387]. Heparin cell coatings were applied by a layer-by-layer 
technique according to previous methods [386]. Cells were incubated in 4 mM EZ-Link 
Sulfo-NHS-LC-Biotin (Pierce) in PBS, then 0.5 mg/mL avidin (Invitrogen) in PBS, and 
finally 5 mg/mL biotin-conjugated heparin in PBS for 30 minutes each at 37°C [383]. 
Spheroids were formed with heparin coated cells as described. Cell viability was assessed 
with LIVE/DEAD staining via confocal microscopy. Stacks with slices every 2 μm were 
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flattened using the Z-project function on Image-J. Incorporation of heparin into the cell 
spheroid was assessed with confocal imaging of the AF633 heparin, and images from the 
center of the stack are presented. H&E and Safranin-O staining as well as qPCR were 
conducted and analyzed as described in Section 4.2.5.  
B3. Results and Discussion 
B3.1 Characterization of Heparin Coated ATDC5 Spheroids 
 Heparin can be incorporated into cell spheroids in several different ways. First, as 
shown in Chapter 4, heparin MPs can be incorporated into cell spheroids, which results in 
highly concentrated pockets of heparin throughout the cell matrix. To obtain a more 
homogenous distribution of heparin throughout the ECM, and to allow interactions at the 
cell surface, we investigated two techniques. First, we used a heparin cell coating method 
[386] to coat cells prior to spheroid formation. Second, we mixed soluble heparin with 
single cells during spheroid formation. For both techniques, we used fluorescently tagged 
heparin to visualize incorporation of 5 mg/mL heparin over the course of 14 days (Figure 
B.1). While both groups showed bright signal for heparin at day 1, we observed a rapid 
decrease in fluorescent intensity by day 7 in the soluble heparin group, while the signal 
persisted in the heparin coating group through day 14, though at diminished intensity 
(Figure B.1). These results indicate that soluble heparin either diffuses out of the cell 
spheroid or is degraded by heparanases over the culture period, and that covalently 
attaching heparin to the cell surface allows maintenance of heparin in the matrix over 
time. Thus, for future studies, we used heparin cell coatings to investigate the 
presentation of heparin at the cell surface.  
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Figure B.1. Heparin (blue) was either incorporated into ATDC5 cell spheroids as a 
coating (top) or as soluble, unfunctionalized heparin (bottom).  In coated groups, signal 
persisted through day 14, while in soluble groups, signal faded rapidly.  
 While previous results have indicated that MSCs show no decrease in viability 
when coated with heparin [386], we wanted to ensure that ATDC5 cells also remain 
viable after being coated with heparin. We found that heparin coated cell spheroids 
appeared viable after seven days of culture (Figure B.2). Thus, it is possible to use 
heparin cell coating techniques to investigate the influence of heparin located near the 
cell surface on cell differentiation.  
 
Figure B.2. Heparin coatings did not negatively impact ATDC5 cell spheroid viability 




B3.2 Chondrocytic Differentiation of Heparin Coated ATDC5 Spheroids 
 To investigate the ability of heparin cell coatings to modulate chondrocytic 
differentiation, we cultured heparin coated cell spheroids for 18 days on rotary culture. 
We saw no differences in viability between the heparin coating group and the cell only 
group at day 18 (data not shown). H&E staining of spheroid sections showed no 
observable differences between the heparin coating group and the cell only control, and 
both groups increased in size over time and developed the thick border that we have 
found to be characteristic of ATDC5 cell spheroids (Figure B.3). Interestingly, in 
previous work from our lab, a rounded cell morphology was observed in heparin coated 
MSC aggregates, possibly because the coating influences cell packing within the 
aggregate [195]. The absence of this morphology in ATDC5 spheroids may be due to the 
rapid proliferation or matrix deposition of this cell line compared to MSCs. 
 
Figure B.3. H&E staining of ATDC5 spheroids with coating (left) and no coating (right) 
indicates no major morphological differences between groups over 18 days of culture.   
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 To evaluate the influence of the heparin coating on differentiation, spheroids were 
stained with Safranin-O to assess GAG deposition. As they are composed of GAGs, 
heparin cell coatings could potentially be visible after staining, but were not be detected 
in day 1 staining (Figure B.4). This indicates that the heparin coating was at a 
concentration below the detection limit of the stain. At day 6, a transient increase in GAG 
deposition staining was observed in some of the heparin coated spheroid groups, unlike 
the cell only controls. However, by days 12 and 18, GAG deposition appeared similar in 
both groups and possibly increased in the cell only group as compared to the heparin cell 
coating group. Overall, it appeared the GAG deposition was not strongly affected by 
heparin cell coatings. 
 
Figure B.4. Safranin-O staining of ATDC5 spheroids with coating (left) and no coating 
(right) indicates similar staining in all groups over time. 
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 Gene expression was assessed for differentiation markers collagen II, aggrecan, 
and collagen X. Overall, it was observed that gene expression was similar between the 
two groups over the course of the experiments, with slight decreases in aggrecan at day 6 
and collagen X at day 18 in the heparin cell coating group (Figure B.5). This combined 
with the GAG staining indicate that the heparin cell coating might induce a transient 
effect in ATDC5 cell differentiation, but generally did not affect differentiation.  
 
Figure B.5. Gene expression for ATDC5 spheroids with heparin coating (white) and cell 
only (black) for collagen II, aggrecan, and collagen X (*= significantly different than  
indicated group, p<0.05). 
 The lack of differences between the heparin coating and cell only groups may be 
explained by several different reasons. First, ATDC5 cells are known to proliferate 
rapidly, as evidenced by the increasing size of spheroids over the experimental time 
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course (Figure B.3), which would result in cells with reduced levels of the coating after 
cell division. In addition, ATDC5 cells lay down considerable amounts of GAG over 
time (Figure B.4), which would likely overpower the heparin cell coating except at very 
early timepoints. In the future, increasing the concentration of heparin coated to the cell 
surface could be investigated to initiate a stronger response.  
 In previous work, it has been observed that growth factor delivery to heparin-
coated aggregates can modulate cell behavior. For example, we have seen that heparin 
coated MSC aggregates showed enhanced proliferation in the presence of FGF-2 [195]. 
Also, chondrocytic MSC differentiation was enhanced in TGFβ-1 containing media in 
heparin and desulfated heparin groups as compared to the cell only control [195]. Thus, 
both of these studies indicate that while heparin cell coatings alone do not affect 
differentiation, they may be able to manipulate heparin-binding growth factors in a way 
that modulates cell behavior. Overall, while these studies indicate that heparin cell 
coatings did not affect ATDC5 cells, future studies to investigate the effect of heparin 
presentation on growth factor delivery could be conducted with these coatings. 
B4. Conclusion 
 These studies indicate that it is possible to coat ATDC5 cells with a heparin cell 
coating and maintain cell viability, and that the coating will remain in the spheroid for at 
least fourteen days. No changes in differentiation were observed in the heparin cell 
coating group, possibly because ATDC5 cells proliferate rapidly and deposit large 
amounts of endogenous GAG. Overall, future studies might investigate increasing the 
concentration of the heparin cell coating or use of the coating to modulate exogenous 
growth factors presentation to ATDC5 cells.   
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APPENDIX C 
SPATIAL CONTROL OVER HEPARIN MPS IN ATDC5 
SPHEROIDS 
C1. Introduction 
 The field of tissue engineering strives to better mimic the structural complexity of 
native tissue in order to better mimic its function. A variety of approaches have been 
implemented to achieve these goals, including “top-down” and “bottom-up” engineering 
approaches. Top-down approaches include seeding cells into a pre-formed scaffold, in 
hopes that with the guidance of the scaffold’s properties, the cells will rearrange and 
generate a tissue similar to one found in the body [388,389]. While useful at times, top-
down approaches are limited by the requirement for a starting scaffold, which can reduce 
the number of cell-cell contacts and can provide potentially undesirable signals to the 
cells [390].  In bottom-up approaches, small tissue building blocks, or modules, are 
pieced together to make a larger tissue [388]. Modules can consist of materials laden with 
cells, cell sheets, or dense cell aggregates, called spheroids [388]. Spheroids are of 
particular interest, as these scaffold-free modules have abundant opportunity for cell-cell 
and cell-ECM contacts [388]. Still, spatially controlled differentiation within the spheroid 
can be difficult to achieve [250,263].  
 Recently, several studies have presented methods to achieve spatial patterning of 
cells and materials within cell spheroids. One study showed that microfluidic techniques 
could be used to generate “janus” spheroids, or spheroids with different cell types in each 
hemisphere [391]. Another study showed the ability to use magnetic particles to spatially 
orient and locate spheroids [250]. Finally, it was also shown that when BMP-4 loaded 
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microparticles were incorporated into only one hemisphere of an embryoid body, 
differentiation markers were confined to the cells in that hemisphere [263]. These studies 
indicate the potential to spatially modulate differentiation in cell aggregates, which would 
allow for further specification in modules used to build larger tissues.  
 As in one example mentioned above, integration of materials within cell 
aggregates has emerged as a method to direct cell differentiation 
[220,232,233,250,253,259,263]. This approach allows for homogenous delivery of 
biomolecules throughout the cell aggregate, which is not always possible when 
biomolecules are delivered to the external media due to diffusion limitations [263,315]. 
Thus, in these studies, we were interested in spatially modulating differentiation within 
the ATDC5 spheroids by localizing heparin MPs within one hemisphere of the spheroid. 
As described in Chapter 5, heparin MPs have been observed to delay or prevent 
differentiation when cultured throughout ATDC5 spheroids, indicating that they 
potentially could spatially modulate differentiation if localized into one hemisphere.  
 Thus, in this work, we developed spheroids with spatially localized MPs using a 
method involving pelleting of cells in agarose wells, similar to a method used in previous 
studies [263,389]. This method is advantageous, as it does not require the specialized 
equipment necessary for techniques such as microfluidics and photolithography [390]. By 
creating spheroids of cells that differentiate at different rates, it may be possible to 
develop gradients in differentiation, as observed in tissues like the growth plate [23]. 
These tissue modules could then be used as model systems to better understand tissue 
function, or eventually be translated into tissue replacements for a variety of applications.  
C2. Materials and Methods 
 AF633 Heparin MPs were prepared as described in Section 5.2.2. ATDC5 were 
expanded in monolayer and cultured in spheroid culture as described Section 4.2.3, with 
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the following differences. Monolayer ATDC5 cells were stained with Cell Tracker 
Orange or Green (Invitrogen) according to the manufacturer’s protocol, then lifted and 
pelleted in agarose wells to form 350 cell spheroids. One group of the green cells also 
contained AF633 tagged heparin MPs at a 6:1 MP:cell ratio. After 24 hours, orange 
spheroid groups were popped out of agarose wells using a wide bore pipette and added to 
the green MP containing and green cell only groups at a 2:1 orange spheroid:green 
spheroid ratio.  Spheroids were incubated for an additional 24 hours to allow merging and 
then popped out and cultured in mineralization media on rotary culture.   
C3. Results and Discussion 
 Several methods were attempted in order to make spatially organized spheroids. 
For one set of studies, 350 cell spheroids were formed for 6 hours and cell in suspension 
were added on top of spheroids. This method did not result in spatial separation of the 
two layers, likely due to mixing of cell in spheroids that were not fully formed. Thus, a 
24 hour incubation to fully form spheroids was chosen. In addition, the ratios of 
spheroids on top and on bottom were varied and included 2:1, 1:1 and 1:2 ratios. A 2:1 
ratio of spheroids on top compared to those on bottom resulted in the most efficient 
formation of spatially organized spheroids (only 2:1 data shown).  
 Immediately after formation, spatially organized spheroids showed separation of 
the two distinct cell populations: green stained cells with heparin MPs throughout the 
matrix and red/orange stained cells with no MPs (Figure C.1, Day 1). These results were 
encouraging, as they indicated that heparin MPs could be spatially confined to one 
hemisphere in cell spheroids. However, after six days in culture, cell populations and 
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MPs had mixed, resulting in spheroids with cells and MPs evenly spread throughout the 
matrix (Figure C.1, Day 6). As the goal for this work was to evaluate the possibility of 
spatially controlling differentiation, these results indicated that the ATDC5 cell line is not 
the optimal cell type for these studies.  
 
Figure C.1. Spatially organized cell spheroids at day 1 and day 6. Heparin MPs are shown 
in blue, cell population 1in red, and cell population 2 in green. 
 The ATDC5 cell line is a cancer cell line, which allows ATDC5 cells to grow 
quickly. They also deposit substantial amounts of ECM molecules such as GAG and 
collagen II [304,305,308–313], which likely results in cell re-arrangement. This indicates 
that spatial organization may not be possible in ATDC5 cell spheroids due to 
characteristics specific to its cell type. Thus, the application of this technique to other cell 
types that do not proliferate as quickly or lay down as much matrix may be a possible 
means to gain spatial control over cellular differentiation.   
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C4. Conclusion 
 A technique to spatially control cells within spheroids was developed by 
combining two populations of pre-formed spheroids. This technique resulted in spatial 
separation in ATDC5 cell spheroids at early timepoints and confinement of heparin MPs 
to one hemisphere of the spheroids. However, spatial separation was lost after six days in 
culture, likely due to the high rate of ATDC5 cell proliferation and matrix deposition. 
Overall, this technique allows for at least initial spatial separation and may be more 




HEPARIN MPS TO MODULATE OSTEOGENIC 
DIFFERENTIATION IN MC3T3 CELLS 
D1. Introduction 
 Craniosynostosis involves the premature ossification of one or more cranial vault 
sutures [207,208]. Surgical intervention is currently the only treatment choice, and 
involves surgical removal of calvarial bones, which are then reshaped and reattached. 
Unfortunately, even after surgery, resynostosis can still occur due to abnormally high 
osteogenic potential [207]. Antibodies and other protein inhibitors against osteogenic 
proteins such as BMPs and TGFβs have been applied after surgery in animal models to 
prevent resynostosis, but have had only partial success [209,210,334], likely due to the 
short half-life of these molecules in vivo. Thus, we were interested in utilizing heparin 
MPs as a means to sequester osteogenic growth factors to prevent resynostosis. As a 
proof-of-principle study, the ability of heparin MPs to modulate the differentiation of 
MC3T3-E1 cells, a newborn mouse calvarial-osteoblast cell line known to undergo 
osteoblastic differentiation, was evaluated [392,393].  
D.2 Materials and Methods 
D.2.1 MC3T3 Cell Culture  
 MC3T3 cells were expanded in maintenance media (αMEM, 2 mM L-glutamine, 
500 IU Penicillin, 500 µg/mL Streptomycin, and 10% FBS (Atlanta Biologics)) and 
experiments were conducted in differentiation media (maintenance media plus 10 mM 
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sodium β-glycerophosphate pentahydrate (Alfa Aesar) and 50 µg/ml L-ascorbic acid -2-
phosphate sequimmagnesium salt hydrate (Sigma-Aldrich)). Cells were plated at 5000 
cells/cm
2
 in a 12-well plate and cultured in maintenance media until they reached 
confluence (3 days). Cells were then switched to differentiation media and treatment 
groups were added. Heparin MPs were added at 3.28 mg/transwell. Cells were fed every 
two days.  
D.2.2 qPCR and Gene Expression Analysis 
  Analysis of gene expression was carried out using qPCR and normalized to the 
house-keeping gene RSP-18, as described in Section 4.2.4. Sequences for RUNX2 and 
Collagen I are listed below: 
Table D.1 National Library of Medicine accession number and primer sequences for 
target genes in qPCR 








D.2.3 ALP Activity and DNA Content 
 Cell lysis was carried out in a similar fashion to the process described in Section 
4.2.4 except that cells were incubated in 0.1% Triton-X100. ALP activity was assessed as 
described in Section 5.2.5 and DNA content as described in Section 4.2.4. 
D.2.4 Statistical Analysis 




D.3 Results and Discussion 
 In order to determine if heparin MPs could potentially be used as a therapeutic 
materials for craniosynostosis, osteoblastic MC3T3 cells were cultured for fourteen days 
in transwell with heparin MPs. Gene expression for osteoblastic markers Collagen I and 
RUNX2 were assessed and no differences in gene expression were observed at days 7 or 
14 (Figure D.1). ALP expression was assessed and then normalized to DNA content at 
days 7 and 14, and was found to be increased in heparin MP groups compared to cell 
controls (Figure D.1). Overall, these results indicate that heparin MPs have little effect on 
MC3T3 cells, and as ALP activity is increased in heparin MP groups, it is possible that 
differentiation is actually accelerated in the presence of heparin MPs. Additional outcome 
measures, such as assessment of matrix mineralization and analyses at later time points, 
could provide more insight into how heparin MPs modulate MC3T3 cell differentiation. 
It is likely that heparin MPs affect different cell types in different ways, depending upon 
the growth factors present in the cellular microenvironment. Further analyses would need 
to be conducted to determine which proteins were bound by heparin MPs in MC3T3 cell 
culture as compared to ATDC5 cell culture, which could help elucidate reasons for 
differences observed. In addition, previous studies have indicated that the ability of 
heparan sulfate to enhance healing in a critical sized rat femur defect was dose dependent 
[197], suggesting that additional dosing studies may be required to achieve desired 
results. Overall, these results indicate that more studies need to be conducted to 
understand how heparin MPs can modulate other differentiation processes in vitro.  
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Figure D.1 Osteoblastic MC3T3 cells were cultured with or without heparin MPs in 
transwell for fourteen days and assessed for osteoblastic markers collagen I and RUNX2. 
ALP activity was measured and normalized to DNA content (*=significantly different 
than indicated group, p<0.05). 
 




E.1 Supplementary Figures for Chapter 3 
 All methods, results, and discussion for these figures are included in Chapter 3. 
 
Figure E.1. Principal Component Analysis (PCA) was conducted to determine if 
difference in gene expression resulted in clustering of culture configuration or glucose 
levels prior to further assigning of classes for PLS-DA. (A) PCA for the entire adipocyte 
gene expression data set yielded two principal components that discriminated adipocytes 
by culture configuration (R
2
X = 0.84, Q
2
 = 0.74). (B) PCA score and loading plots for 
AAA (R
2
X = 0.74, Q
2
 = 0.45), AMA (R
2
X = 0.65, Q
2
 = 0.25), and OMA (R
2




= 0.56) cultures yielded one PC. Observed clustering by glucose level warranted further 
investigated with PLS-DA for AAA. (C) PLS-DA weight plot for AAA model in Figure 
3.2C.  
 
Figure E.2. Images were captured using confocal microscopy of calcein (green, live) and 
ethidium bromide (red, dead) staining in each experimental condition. Merged 
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representative images are presented here. Representative images of adipocytes (A), 
osteoblasts (B), and MSCs (C) on days 1 and 7 at normal and high glucose conditions in 
each culture configuration. 
 
Figure E.3. PCA was conducted within culture configuration datasets to determine if 
difference in gene expression resulted in clustering glucose levels prior to further 
assigning of classes for PLS-DA. (A) PCA score and loading plots for OOO (R
2
X = 0.71, 
Q
2
 = 0.52), OMO (R
2
X = 0.72, Q
2
 = 0.51), and OMA (R
2
X = 0.72, Q
2
 = 0.41) cultures 
yielded one PC. Observed clustering by glucose level warranted further investigated with 
PLS-DA for OOO and OMA configuration for classes assigned according to glucose 
level. (B) PLS-DA weight plot for OOO and OMA models in Figure 3.4C. 
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Figure E.4. PCA was conducted to determine if difference in gene expression resulted in 
clustering of culture configuration or glucose levels prior to further assigning of classes 
for PLS-DA. PCA for the entire MSC gene expression data set yielded two principal 
components and clustering by culture configuration (R
2
X = 0.66, Q
2
 = 0.36). 
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Figure E.5 PCA was conducted within culture configuration datasets to determine if 
difference in gene expression resulted in clustering glucose levels prior to further 
assigning of classes for PLS-DA. PCA score and loading plots for MMM (R
2
X = 0.66, Q
2
 
= -0.1), OMO (R
2
X = 0.73, Q
2
 = 0.43), AMA (R
2
X = 0.65, Q
2





 = 0.02) cultures yielded one PC.  
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Figure E.6. Observed clustering by glucose level warranted further investigated with 
PLS-DA for OMO and AMA culture configurations with classes assigned according to 
glucose level. PLS-DA score and weight plot for OMO (R
2
Y = 0.82, Q
2
 = 0.73) and AMA 
(R
2
Y = 0.62, Q
2
 = 0.41). 
E.2 Gene Expression Profiles for ATDC5 Cells in Monolayer  and Spheroid Culture 
E.2.1 Materials and Methods 
 ATDC5 cells were cultured in monolayer in 12 well plates for 22 days or in 
spheroids for 18 days in mineralization media. Further details can be found in Section 
4.2.3. Analysis of gene expression was carried out using qPCR and normalized to the 
house-keeping gene RSP-18, as described in Section 4.2.4. Sequences for aggrecan, 




Table E.1 National Library of Medicine accession number and primer sequences for 
target genes in qPCR in ATDC5 monolayer study 




Statistical analysis is described in Section 4.2.7.  
E.2.2 Results and Discussion 
 In monolayer culture, low levels of gene expression for all genes were observed at 
day 1, with increases at day 6 and a maximum expression level at day 12. For Ihh and 
aggrecan, decreases were observed by day 18, and for collagen II and X, by day 22 
(Figure E.7). Overall, this upregulation between days 6-12 and gradual decrease of gene 
expression markers at longer times in culture is similar to what has been observed in past 
experiments [309]. 
 
Figure E7. Gene expression of collagen II, aggrecan, Ihh, and collagen X for ATDC5 
cells in monolayer culture for 22 days. Each gene is normalized to the RSP-18 
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housekeeping gene at each timepoint (a similar letter = not significantly different, 
p<0.05).  
 In spheroid culture, low levels of gene expression for all genes were observed at 
day 1, with increases at day 6 for collagen II, aggrecan, and Ihh, and increases at day 12 
for collagen X. A maximum expression level for collagen II was observed at day 12, 
while aggrecan, Ihh, and collagen X continued increasing throughout the course of 
culture (Figure E.8). Overall, ATDC5 gene expression in spheroid culture was slightly 
delayed as compared to gene expression in monolayer culture, and is similar to what has 
been observed in ATDC5 aggregate culture in previous experiments [305]. 
 
Figure E8. Gene expression of coll II, aggrecan, Ihh, and collagen X for ATDC5 cells in 
spheroid culture for 18 days. Each gene is normalized to the RSP-18 housekeeping gene 
at each timepoint (a similar letter = not significantly different, p<0.05). 
E.3 Additional Bioactivity Data for Pre-Loaded Core-Shell MPs 
E.3.1 Materials and Methods 
 Microparticles were prepared and sterilized as described in Sections 5.2.4 and 
5.2.5. MPs were incubated for 1.5 days prior to being added to cells for pre-degradation. 
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This allowed MP shell degradation to occur during the three day cell assay (while 
degradation occurs throughout the entire time course, the majority of the PEG-based MP 
degradation occurred between days 3-6 for these MPs; Figure 5.1C). All core-shell and 
heparin MP groups had 0.02 mg of heparin and the degradable PEG-based control group 
had the same number of MPs as the core-shell group. Cells were cultured for 3 days and 
then media/MPs were removed. C2C12 cell culture and ALP assay was conducted as 
described in Section 5.2.5.  
E.3.2 Results and Discussion 
 Degradable core-shell and core shell microparticles induced a lower C2C12 ALP 
activity than the soluble control (27.6+14.6% and 12.9+1.6% of soluble control, 
respectively; Figure E9). No signal was observed for groups without BMP-2, and an 
elevated DNA content was observed in all groups subjected to BMP-2 as compared to 
those without BMP-2. No trends in DNA content were observed between groups. 
 
Figure E9. Degradable (Deg) core-shell MPs modulate loaded heparin MP delivery to 
cells. Normalized ALP activity for deg core-shell, core-shell, and soluble BMP-2 groups 
(non-loaded groups showed no signal; *=significantly different from soluble group, 
p<0.05, n=4). 
 225 
 Taken together with results presented in Chapter 5, these results suggest that 
degradable core-shell MPs have the potential to temporally modulate protein presentation 
to cells. While two days of pre-degradation did not result in sufficient degradation to 
initiate a cell response (suggesting that many heparin MPs were still encapsulated in PEG 
shells) (Figure E9), three days of pre-degradation was sufficient to initiate a cell response 
(suggesting that many heparin MPs had been released from PEG shells) (Figure 5.5). In 
the future, assays that can capture immediate changes in cell behavior in response to 
protein presentation could better highlight the potential of these MPs to temporally 
modulate protein presentation. 
E.4 Soluble Heparin Release from Non-Degradable 100% Heparin MAm MPs 
E.4.1 Materials and Methods 
 Heparin MAm MPs were formed and sterilized as described in Section 4.2.2. 
Heparin MPs were incubated in a PBS solution at a 0.2 mg/mL concentration at 37°C on 
a shaker plate. Supernatant was removed and saved for analysis at days 7, 14, and 21. 
Supernatant was replaced with fresh PBS at each timepoint. The surfen assay (described 
in Section A.4) was used to determine the total mass of soluble heparin released into the 
supernatant at each timepoint.  
E.4.2 Results and Discussion 
 Over the course of 21 days, heparin MPs lost less than 3% of their total mass to 
heparin shedding. This indicates that for the non-degradable 100% heparin MPs used in 
this work, very little heparin was released throughout the experiments conducted. In cell 
 226 
studies, daily media changes would have likely removed most of the released heparin, 
possibly before it could interact with cells. Thus, it is unlikely that soluble heparin 
released from 100% heparin MPs was a major contributor to resulting cell phenotype.  
 
Figure E10. Percentage of total heparin in MPs shed over the course of 21 days. Less than 






F.1. Assumptions for Protein Release Requirements for Heparin-PEG MPs 
 The assumptions listed here describe why 20 µg of protein was used as a lower 
cut-off to determine if subsequent assays should be conducted on protein released from 
heparin-PEG MPs: 
1. ELISA assays have the lowest detection limits of the assays considered (pg/mL as 
compared to ng/mL for western blots and ng-µg/mL for mass spectrometry). 
2. Based on the number of ATDC5 cells plated in these experiments, the doubling 
time of these cells, and previous reports of protein secreted on a per cell and time 
basis, an estimated 10 ng of protein could be released by ATDC5 cells in a 24 
hour period [311–313].  
3. Based on the concentration of FBS in the media used for these experiments and 
previous reports about concentration of protein in FBS [327], about 5000 µg 
protein from FBS would be in each cell culture well.  
4. Assuming that about 40% of the protein in serum is heparin-binding (based on 
break-down of serum components and which of those are known to bind heparin 
[175,180,326,327,330,332]), about 2000 µg of serum proteins could be bound by 
heparin MPs. 
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5. Estimating that 10 ng of protein is secreted by cells and all of this protein can bind 
to heparin MPs, then 0.0005% of the protein bound to heparin MPs would be cell-
secreted vs. from the serum: 
𝟎. 𝟎𝟏 µ𝒈 𝒄𝒆𝒍𝒍 𝒔𝒆𝒄𝒓𝒆𝒕𝒆𝒅 𝒑𝒓𝒐𝒕𝒆𝒊𝒏𝒔
𝟐𝟎𝟎𝟎 µ𝒈 𝒔𝒆𝒓𝒖𝒎 𝒑𝒓𝒐𝒕𝒆𝒊𝒏𝒔
= 𝟎. 𝟎𝟎𝟎𝟎𝟎𝟓, 𝒐𝒓 𝟎. 𝟎𝟎𝟎𝟓% 
6. To enter a range detectable by ELISA (~100 pg/mL) an absolute minimum of 20 
µg of total protein is required: 
𝟎. 𝟎𝟎𝟎𝟎𝟎𝟓(𝒙 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏) = 𝟏𝟎𝟎
𝒑𝒈
𝒎𝑳




7.  This estimate is the best-case scenario estimate for detection by ELISA. 100-
1000s of µg would be required for western blots or mass spectrometry.  
F.2 Methods for Relamination Study (Figure 7.1) 
 PEG-diacrylate (PEG-DA, Mn = 8kDa), and PEG-RGD (Mn = 3.4kDa) were 
synthesized as described in Section 3.2.2. The collagenase-sensitive glue was synthesized 
by reacting peptides (GGGLGPAGGK) with acrl-PEG-succinimidyl valerate (Acrl-PEG-
SVA; Mn ~3.4 kDa) as described in Section 3.2.2. Tri-laminates were prepared from 
PEG-DA and PEG-RGD (cell-seeded gels only) solutions with 50 x 10
6
 cells/mL human 
MSCs, passage 3. Using serial photolithography, a collagenase-sensitive glue was 
patterned between two cell-laden PEG-DA layers. After 1 day, laminates were degraded 
(collagenase, 1100 U/mL), immediately soaked in fresh media for 1 hour, and re-
laminated with collagenase-sensitive glue. Cell viability at 1 day after initial fabrication 
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and 3 days after re-lamination (n=3) was observed using LIVE/DEAD stain. Viability 
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